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ABSTRACT 
Ann Emery: Regulation of HIV-1 Splicing 
(Under the direction of Ronald Swanstrom) 
 
 The Human Immunodeficiency Virus Type 1 (HIV-1) has a single primary transcript – full-length 
genomic RNA.  Left unspliced, it serves as either genomic RNA or as mRNA for the viral reverse 
transcriptase, protease, integrase, and structural proteins.  The mRNAs for all other viral proteins require 
splicing of the full-length transcript.  HIV-1 undergoes a complex program of splicing and suppression of 
splicing to make more than 50 transcript types.  Since these complex splicing patterns are essential for 
viral replication, splicing disruption could be a point of vulnerability given a detailed understanding of the 
steps involved.   
 In order to assess the regulation of splicing, the products of splicing have to be quantifiable. This 
dissertation describes two Primer ID-tagged deep sequencing assays developed to quantify HIV-1 
splicing in the context of viral infection/transfection and in the context of a full-length viral genome.  The 
depth of sequencing allows quantification of even rare splicing events.   
 Using these deep sequencing assays I examined splicing across HIV-1 subtypes and between 
HIV-1 and SIVmac239 and found that while patterns of splicing are well conserved, wide variation in 
acceptor usage is tolerated among different HIV-1 strains.  Correct splicing depends on cis-acting control 
sequences interacting with cellular splicing factors.  I quantified the effects of mutations that alter these 
sequences or the secondary RNA structures containing them.  I reevaluated the effects of previously 
characterized splicing regulatory sequences, validating the functions of some but redefining others.  In 
collaborative efforts I showed that mutation of splicing factor binding sites or knock down of cellular 
splicing proteins produces specific splicing phenotypes.  Analysis of a set of global silent mutations 
across the HIV-1 genome found regions of the viral genome that interfere with suppression of splicing and 
carry a high fitness cost.   
 
 iv 
These experiments show that HIV-1 splicing regulation involves more complex patterns of factor 
binding and cooperative interactions than previously described, suggesting that existing models are 
overly simplistic, and my studies contribute to a more accurate description and understanding of HIV-1 
splicing. 
 v 
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CHAPTER 1: INTRODUCTION 
Human Immunodeficiency Virus 
The human immunodeficiency virus is the cause of the current AIDS pandemic.  There are two 
virus types, HIV-1 and HIV-2, both resulting from multiple cross-species transmission events of simian 
immunodeficiency viruses (SIV) (1). HIV-1 is the primary and most virulent of the two types and the one 
studied in this thesis. 
HIV-1 is a retrovirus and like all retroviruses, it has a positive single-stranded RNA genome.  Two 
copies of this genome are packaged into a viral protein capsid and surrounded by a membrane derived 
from the host cell.  HIV-1 targets CD4+ cells and the initial step of HIV-1 infection is recognition of the 
host cell CD4 receptor by a trimer of the viral envelope (Env) surface antigen.  After binding the CD4 
receptor Env becomes competent to bind a co-receptor, either CCR5 or CXCR4, and undergoes a 
conformational change that fuses the viral membrane with the host cell membrane and releases the viral 
contents into the cell (2).  After entry the viral capsid largely disassembles, allowing the viral reverse 
transcriptase to make a double-stranded DNA copy from the genomic RNA template. The viral integrase 
protein (IN) forms a complex with the ends of the linear viral DNA and inserts it into the host cell genome.  
High levels of transcription of viral RNA begin after integration, leading to high levels of viral protein 
production. 
There are eleven HIV-1 proteins.  The Gag precursor polyprotein is cleaved by the HIV-1 
protease (PR) to form the components of the capsid structure with Env trimers studding the membrane 
surface of the particle. The Integrase (IN) protein and reverse transcriptase (RT) are cleaved from the C-
terminal end of the Gag-Pro-Pol polyprotein (3).  The other viral proteins – Vpu, Vif, Vpr, Tat, Rev, and 
Nef – are regulatory proteins. Only one type of viral transcript is made – a full-length positive strand that 
can be used as genomic RNA of progeny viruses or as mRNA for synthesis of Gag and Gag-Pro-Pol.  
Other viral transcripts are made by alternative splicing of this full-length transcript (4, 5). 
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The viral proteins have multiple known functions and ongoing studies continue to discover and 
characterize additional functions (6). Protein function is linked to the regulation of its expression and 
alternative splicing is a major feature of gene regulation for HIV-1. 
Env and Vpu have a common transcript.  Although the Vpu open reading frame is upstream of 
Env, leaky or discontinuous ribosomal scanning may bypass the Vpu start codon and continue to the Env 
start codon (7).  Vpu stands for “viral protein U” (8) and it functions to downregulate CD4 from the cell 
surface and degrade it in the endoplasmic reticulum (ER).  This may facilitate viral particle production by 
preventing Env from binding to CD4 in the ER, directing it instead to virus particles (9).  Vpu also 
functions to downregulate BST-2 (also known as tetherin), a cellular membrane-associated protein that 
stalls release of viral particles.  In the absence of Vpu, tetherin inhibits viral particle release by tethering 
the budding virus to the host cell membrane (10). 
Viral infectivity factor (Vif) counteracts the cellular restriction factor APOBEC3G (A3G) and 3F 
and is indispensable for viral replication in cells expressing these proteins.  A3G and A3F proteins are 
packaged in HIV-1 virions and cause mutations during reverse transcription.  Vif targets A3G/F for 
proteosomal degradation (6).  In the absence of Vif, the viral genome becomes hypermutated (11, 12).  
Viral Protein R (Vpr) has several known functions.  It induces cell cycle arrest in the G2 stage 
(13).  Vpr interacts with the ubiquitin ligase complex to target cellular proteins for degradation and is 
involved in the nuclear import of the pre-integration complex (14).  Vpr-defective virus also has a 
transcription defect (15).  
The HIV-1 Tat protein is required for efficient elongation of viral transcripts.  It recruits the 
transcription factor P-TEFb from a cellular storage complex and brings it to the TAR loop, a region of viral 
RNA secondary structure.  This Tat/P-TEFb/TAR complex interacts with the elongating RNA polymerase 
to greatly increase processivity (4).  Viral transcripts abort prematurely without sufficient Tat (16) and it is 
thought that this may be associated with viral latency (17). 
Generally, only completely spliced transcripts are transported from the nucleus to the cytoplasm 
(18).  HIV-1 unspliced and partially spliced transcripts retain all or one intron respectively and would 
normally be targeted for degradation.  The viral protein Rev connects these incompletely spliced RNAs to 
the Crm1 nuclear export pathway.  Rev binds both a highly structured RNA sequence called the Rev 
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response element (RRE) and Crm1 and in this way transcripts with retained introns are exported to the 
cytoplasm (19-21). 
Negative factor (Nef) modulates the immune response of the infected cell to accommodate viral 
replication by downregulating CD4 and MHC Class I from the cell surface (22, 23).  Nef also suppresses 
the apoptotic response and counteracts the anti-viral effect of SERINCs, a family of host proteins (24) that 
are included in viral particles and block entry into the cell (25). 
Viral assembly takes place at the cellular membrane.  Multiple domains of Gag target it to the cell 
membrane, bind two copies of the viral genome, and make numerous protein-protein interactions.  These 
proteins are incorporated into the viral capsid and include the viral reverse transcriptase, Vif, and 
integrase.  Trimers of envelope proteins are embedded in the cell membrane so as to be on the outer 
surface of the virion as it buds from the cell (3). 
Splicing 
Most eukaryotic genes contain short coding sequences (exons) interspersed with long non-coding 
sequences (introns).  In 1977 reports of splicing in adenovirus were published (26, 27) and soon splicing 
of discontinuous genes was recognized as a common feature across eukaryotic species (28).  After a pre-
mRNA is transcribed it must be completely processed before it can be exported to the cytoplasm and 
translated.  This processing includes adding a poly A sequence at the 3’ end, attaching a 5’ cap, and 
splicing to excise the introns and join the exons. 
The terms exon and intron can be confusing so it helps to know where these names originated.  
Some parts of the pre-mRNA were expressed in protein so they were called exons.  Exons were flanked 
by intervening sequences, hence called introns. Exons are typically 100-200 bases in length.  The 
average length of a vertebrate exon is 137 bases with less than 1% of exons longer than 400 bases (29).  
Introns are longer – generally 1000-2000 bases although some are much longer.  The 5’ end of an intron 
is called the donor and the 3’ end is the acceptor.  Splicing cuts out the sequence between the donor and 
acceptor. 
Correct splicing requires recognition of the splice sites.  Every intron has three core splicing 
signal consensus sequences that are recognized by the splicing machinery.  These are the 5’ donor 
sequence (recognized by U1), and the 3’ acceptor sequence and branch point/poly pyrimidine tract 
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sequences (both recognized by U2).  The 5’ and 3’ consensus sequences are located at each end of the 
intron (Figure 1.1). The branch point and polypyrimidine tract (PPT) sequences are about 20 bases long 
and begin about 25 to 30 bases upstream of the 3’ acceptor site.  Almost without exception intronic 
sequences begin with GU and end with AG and the branch point is an A.  HIV-1 is an exception and has 
some non-adenosine branch points (30, 31).  The terminal exons obviously need a different set of 
recognition signals.  For the 5’ terminal exon, the 7-methyl-guanosine cap may be essential for exon 
recognition, as the cap and its binding proteins are required for splicing in experimental systems (32).  
The 3’ terminal exon may be recognized by polyadenylation.  Splicing and polyadenylation are coupled 
and splicing of an upstream intron upregulates polyadenylation but mutation of the final 3’ splice site 
interferes with the polyadenylation process (33).  
 
  
Figure 1.1. Splicing Signal Sequences. 
 
 Splicing requires two transesterification reactions catalyzed by the spliceosome, a huge cellular 
splicing machine (34).  This two-step process is catalyzed by a set of five ribonucleoproteins called 
snRNPs (35), numbered U1, U2, U4, U5, and U6.  These snRNPs and a large number of associated 
proteins combine to create the spliceosome.  A proteomic analysis was done to identify spliceosomal 
proteins and 145 distinct proteins were identified (36), although the actual number may be even larger.  A 
collective review of splicing factor analyses lists almost 300 proteins, making the spliceosome the biggest 
macromolecular machine in the cell (37, 38). 
 The first step of splicing is the binding through complementary base-pairing of snRNPs U1 to the 
5’splice donor site and of U2 to the 3’ acceptor site and branch point sequence.  U2 pairs with the branch 
point sequence is such a way as to cause the branch point adenosine to bulge out and expose its 2’ 
hydroxyl group in preparation for nucleophilic attack.  These weak base pairings are stabilized by other 
protein factors, and in particular by the cellular SR proteins.  These U1 and U2 binding events form the E 
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complex (Figure 1.2) (35, 39, 40) and are often depicted as U1 and U2 binding to opposite ends of an 
intron.  In most eukaryotic genes, however, U1 and U2 actually pair up on opposite ends of an exon. This 
is called exon definition (29). 
 
  
Figure 1.2. Spliceosome E Complex. 
 
 In the next step, spliceosome proteins assist U1 and U2 to interact across the intron to form the A 
complex (Figure 1.3).  The transition from exon definition to intron definition is not as yet understood.  
This U1-U2 interaction puts the bulged-out branch point A into proximity with the 5’ donor site (35, 39, 
40). 
 
 
Figure 1.3. Spliceosome A Complex. 
 
 At this point a trimer of the remaining three snRNPs - U4, U5, and U6 – is recruited to the pre-
spliceosome to form the B complex (Figure 1.4).  A joint structure containing U4 and U6 binds to U2, and 
U5 interacts with both of the exons about to be spliced, perhaps holding them in proximity for the catalytic 
step ahead (41). 
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Figure 1.4. Spliceosome B Complex. 
 
 The B complex undergoes rearrangement (42).  Assisted by helicases, the snRNPs remodel their 
base pairings.  U6 unwinds from U4 and replaces U1 binding at the 5’ splice site while remaining bound 
to U2 at the 3’splice site.  U1 and U4 are released.  U5 continues to bind both exons.  This set of 
rearrangements remodels U2 and U6 into a catalytically active structure (43, 44) and the first splicing 
reaction occurs, joining the branch point A to the 5’ splice site in a lariat formation.  This stage of the 
spliceosome is called complex B* (Figure 1.5). 
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Figure 1.5. Spliceosome B* Complex 
 
 The resulting partially spliced products form complex C (Figure 1.6).  Another set of 
rearrangements leads to catalysis of the second splicing nucleophilic attack –the 3’hydroxyl at the free 5’ 
donor splice site attacks the phosphate at the end of the intron (the 3’ splice site), displacing the lariat and 
connecting the exons (35, 39, 40). 
 
 
Figure 1.6. Spliceosome C Complex. 
 
 Once splicing is completed the snRNPs dissociate from the spliced exons to be recycled and the 
lariat is rapidly degraded (Figure 1.7). 
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Figure 1.7. Post-Splicing Products. 
 
 Splicing requires ATP.  The multiple remodeling steps involve a collection of core splicing factors, 
many of them ATP-dependent RNA helicases (37).  The stages of spliceosome assembly are reversible 
in vitro, and this may give the splicing machinery the ability to form, release, and reform on optimal or 
correct sites to increase splicing fidelity (45, 46). 
 The spliceosome does not processively travel down the pre-mRNA, but appears to be formed de 
novo for each intron excision, meaning that a transcript with multiple introns will require a new 
spliceosome to assemble for each splicing event (47).  The spliceosome can self-organize in vitro and 
does so in the precise series of steps described above. These steps are well documented and agreed on 
(37, 39, 40, 48, 49). 
 Recent studies describe the structural conformations of the spliceosome intermediate and 
catalytic states (50-57).  These structural studies have used in vitro one intron systems that block the 
splicing reaction at a specific point.  The results are instructive but may not fully represent the situation in 
vivo where cellular transcripts have multiple introns and also undergo additional pre-mRNA processing. 
 Although the spliceosome is generally thought of as the “splicing machine,” work by the Sperling 
laboratory has found that in nuclei isolated in physiological conditions, spliceosomes are assembled into a 
tetrameric form called the supraspliceosome (58-61).  A supraspliceosome consists of four individual 
spliceosomal subunits multimerized around a single pre-mRNA.  Whereas studies involving individual 
spliceosomes indicate that a spliceosome forms on each intron/exon, catalyzes splicing, and then 
disassembles; studies of supraspliceosomes suggest that a supraspliceosome assembles in a 1:1 ratio to 
pre-mRNAs and that splicing of the entire transcript takes place within this supraspliceosome, regardless 
of the number of introns in the unspliced transcript (62).  This would require some 
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movement/rearrangement of the transcript through the supraspliceosome structure - that mechanism has 
not yet been described.  Although studies of individual spliceosomes detail a complex temporal 
association of the five splicing snRNPs, all five are continually associated with the supraspliceosome.   
 Additional factors involved in pre-mRNA processing have been found in the supraspliceosome 
structure.  hnRNP and SR proteins control alternative splicing and are both found in the 
supraspliceosome.    Additionally, Drosha and its cofactor DGCR8, components of pre-miRNA 
processing, have also been found in the supraspliceosome, suggesting that miRNA processing and 
splicing may be connected.  mRNAs must be capped at the 5’ end and polyadenylated at the 3’ end, and 
components required for end processing have also been found in supraspliceosomes (63).  ADAR editing 
is another component of pre-mRNA processing.  ADAR proteins make A to I edits in double stranded 
RNA.  Supraspliceosomes were found to contain both ADAR1 and ADAR2 (64).  The collective presence 
of all of these pre-mRNA processing elements suggests that the supraspliceosome is a cellular machine 
designed to carry out multiple pre-mRNA processing steps in a common location (65). Much work has 
been done to characterize the structure of the supraspliceosome (40).  The resulting structures suggest 
that a single supraspliceosome is associated with a single pre-mRNA and fragmenting the transcript 
results in dissolution of the supraspliceosome into four separate spliceosomes, which can be 
reassembled by adding an intact transcript.  This hints that the pre-mRNA itself is an integral part of the 
supraspliceosome structure.  Each spliceosome directs one exon to a central cavity of the 
supraspliceosome, bringing the exons into close proximity with the introns looped out around the exterior 
of the structure.   Each spliceosome subunit can splice out the intron looped out around it, thus the 
supraspliceosome could splice out four introns at a time, though it is not known if splices occur in a 5’ to 
3’ order within the supraspliceosome.  It has been hypothesized that an exon that got included in the 
external intron loop would be skipped (61), one possible pathway for alternative splicing.   
 Splicing happens with high accuracy but the information in the core splicing signals is not 
sufficient to define splice junctions (66).  Numerous false splicing signals exist in introns, sometimes even 
in exon-like pairs, and yet these cryptic sites are seldom used (67).  An additional layer of control is 
needed to correctly identify genuine exons, so there are cis-acting splicing regulatory elements (or SREs).  
Splicing regulatory elements are short sequence elements of 5 to 20 bases that bind trans-acting 
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proteins. This helps identify valid splice sites and enhance or repress splicing.  These SREs can occur in 
introns, where they are called intronic splicing suppressors (ISS) or intronic splicing enhancers (ISE).  
More often they are found in exons, called exonic splicing silencers (ESS) or exonic splicing enhancers 
(ESE) (68).  
 The two classes of cellular proteins that act as trans-factors are the SR proteins and the hnRNP 
proteins.  SR proteins are a family of cellular proteins named for their serine-arginine rich motifs (RS 
motifs) (69). Although SR proteins are a related family of proteins, the heterogeneous nuclear 
ribonucleoproteins (hnRNP) are a heterogeneous group of RNA binding proteins that associate with pre-
mRNAs in the nucleus, as the name implies.  In general, SR proteins activate splicing and hnRNP 
proteins suppress splicing, but their activity is context dependent (70-72).  This context-dependent 
behavior of SREs initially seems random but in fact follows some highly predictable, if complex, patterns 
and rules (73).   
 It’s known that SR and hnRNP proteins bind to splicing regulatory elements (74) and available 
evidence suggests that this binding recruits other proteins, either to construct a spliceosome or to make a 
large enough protein concatenation to block splice sites.  This idea is further supported by experiments 
that tether an hnRNP or SR protein near a splice site, producing the effect of an ESS or an ESE 
respectively (75-78).  Efforts have been made to discover the binding motifs of hnRNP and SR proteins 
using SELEX (to identify optimal binding sequences (Tian, 1995 #196)) and computational approaches 
(79, 80) to predict SREs, including an HIV-1 specific screening algorithm (81). These approaches have 
met with variable success.  The redundancy of the proteins and the degeneracy of binding motifs make it 
difficult to say for certain which protein or proteins control a particular splicing event. 
 Some SREs may act at a distance from the affected splice site.   For example, hnRNP A1 binds 
specifically to SREs but also to RNA generally.  Once bound, hnRNP H1 multimerizes along the RNA to 
occlude binding sites of SR proteins and spliceosome components, and also loops out to simultaneously 
bind to more distal SREs, which may explain how ESS elements outside the splicing area can suppress 
splicing (82, 83).   
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  ESEs are important for exon recognition and constitutive exons and all exons have an ESE (84, 
85).  An ESE and an ESS in the same exon can competitively bind to SR or hnRNP proteins respectively 
to enhance or repress spliceosome formation across the exon (86). 
 There is evidence that cellular SREs are associated with RNA secondary structures, in particular 
the loops of stem-loop structures (89, 90), and that perturbation or stabilization of structural features may 
alter splicing by masking or unmasking splicing sites or regulatory elements (91).  Secondary structures 
control some HIV-1 splicing events (92), as will be demonstrated in Chapter 2. 
 As with the core splicing signals, splicing motifs are highly overrepresented relative to valid 
usage.  Splicing regulatory elements are short sequences and thus any given element will be present in 
far more locations than actual SREs exist.  Presumably all these candidate sites are not recognized by 
trans-acting cellular factors, just as all pseudo-splice sites are not recognized.  Splicing factors can 
recognize multiple sequence motifs, and a given sequence motif can be recognized by redundant splicing 
factors.   Any one exon can be controlled by multiple SREs. The possibilities that feed into splicing 
decisions are numerous and complex, and many co-operating/competing factors play into the final 
splicing outcome (35).  This suggests that some complex combinatorial code exists to selectively identify 
genuine splice sites distinct from the background noise, a code that as yet remains uncracked (68, 85, 87, 
88). 
Alternative Splicing 
 Alternative splicing is a mechanism in which exons can be used in different arrangements to give 
specific activities and functions to the resulting proteins (93, 94).  There are various types of alternative 
splicing seen in cellular transcripts.  The following figures illustrate the three types of alternative splicing 
also seen in HIV-1: intron retention, exon skipping, and multiple acceptor sites (68, 95). 
 A typical cellular pre-mRNA transcript is represented by Figure 1.8 - short exons interspersed 
with long introns. Exons are recognized by the splicing signal sequences on each end that identify donor 
and acceptor sites spaced at an appropriate exon length.  Spliceosome elements assemble at both ends 
of the exon, the exons are brought together, the spliceosomes assemble across the introns, and splicing 
occurs.   
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Figure 1.8. Exon Recognition and Inclusion. 
 
 It is interesting that in cellular transcripts, all the introns are spliced out – intron retention is a rare 
type of alternative splicing (Figure 1.9).  In HIV-1, introns are retained and splicing is so heavily 
suppressed that the majority of HIV-1 transcripts remain completely unspliced.  The mechanism for intron 
retention is not known.  
 
 
Figure 1.9. Intron Retention. 
 
 Constitutive exons are present in every transcript but there are also alternate exons that are 
sometimes skipped.  If the exon does not get defined, as shown in Figure 1.10, then it is considered part 
of the intron and is left out.   
 
 
Figure 1.10. Undefined Exon Skipped. 
 
 Some exons have more than one possible 3’ acceptor site, as illustrated by the orange and 
yellow exon in Figure 1.11.  Depending on where the spliceosome components bind, the yellow sequence 
will be included or left out. 
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Figure 1.11. Alternative Acceptor Usage. 
 
 More than one-third of alternate splicing involves alternate exons, and more than one-fourth 
involves the use of alternate donor or acceptor splice sites (95).  Other types of alternative splicing 
include multiple 5’ donor sites, mutually exclusive exons, and alternative leader or terminal sequences 
(68). 
 SREs and the SR and hnRNP trans-acting proteins act competitively to control alternate splicing. 
A constitutive exon has the splice acceptor and donor signal sequences at each end of the exon and at 
least one exonic splicing enhancer (ESE) (Figure 1.12).  This ESE is bound by one of the family of SR 
proteins.  The SR proteins recruit and stabilize the formation of the early spliceosome spanning the exon 
(96).  This defines the exon allowing it to be included.  An alternate exon also has the splicing signal 
sequences at the exon boundaries, but it has two splicing regulatory elements - an enhancer (ESE) and a 
silencer (ESS).  What happens depends on which protein gets there first.  If an SR protein binds to the 
enhancer then the spliceosome begins to assemble, the exon is defined, and the exon gets included.  
However, if an hnRNP protein binds to the silencer first then spliceosome assembly is blocked and the 
exon isn’t recognized and gets skipped.  Thus every exon must have at least one enhancer and every 
alternative exon must also have a silencer.   
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Figure 1.12. Inclusion or Skipping of an Alternative Exon. 
 
 Pseudo/cryptic splice sites typically have silencer elements, particularly those near a constitutive 
splice site.  This may help ensure the usage of correct splice sites, and this type of silencer is seen in 
HIV-1 (76, 95, 97).  
 It is not always clear what function, if any, results from many alternatively spliced cellular 
transcripts.  One interesting idea is that some transcripts may include exons that bind and sequester 
protein factors, making them unavailable (98). Most alternatively spliced transcripts are present at low 
levels.  One evolutionary hypothesis is that these low levels give the cell a chance to try out a new protein 
isoform while maintaining adequate production of the previous isoform (83).  Only about 10% of alternate 
splicing products have a clearly predictable functional effect but many would be predicted to alter protein 
surfaces and thereby alter interaction partners (95).   
 Some functional roles for alternative splicing have been discovered in development and immune 
response.  One well-studied area of alternative splicing is its role in neuronal development (99).  The 
mechanisms are not yet known, but the splicing differences are specific to cell types.  Alternative splicing 
has also been documented in activated T-cells, the primary host cells for HIV-1 (100, 101).  HIV-1 
infection of macrophages was shown to change the balance of SR and hnRNP proteins over time (102).  
 Many alternatively spliced transcripts cause frame shifts and introduce a termination codon.  This 
allows the cell to recognize and remove aberrant transcripts by a process called nonsense-mediated 
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decay (NMD) (103).  It’s been predicted that up to one-third of alternative splicing events introduce 
premature stop codons that subject them to NMD (104).   
 Changes to splicing can have pathological effects.  A well-known example is mutation of the SMN 
(survival motor neuron) gene.  A point mutation damages an ESE, causing an exon to be skipped. The 
shorter protein is rapidly degraded and this loss of function is the cause of spinal muscular atrophy (105).  
Interestingly, spinal muscular atrophy is one of the first diseases to be successfully treating by controlling 
a specific splicing event with an antisense oligonucleotide (106).  Perhaps as many as half of genetic 
diseases are mutations that cause aberrant alternative splicing (95). 
Splicing in HIV-1 
 Figure 1.13 is a simplified illustration of splicing in HIV-1.  There are four donor sites and six 
acceptor sites.  This figure is not drawn to scale – splice sites A1 through A5 actually occupy a 1 kilobase 
sequence in the middle of the genome.  Only one mRNA type is transcribed – a full length genomic RNA, 
represented by the black bar.  If this RNA is not spliced it serves as either a gag/pro/pol mRNA, or as 
genomic RNA (5, 107). 
 
 
Figure 1.13. Splicing in HIV-1. 
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 If HIV-1 mRNA splices there are two basic splicing events.  The first event is when D1 is used to 
splice to one of the six downstream acceptor sites.  The spliced transcript generally codes for the first 
open reading frame after the splice, so a splice from D1 to A1 creates an mRNA for Vif, a splice to A2 for 
Vpr, and Tat for A3.  The transcript type for splicing to A4, and A5 is determined by the second splicing 
event. 
 The second major splicing event is from D4 to A7.  This splice removes the env intron and the 
RRE, and joins together the two exons of tat and rev.  All spliced transcripts first splice from D1 to an 
acceptor A1 through A5, and having done so, they may or may not splice out the D4 to A7 sequence.  
Spliced transcripts are divided into two size classes, depending on whether or not the D4-A7 splice 
happens. Retaining the env intron makes a larger class of transcripts collectively known as the 4 kb class 
or incompletely spliced transcripts, while transcripts that splice from D4 to A7 are called the 1.8 kb class 
or completely spliced transcripts.  As discussed above, it is not usual for cellular transcripts to remain 
unspliced or to retain introns. HIV-1 unspliced or incompletely spliced transcripts keep all introns or the 
env intron respectively, and this prevents their nuclear export, so they need the RRE and Rev to connect 
to the Crm1 export pathway (19). 
 There are two additional donor sites, D2 and D3.  Use of D2 or D3 creates small non-coding 
exons. The red bars in Figure 1.13 illustrate the constitutive exons in HIV-1 transcript types.  The grey 
bars represent the small alternative exons created by use of D2 and/or D3.  Either, both, or none can be 
included in a transcript.  These small exons greatly increase the number of possible splice variants (5, 
107).  For each acceptor there are four possible types of transcripts with variable inclusion of the small 
exons, but they are not made in equal amounts.    In general, direct splices, with no small exons, make up 
75-85 % of transcripts.  The exception is nef.  The direct splice from D1 to A7 makes a nef transcript but 
this is an uncommon splicing event.  The majority of nef transcripts splice to A5 (with or without including 
the two small upstream exons) and thus the region between A5 and D4 becomes a 3rd small exon.   
 The purpose of the small exons has thus far eluded discovery.  It’s been proposed that D2 and 
D3 exist to provide exon definition for A1 and A2 respectively to ensure adequate levels of Vif and Vpr, 
though there is not yet sufficient evidence to support this claim (108).  Another possible but not yet 
studied purpose is that binding of U1 to D2 and D3 may stabilize vif and vpr transcripts (108), as has 
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already been observed for D4 and env transcripts (described below).   One study claimed the first small 
exon stimulated protein production while the second small exon reduced it, with the improbable claim that 
this effect was activated after transcription but before splicing (when the small exons come into existence) 
(109).  This notion was refuted in a later study that claimed the small exons do not affect transcript 
stability or protein production (108).  Small exon inclusion does not change any known coding sequences 
or create a new ORF, yet the small exons are well conserved across HIV and SIV. 
 It is of interest that certain splicing events have not been seen.  One such event is the inclusion of 
the small exons in nef transcripts that splice to A7.  A second more interesting omission is transcripts that 
fail to splice at D1 but later splice from D4 to A7.  This transcript type has never yet been reported in 
otherwise fairly comprehensive splicing analyses (5, 107), and I have not found it in quantities above what 
might be caused by PCR artifacts.  This and other data presented later suggest that there are 
mechanisms to suppress certain types of HIV-1 splicing early and completely. 
 Splicing of cellular genes is an accurate process but splicing in HIV-1 is much less precise. 
Splicing is primarily from the major donors to acceptors but there are a number of lesser used sites, most 
often in close proximity to major sites as illustrated in Figure 1.14.  This diagram shows some of the splice 
sites commonly found across different HIV-1 strains but each strain also has its individual minor splice 
sites, sometimes leading to idiosyncratic splicing and protein products (110-112) and even a novel 
transcript size class (107). 
 
 
Figure 1.14. Major and Minor HIV-1 Splice Sites. 
 
 Even though splicing in HIV-1 does some things that cellular transcripts do not do, it is helpful to 
think of HIV from an exon/ intron perspective (Figure 1.15).  The two small exons are alternative exons, 
thus they would be expected to have both enhancers and silencers.  The exon defined by D4 is 
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constitutive but it uses alternate acceptors, so some control elements regulating acceptor usage would be 
predicted. 
 
 
Figure 1.15. HIV-1 from and Exon/Intron Perspective. 
 
 HIV-1 donor sites D1 and D4 are efficient, D2 and D3 less so (108).  HIV-1 acceptor sites are 
described as “weak” compared to the cellular splicing consensus sequence; nevertheless, they must still 
be suppressed to achieve balanced splicing (113-115).  It is certain that all known HIV-1 SREs are not yet 
discovered and characterized but Figure 1.16 shows those that have been described to date. 
 
Figure 1.16. Known HIV-1 SREs. 
 
 D1 is the major splice donor and is used in every spliced transcript, yet it is the least understood.  
Studies that look for regulatory elements near D1 are confounded by other proximal structural and 
functional sequences.  Presumably this would account for the high conservation of the D1 splice 
recognition sequences.  Perturbations of splicing at D1 activate cryptic sites (5, 116) and  prevent viral 
replication, but thus far credible sites of specific regulatory elements have not been published though the 
importance of the regional secondary structure is known (72, 77, 117-121). 
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 There are numerous SREs in and immediately downstream of the first small exon from A1 to D2.  
This exon is only 50 bases long, and such short exons are particularly likely to be skipped, possibly due 
to steric hindrance between the two portions of the spliceosome that must form on each end.  Such tiny 
exons may need additional enhancers to be included (29).  Three ESEs have been characterized 
between A1 and D2: ESEVif (122), and M1 and M2- repeats of the same enhancer sequence (123).  A 
GGGG sequence just downstream of D2 suppresses D2 use (122).  Additional elements have been found 
downstream of D2 that suppress splicing from a cryptic donor site (97, 124).  The strength of splice site 
D2 also controls splicing, and mutations that strengthen or weaken its ability to bind U1 snRNP increase 
or decrease recognition of the exon and thereby splicing to A1 (108, 125).  Attempts have been made to 
identify the SR and hnRNP binding proteins that bind HIV-1 SREs and confer splicing control.  ESEvif 
was found to bind SRp75, M1 and M2 bind ASF/SF2, but the binding protein for GGGG is not yet known.   
 The second small exon between A2 and D3 has an enhancer, ESEVpr (126-128) and a silencer 
ESSV.  ESSV binds the hnRNP A/B proteins and prevents binding of U2AF65 to the viral PPT, preventing 
U2AF65 from stabilizing the binding of U2 and initiating spliceosome formation (126, 129).  ESEVpr may 
bind the SR proteins Tra2 alpha/beta to support binding of U1 to D3 (128).  Another poly-G run called 
G13-2 just downstream of D3 suppresses D3 and thereby splicing to A2.  G13-2 binds hnRNP F/H and 
hnRNP A2/B1 (130), which is typical of G runs (131).   As with D2 and the first small exon, mutations that 
enhance or reduce D3 complementarity to U1 snRNP increase or reduce splicing to A2 and inclusion of 
the second small exon.  Mutations to ESSV or G13-2, or upregulation of D3 cause activation of splicing 
from D1 to A2 such that the number of unspliced transcripts is dramatically reduced.  This situation is 
known as oversplicing and has a severe fitness cost.  Interestingly, ESSV is not well conserved across 
HIV groups (127).  Although splicing branch points are almost invariably A residues, the branch point for 
A2 is a G.  This unusual branch point does not appear to make A2 a less effective acceptor (31). 
 Two SREs downstream of A3 have overlapping binding sites.  ESE2 binds SC35 and ESS2 binds 
hnRNP A1 (132) to either up or down regulate splicing to A3 (115, 133-135).  Both ESE2 and ESS2 are 
not immediately downstream of A3.  A second suppressor even more distal to A3, ESS2p, binds hnRNP 
H (136).  ESE2 and ESS2 are in a long stem-loop structure SLS3. NMR studies have shown that hnRNP 
A1 binds UAG triplets and forms a stable multimer on the SLS3 structure (137).  A3 is in the exon defined 
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by D4 and yet little is known about the interaction of these two sites on each other. Like the silencer 
ESSV that represses use of acceptor A2, ESS2 is also not well conserved across HIV groups (138). 
 A4 has 3 or 4 subsites (depending on the strain) named A4a, A4b, A4c, and A4d and A5 has two 
subsites, A5 and A5b.  All the A4 and A5 sites lie within a 45 base sequence and are alternative 
acceptors in the constitutive exon defined by D4 (see Figure 1.15).  A4a, A4b, A5 and A5b are within a 26 
base sequence.  They share some common regulatory sequences.  Their polypyrimidine tracts overlap 
and are short and interspersed with purines.  There are eight branch points in the A4/5 region and they 
may be used by more than one acceptor.  In the NL4-3 strain, the splice site A4b is also a branch point 
used by A5 (138, 139).   An enhancer named ESE GAR (GAR for guanine/adenine rich) is located just 
downstream of D4 and binds to SF2/ASF and/or SRp40 to activate splicing to A4 and A5 sites. The SR 
protein used may influence the acceptor site that gets defined (140, 141). D4 is the donor involved in the 
second splicing event – removal or retention of the env intron.  While binding of U1 does not always lead 
to splicing at D4, binding of U1 is necessary for the stability of the partially spliced env transcripts (140, 
142), similar to U1 binding in the gag-pro-pol gene region that confers stability to gag transcripts, also 
mediated by SF2/ASF (143).  E42 is the sequence between ESE GAR and D4.  It is required for D4 exon 
definition but the specific sequence elements are not yet defined.  In the partially spliced 4 kb transcript 
class, transcripts that splice to either an A4 or A5 acceptor make a vpu/env transcript.  All of the A4 and 
A5 transcripts support Env protein production, but only transcripts that splice to A5 are efficiently 
translated into Vpu.  The presence or absence of the small exons has no differential effect (144).   
 Although D4 is a strong donor, A7 is a weak acceptor and therefore it is A7 efficiency that 
determines removal or retention of the env intron (30, 113).  Optimizing the A7 splicing signal sequence 
activates D4-A7 splicing even if D4 is weakened (123). The region surrounding A7 is highly structured 
and contains three SREs that control splicing to A7.  The ISS, an intronic splicing silencer, is just 
upstream of A7 inside the env intron and overlaps with the A7 branch point (145-147).  An enhancer and 
silencer, ESE3 and ESS3, are immediately downstream of A7 and also have partial overlap (134).  ESS3 
is composed of two silencing elements – ESS3a and ESS3b (148).  SF2/ASF and hnRNP A1 control 
splicing by competitive binding to the ISS, ESE3 and ESS3 elements.  hnRNP A1 has been shown to 
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bind to the specific ESS3a/b and ISS sequences (147, 149) and cooperatively multimerize to prevent 
binding of SF2/ASF to ESE3 (74, 145, 146). 
Thesis Overview 
 Research is ongoing to correctly identify and characterize HIV-1 SREs, regions of regulatory RNA 
secondary structure, and the trans-acting SR and hnRNP factors that control splicing. This research 
requires methods to quantify splicing and splicing changes.  Previous work has used artificial sub-
genomic constructs to measure splicing.  These sub-genomic constructs are transfected or used in 
cellular extracts and analyzed using agarose gels or Northern blots.  As splicing and the effects of SREs 
are context and structure dependent (68), these artificial constructs, while useful in discovering SREs, 
may not accurately report their effects on splicing in the context of viral infection.   
 Chapter 2 describes a new deep sequencing assay I developed to quantify splicing in HIV-1.  It 
combines Primer ID technology with Illumina paired-end deep sequencing to tally the number of all the 
different splice types in each of the two HIV-1 transcript size classes. This assay was used to measure 
splicing changes caused by changes in temperature and mutation of a secondary structure.  Splicing was 
quantified in a panel of founder and transmitted viruses.  The assay was adapted to measure splicing in 
SIVmac239.  An additional set of programs was written to scan for cryptic splicing and trans-splicing was 
found.  These experiments demonstrate the utility of this splicing assay. 
 The project in Chapter 3 was done in collaboration with the Bieniasz lab at The Rockefeller 
University.  Blocks of synonymous mutations were made across the HIV-1 genome, some of which had 
serious replication defects.  My part in the collaboration was to characterize and quantify changes in 
splicing and to identify new donor and acceptor sites in the original mutations and compensating revertant 
mutants.  Previously unknown splicing control elements were discovered. 
 Chapter 4 is a collaboration with the Kutluay lab at Washington University and the Tolbert lab at 
Case Western University.  This paper presents a study of binding proteins and their effects on HIV-1 
splicing, with a particular emphasis on the role of hnRNP H1.  My contribution quantified the effects of 
cellular splicing factor knock downs and the effect of mutations to hnRNP H1 binding sites. 
 Chapter 5 is a genetic screen of mutations between A5 and D4 and their effects on splicing both 
to upstream acceptors and to downstream splicing from D4 to A7.     
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 Chapter 6 was done in collaboration with the Tolbert lab (Case Western University) and the 
Telesnitsky lab (University of Michigan).  This chapter describes a new random reverse primer and deep 
sequencing assay used to distinguish fully spliced, partially splice, and unspliced transcripts.  Mutations to 
a subset of known HIV-1 SREs were analyzed for splicing. 
 Chapter 7 summarizes the results of my splicing research and discusses directions for future 
research.  
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CHAPTER 2: CHARACTERIZING HIV-1 SPLICING USING NEXT GENERATION SEQUENCING1 
Overview 
 Full-length HIV-1 RNA serves as the genome or as an mRNA, or this RNA undergoes splicing 
using four donors and ten acceptors to create over 50 physiologically relevant transcripts in two size 
classes (1.8 kb and 4 kb).   We developed an assay using Primer ID-tagged deep sequencing to quantify 
HIV-1 splicing.  Using the NL4-3 lab strain we found that A5 (env/nef) is the most commonly used 
acceptor (about 50%) with A3 (tat) the least used (about 3%). Two small exons are made when a splice 
to acceptor A1 or A2 is followed by activation of donor D2 or D3, and the high-level use of D2 and D3 
dramatically reduces the amount of vif and vpr transcripts. We observed distinct patterns of temperature 
sensitivity of splicing to acceptors A1 and A2.  In addition, disruption of a conserved structure proximal to 
A1 caused a ten-fold reduction in all transcripts that utilized A1.  Analysis of a panel of subtype B 
transmitted/founder viruses showed that splicing patterns are conserved, but with surprising variability of 
usage.  A subtype C isolate was similar, while an SIV isolate showed significant differences.  We also 
observed trans-splicing from a downstream donor on one transcript to an upstream acceptor on a 
different transcript which we detected in 0.3% of 1.8 kb RNA reads.  There were several examples of 
splicing suppression when the env intron was retained in the 4 kb size class.  These results demonstrate 
the utility of this assay and identify new examples of HIV-1 splicing regulation. 
Importance 
 During HIV-1 replication over 50 conserved spliced RNA variants are generated. The splicing 
assay described here uses new developments in deep sequencing technology combined with Primer ID-
tagged cDNA primers to efficiently quantify HIV-1 splicing at a depth that allows even low frequency 
splice variants to be monitored.  We have used this assay to examine several features of HIV-1 splicing 
                                                     
1 This chapter was previously published in the Journal of Virology.  The original citation is as follows:  
Emery A, Zhou S, Pollom E, Swanstrom R. Characterizing HIV-1 Splicing by Using Next-Generation Sequencing. 
Journal of virology. 2017;91(6). Epub 2017/01/13. doi: 10.1128/jvi.02515-16. PubMed PMID: 28077653; PubMed 
Central PMCID: PMCPMC5331825. 
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and to identify new examples of different mechanisms of regulation of these splicing patterns.  This 
splicing assay can be used to explore in detail how HIV-1 splicing is regulated and, with moderate 
throughput, could be used to screen for structural elements, small molecules, and host factors that alter 
these relatively conserved splicing patterns.  
Introduction 
HIV-1 is a plus-stranded RNA virus that replicates through an obligatory integrated DNA 
intermediate.  The virus encodes 10 genes and uses several different strategies to allow expression of 
these genes, given that eukaryotes typically translate only the first open reading frame (ORF) of an 
mRNA.  Unspliced full-length transcripts code for the Gag and Gag-Pro-Pol polyproteins.  The remaining 
seven viral proteins are translated from over 50 mRNA variants generated by the host cell splicing 
machinery (1).  
 HIV-1 splicing has been extensively studied, and the splice variants and splice regulatory 
sequences are well characterized (2, 3), mostly using the laboratory strain NL4-3.  Approximately one-half 
of the initial full-length transcripts remain unspliced and serve as either genomic RNA or as mRNA for the 
Gag and Gag-Pro-Pol polyproteins (Figure 2.1).  The remaining half of the full-length transcripts are 
spliced (1).  All spliced RNAs use donor site 1 (D1) in the 5' noncoding region, and one of ten 
downstream acceptor sites (A1, A2, A3, A4a, A4b, A4c, A4d, A5, A5b, A7) (2, 4).   About half of the 
spliced RNAs also undergo further splicing to remove the D4 – A7 env intron (2).  These smaller RNAs 
are referred to as the completely spliced or 1.8 kb size class.  Spliced RNAs that retain the D4 – A7 intron 
are known as the incompletely spliced or 4 kb size class.  Completely spliced transcripts are exported 
from the nucleus using cellular pathways; however, the incompletely spliced and full-length transcripts 
require a viral protein, Rev, for nuclear export.  The D4-A7 intron contains the Rev binding sequence, the 
RRE (Rev Response Element).  With increasing concentrations of Rev the expression pattern is altered 
by allowing incompletely spliced RNAs to exit the nucleus (5, 6).  As a rule, the major splice products are 
produced from a direct splicing event between D1 and one of the acceptor sites (Figure 2.1).  The 
ensuing transcript is generally translated from the first ORF downstream of this direct splice junction.  
Thus D1-A1 splicing makes a vif transcript, D1-A2 a vpr transcript, and so on.  The fact that D1 is 
engaged as a splice donor in only a fraction of the full-length transcripts, that D1 splicing must singly 
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engage a number of different downstream splice acceptor sites, and that splicing of the D4-A7 intron is 
itself regulated all point to a highly orchestrated pattern of splicing to allow adequate expression of each 
of the viral proteins. 
 
Figure 2.1. HIV-1 Splice Patterns and Primer Locations.  
Blue = forward primer.  Red = 1.8 kb class Primer ID tagged reverse primer.  Green = 4 kb class Primer ID tagged 
reverse primer.  Grey boxes are small exons or sequences that may or may not be present in the respective 
transcripts.  Adapted from Purcell (2). 
 
 Even greater splicing complexity comes from the use of two additional donor sites, D2 and D3, 
that create two small exons, A1-D2 and A2-D3, one or both of which may be included in splice variants 
for the downstream genes (2).  The purpose of these small exons is unknown and they are present in 
only a small fraction of RNAs. They do not code for any known regulatory elements or alternative 
proteins, and mutations that prevent their use have shown contradictory results regarding fitness, 
transcript stability, and splicing effects (1, 7-10). Other studies have searched for regulatory sequence 
elements around the major splice acceptors, and different types of regulatory elements have been 
identified that control the utilization of splice sites (10-13).  Sequence elements outside of the specific 
splice site sequences bind cellular factors that enhance or suppress donor or acceptor usage, often in a 
concerted or competitive manner (14, 15).  Mutations in these elements have been reported to alter 
splicing (1, 2).  
The major splicing elements of HIV-1 subtypes B and C were originally defined using assays that 
require RT-PCR amplification of splice variants followed by cloning and sequencing of clones.  Another 
approach to assaying splicing has been to identify the RT-PCR products of the individual splice variants 
by size (2, 16).  Studies assessing the effects of control element mutations on splicing have often been 
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done using incomplete viral RNAs, such as single intron mini-genes, simplifying the analysis but placing 
splicing outside of the context of the entire viral genome.  More recently a deep sequencing approach 
used the PacBio platform with its long read capability to characterize HIV-1 splicing in extensive detail.  
This approach confirmed the previously described splice variants and discovered new ones (3).  
Here we report a new assay to analyze HIV-1 splicing based on the Illumina MiSeq deep 
sequencing platform.  We used the assay to quantify the splicing patterns within each mRNA size class in 
HIV-1NL4-3 infection and after transfection of an infectious clone. We quantified acceptor usage and the 
differential usage of minor splice donors D2 and D3 in the two mRNA size classes, one of several 
examples where splicing was differentially regulated between the two size classes. We observed that two 
silent mutations designed to disrupt a conserved element of secondary structure, SLSA1 (stem-loop 
containing splice acceptor A1), caused a 10-fold decrease in splicing to A1, linking this feature of 
secondary structure to regulation of A1 usage.  We examined the stability of splicing as a function of 
temperature and observed two distinct patterns of temperature sensitivity, with splicing to A2 increased at 
the lower temperature but inhibited at the higher temperature while splicing to A1 was just inhibited at the 
higher temperature.  We found the combined effects of the SLSA1 mutation and temperature were 
additive in their effects on A1.  We also examined the extent to which complex splicing patterns are 
conserved by assaying splicing in a panel of transmitted/founder viruses, which showed that most 
features of HIV-1 splicing are highly conserved, although examples of variability in the frequency of use 
were seen.  We adapted the assay to quantify splicing in a subtype C isolate and found high conservation 
compared to subtype B.  Analysis of splicing in an SIV isolate revealed many conserved features but also 
significant differences.  We detected trans-splicing between different transcripts and even between 
transcripts from different proviruses.  Collectively these results provide greatly enhanced quantification of 
splicing in the context of viral infection and offer new insights into HIV-1 splicing and its regulation. 
Materials and Methods 
Viruses 
A panel of full-length transmitted/founder (T/F) HIV-1 infectious molecular clones was obtained 
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Dr. John Kappes (17-20).  
Clones are identified by the last two digits of their identification number.  The infectious clone pNL4-3 was 
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obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Malcolm Martin 
(21), and the SLSA1 mutant virus was made as described in Pollom et al. (22).  Virus was produced by 
transfecting 293T cells using 4 µg of a viral DNA clone/well of a 6 well plate for the SLSA1 experiment 
and 1 µg/well for the T/F viruses, using FuGene (Promega) transfection reagent as per the FuGene 
protocol database.  At 48 hours after transfection, the medium was removed and filtered through a 45 µm 
filter, then frozen in aliquots at -80˚ C for later use.  pZM247Fv2 was obtained through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Beatrice Hahn (23).  A partial env deletion of 
this clone, pZM247v2∆env, was obtained from Dr. Sarah Joseph.  VSV G-pseudotyped pZM247v2∆env 
virus was produced by cotransfecting 293T cells with 5 µg each of the pZM247v2∆env plasmid and a 
VSV G expression plasmid in a T75 flask, as per the FuGene protocol database, and harvested and 
filtered as above.  A molecular clone of SIVmac239 was obtained from Dr. Ronald Desrosiers (24) and 
used to produce virus by transfection. 
Cells 
 CEMx174 cells were used for HIV-1 infections.  Cells were cultured in RPMI plus 10% fetal 
bovine serum (FBS) with added penicillin and streptomycin.  For the SLSA1 mutant/temperature gradient 
experiment, 2 x 106 cells were pelleted and resuspended in 800 µl of medium with either the SLSA1 or 
NL4-3 virus and incubated for 45 minutes, then brought to a total volume of 50ml of RPMI with FBS. The 
cells were then incubated at 37˚ C for 4 days, until syncytia were evident.  An aliquot of 10 ml of each 
culture (with cells) was put into each of 3 flasks and incubated for 6 hours at 33˚, 37˚, or 41˚ C, then the 
cells were harvested for RNA extraction.  The T/F virus molecular clones were transfected into 293T cells 
plated the day before at 5 x 105 cells/well of a six well plate.  Cells were harvested 48 hours post 
transfection for RNA extraction.  8E5 cells [8E5 cells were obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH, 8E5/LAV from Dr. Thomas Folks (25)], a clonal cell line producing 
virus from a single defective provirus, were super-infected with VSV G-pseudotyped subtype C 
pZM247v2∆env virus.  5 x 107 8E5 cells were pelleted and resuspended in 40 ml of medium with the 
pseudotyped virus and aliquots were harvested between 1 and 3 days post super-infection. 
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RNA extraction, cDNA synthesis, and Illumina MiSeq library preparation 
 Total cellular RNA was extracted using the RNeasy Plus Mini Kit (Qiagen), with the QIAshredder 
to homogenize cell lysates (Qiagen) and including 1% β-mercaptoethanol in the lysis buffer.  Primers 
used for cDNA synthesis for NL4-3 and 8E5 cells, the T/F strains, pZM247v2∆env, and SIVmac239 are 
shown in Tables 1 and 2.  All primers were resuspended at a concentration of 10 mM.  Indexed primers 
were obtained from Integrated DNA Technologies custom oligos, with hand mixing to optimize random 
base incorporation.  For the SLSA1 and temperature experiments, 2 µg of total cellular RNA from each 
sample was mixed with 1 µl of 10 mM dNTPs, 0.5 µl of the indicated reverse primer, and dH2O to 13 µl. 
The samples were heated to 65˚ C for 5 minutes, then held at 4˚ C.  To each tube was added 1 µl of 0.1 
M dithiothreitol, 1 µl RNaseOUT (ThermoFisher), 4 µl of 5x SuperScript III RT buffer, and 1 µl SuperScript 
III Reverse Transcriptase (ThermoFisher), then heated to 55˚ C for 1 hour followed by 70˚ C for 15 
minutes.  An aliquot of 1 µl Ribonuclease H (ThermoFisher) was added to each sample which was then 
incubated at 37˚ C for 20 minutes.  cDNA synthesis for the T/F virus samples and SIVmac239 was the 
same except 4 µg of total cellular RNA was used.  cDNA synthesis for the pZM247v2∆env-infected 8E5 
cells was done using two reverse primers for each size class, one specific to the 8E5 virus (the NL4-3 
primers) and one specific to the pZM247Fv2 virus.  cDNAs were purified and the Primer ID cDNA primer 
removed using Agencourt RNAClean XP beads (Beckman Coulter) as per protocol with a 2:1 ratio of 
beads to sample volume.  Illumina libraries for the SLSA1 mutant and temperature gradient samples, 
VSV G-pseudotyped pZM247v2∆env, and SIVmac239 were made using two successive rounds of PCR 
amplification.  For the first PCR, 1 µg cDNA template, 1 µl dNTPs, 2.5 µl ADPT_2a reverse primer, 2.5 µl 
idx_fp forward primer, 0.4 µl KAPA Robust Hot Start Polymerase (KAPA Biosystems), 7.5 % DMSO, 10 µl 
KAPA A Buffer, 10 µl KAPA Enhancer 1, and dH2O to 50 µl were combined and cycled with an initial 
denaturation at 95˚ C for 5 minutes, followed by 3 cycles each consisting of 95˚ for 30 seconds, 
progressively decreasing annealing temperatures of 64˚, 61˚, 58˚, 55˚, and 52˚ C for 15 seconds, and 72˚ 
C for 2 minutes, then 5 more cycles with an annealing temperature at 50 C.  The final extension was 72˚ 
C for 10 minutes.  PCR products were purified and primers removed using AMPure XP Beads (Beckman 
Coulter) as per protocol, using a 1.6:1 ratio of beads:PCR volume.  An aliquot of 3 µl of the cleaned 
product from this first PCR was used as template for the second PCR, added to 10 µl KAPA A buffer, 1 µl 
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dNTPs, 2.5 µl UniAdpt forward primer, 2.5 µl IllIndAdpt forward primer, 0.4 µl KAPA Robust Hot Start 
Polymerase, 5% DMSO, 10 µl KAPA Enhancer 1, and dH2O to 50 µl.  Cycling conditions were as for the 
first PCR but with annealing temperatures of 66˚, 63˚, and 60˚ C each for 3 cycles, followed by 25 cycles 
with an annealing temperature of 58˚ C.  "N"s in the IllIndAdpt forward primer are specific sequences that 
bar code each sample to allow multiplexing in the Illumina sequencing reaction.  PCR products were 
visualized on a 2% agarose gel, then cleaned as before using AMPure XP Beads.  T/F virus samples:  4 
µg of total cellular RNA was used as input to the cDNA reactions as described above.  cDNAs were 
forward tagged as follows.  An aliquot of 1 µg of purified cDNA, 0.5 µl forward primer lidx_fp_I (or the 
appropriate sample-specific forward primer), 1 µl dNTPs, and dH2O to 14.8 µl were heated to 75˚ C and 
then cooled in 1˚ C increments for 30 seconds until reaching 45˚ C.  To each sample was added 0.2 µl 
Phusion HF, 4 µl Phusion 5x buffer, and 1 µl DMSO.  Samples were then heated to 45˚ C and the 
temperature was increased in 1 degree increments every 10 seconds until reaching 72˚ C, where it was 
held for 10 minutes.  Following forward tagging, the samples were purified using DNA XP beads as 
described above but eluted in 23 µl.  An aliquot of 21.1 µl of the purified tagged forward strand was input 
into a second PCR as above, with the following cycle changes:  initial denaturation at 95˚ C for 5 minutes; 
then 3x each touchdown cycles using progressively cooler annealing temperatures – 95˚ C for 30 
seconds, annealing at 64˚, 61˚, 58˚, 55˚, and 52˚ C for 15 seconds, extension for 2 minutes at 72˚ C; then 
20 cycles with annealing temperature at 50˚ C; and a final extension at 72˚ C for 10 minutes.   
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Table 2.1. Primers Used in This Study. 
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Table 2.2. Primers Used for Each Sample. 
 
Sequencing 
 Libraries were mixed/multiplexed and sequenced using the 300 base paired-end read Illumina 
Miseq platform.  Reads were sorted using the Illumina bcl2fastq pipeline (v.1.8.4) to separate the 
multiplexed samples.  All samples were loaded at a concentration of 8 pM with 15 % PhiX double-
stranded DNA fragments to optimize cluster formation.  Sequencing data files are available in the SRA 
database, BioProject ID: PRJNA324601.  Because of quality control features that are intrinsic to each 
sequencing run, comparisons of relative abundance of spliced RNAs between samples are most reliably 
accomplished when the samples are multiplexed in the same sequencing run. 
Splicing analysis 
 Data analysis and splicing quantification were done using an in-house pipeline written in Ruby.  
Using the combined data from the forward and reverse reads, this program identifies the specific splice 
variant for each paired-end read and bins the reads by Primer ID to prevent skewing from PCR 
resampling.  The same sorting program was used for both the SLSA1 mutant and temperature gradient 
experiments.  Separate programs were adapted to the specific primers and sequence of each T/F virus, 
as well as for pZM247Fv2 and SIVmac239.  Rare alternative donor and acceptor splice sites were 
identified using a program that compares data reads to a reference sequence and identifies the base 
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where a splice discontinuity occurs and the base it splices to.  Specific rare acceptor site usage was 
quantified using a modification to the basic splicing identification program.  These programs are available 
at https://github.com/SwanstromLab/SPLICING. 
Results 
Description of a new splicing assay 
 We developed a new HIV-1 splicing assay that combines deep sequencing with the previously 
developed Primer ID technology (26). In this assay, total cellular RNA from infected or transfected cells is 
extracted and used in two different cDNA reactions, each one specific to the two different viral mRNA size 
classes (1.8 kb and 4 kb).  The 3' end of the cDNA primer used to capture the 4 kb size class of viral 
RNAs is placed near the 5’ end of the D4 – A7 env intron (Figure 2.1, shown in green).  This intron is 
removed from the 1.8 kb size class RNAs so this primer is specific for the 4 kb class.  The cDNA primer 
for the 1.8 kb class is shown in red.  The 3' end of this primer spans the D4 – A7 splice junction, which 
forms only in the 1.8 kb RNAs.  Each of the cDNA primers includes a common sequence at its 5' end that 
serves as the sequence of the reverse primer in PCR. The forward PCR primer, shown in blue, is 
upstream of D1 and is used in the PCR amplification of both size classes. 
The Primer ID portion of the cDNA primer is an internal random sequence tag in the primer that is 
used to identify and quantify individual viral RNA templates. The cDNA primers are synthesized with this 
internal random nucleotide sequence block.  This creates random combinations of primer tags.  Given a 
sufficient excess of random sequence tags relative to sample templates, any one viral RNA template will 
be primed with a unique random sequence in the cDNA primer that is then incorporated into the cDNA.  
The same sequence tag, present in the cDNA primer, will be present on all PCR products that come from 
this one viral RNA template.  The cDNAs are then PCR amplified, made into an Illumina library and 
sequenced using Miseq paired-end sequencing. Each sample produces millions of sequence reads.  In 
the Illumina paired-end method, each read contains approximately 300 bases starting from the forward 
primer, and similarly, a corresponding 300 base reverse sequence beginning with the Primer ID and 
reverse primer that is paired to the read from the other end.  The combined information from the paired-
end reads is sufficient to distinguish all splice variants except nef 1 (a direct splice from D1 to A7), which 
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lies outside of the primer range.  The inclusion of Illumina indexed linkers allows multiplexing of multiple 
samples in a single sequencing run. 
A sorting program first reads the forward sequence and identifies the donor and acceptor sites in 
the spliced RNA template, then does the same for the reverse read, and combines the information to give 
a pattern of splice junctions.  These patterns are sorted according to Primer ID.  All reads with the same 
Primer ID sequence are condensed into a single splice junction pattern and that pattern is matched to a 
known splice variant.  Regardless of the number of times a specific Primer ID sequence occurs in the 
sequencing output, each unique Primer ID tag is counted as a single observation of an mRNA molecule.  
For the reported experiments the sequencing depth typically ranged from 100,000 to 500,000 unique 
Primer IDs indicating this number of independent mRNA templates queried, allowing the accurate 
quantification of the normal viral spliced RNAs and the reliable detection of rare or cryptic events.  
Quantification of acceptor splice site usage in NL4-3 
 CEMx174 cells were infected with HIV-1NL4-3 and the cells grown in culture until syncytia formed, 
as evidence of a robust but asynchronous infection.  Total cellular RNA was extracted and used as input 
for the sequencing and quantification of spliced viral mRNAs.  An overview of the data is as follows. 
Essentially all spliced viral transcripts use D1 and splice to a downstream acceptor site. Although there 
are multiple A4 and A5 acceptors, they are grouped together (as A4 or A5) in the following figures.  
Relative usage of each acceptor for both size classes is shown in Figure 2.2A. The patterns are 
somewhat similar in both size classes, with env A5 as the most commonly used acceptor, and tat A3 the 
least used acceptor.  A previous study suggested HIV-1 splicing is sequential (27) and the relative 
proportions in each size class suggests that the choice of upstream splice acceptor site differentially 
influences downstream splicing (i.e. of the D4-A7 intron).  A transcript spliced from D1 to A1, A3, or A4 
has an increased probability of splicing from D4 to A7, and so being a 1.8 kb transcript.  In contrast, a 
splice between D1 and A2 does not affect the use of D4 and A7, while splicing from D1 to A5 skews 
toward suppressing the use of D4 and A7 thereby including the env intron (a 4 kb transcript). Thus the 
use of D4 and A7 appears to be differentially impacted by the choice of the upstream splice acceptor by 
D1.  
 
 44 
 
Figure 2.2 Quantification of HIV-1 Splicing Patterns.   
A) Acceptor usage from D1 in the two size classes.  Circles represent all transcripts in size class.  B) Circles 
represent the total splices from D1 to A1. Shown are proportions that splice again at D2 and those that remain vif 
transcripts. C) Circles represent the total splices to A2, and the proportions that splice again at D3 compared to those 
that remain vpr transcripts.  D) Circles represent all transcripts in size class.  Shown are proportions of transcripts that 
contain either one, both, or no small exons.  SX1 = small exon 1, SX2 = small exon 2. 
 
Splicing events from D1 to A1 or A2 initially make a vif or vpr mRNA, respectively.  However, a 
splice to A1 most often splices again by utilizing the nearby downstream donor D2 to create small exon 1 
(SX1), with D2 splicing to one of the other downstream acceptor sites, A2-A5 (Figure 2.2B).  Thus the 
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initial splicing to A1 results is a relatively low number of vif transcripts in both size classes, with the use of 
D2 reducing the potential number of vif transcripts by over 95%. 
 The splicing events from D1 to A2 have a different outcome in the two size classes with respect 
to the utilization of the adjacent D3 donor to generate small exon 2 (SX2) (Figure 2.2C).  In the 1.8 kb 
class, most A2 splices utilize D3 to create the small exon 2 by splicing to A3-5; however, in the 4 kb class, 
31% of splices to A2 remain as vpr transcripts.  This suggests that D3 usage affects downstream D4 
usage, such that the inclusion of small exon two (i.e. the use of D3) increases the probability of splicing 
from D4 to A7 with removal of the env intron.  Alternatively, the same mechanism that suppresses D4 
utilization to create the 4 kb env mRNA may also suppress utilization of D3.  
Transcripts with either or both small exons are present at twice the frequency in 1.8 kb transcripts 
compared to 4 kb transcripts (Figure 2.2D), an observation that is partially driven by the disproportionate 
inclusion of small exon 2 in the 1.8 kb mRNAs (Figure 2.2C), but primarily driven by the increased use of 
A1 (and the small exon from A1-D2) in the 1.8kb mRNAs (Figure 2.2A and 2.2B).  This suggests that 
inclusion of small exons up-regulates splicing from D4-A7.  It is curious that in the vast majority of cases, 
splicing to A1/vif and A2/vpr are followed by subsequent splicing at D2 and D3, respectively; however, the 
majority of the A3-A5 transcripts are the result of a direct splice from D1 and do not include the small 
exons (Figure 2.2D). This suggests that the main function of D2 and D3 are to down regulate the 
expression of vif and vpr beyond what can be accomplished through differential splicing among the splice 
acceptor sites.  The high frequency use of D2 and D3 would also be expected in exon definition 
(discussed below), however this highlights the unexpected difference in D3 use between the size classes.  
In this analysis we have likely underestimated A1 and A2 usage due to differences in the length of cDNA 
product needed to see splicing to the proximal splice acceptor sites A3-A5 (within 300 nucleotides) 
compared the distance from the cDNA primer to A1 (1100 nucleotides); however, the use of Primer ID 
corrects for any subsequent skewing in amplification efficiency of longer versus shorter PCR products. 
Differential effects of temperature on splicing 
HIV-1 splicing must function through the presence of sub-optimal splice donor and acceptor sites 
to allow for a vast array of splicing outcomes.  Inefficient pairing of these sub-optimal sites with the 
cellular splicing machinery has been shown to affect donor and acceptor usage (10, 15, 28-30).  We 
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reasoned that some of these interactions with the cellular splicing machinery could be temperature 
sensitive.  Temperature changes might also affect the stability of RNA secondary structures that work in 
cis to regulate splicing.  To test the effects of temperature, a culture of CEMx174 cells infected with HIV-
1NL4-3 was split into 3 flasks that were then incubated for 6 hours at 33, 37, or 41 C.  At the end of 6 
hours RNA was extracted from the cells and the viral splice products were measured (Figure 2.3).  In 
general, increasing temperature modestly up-regulated splice variants without small exons 1 or 2.  
However, splice acceptors A1 and A2 were sensitive to temperature and showed different responses to 
temperature changes.  Splicing to A1 decreased with increasing temperature, and this was seen for both 
the vif transcript and all transcripts that include SX1 defined by A1 and D2 usage.  Similarly, all splices to 
A2 also decreased with increasing temperature, but were additionally significantly up-regulated at lower 
temperature, including vpr transcripts and transcripts including SX2 between A2 and D3.  Transcripts that 
use both A1 and A2 showed the more dominant effect of A2 alone.  Thus we see distinctive temperature 
sensitivities of the splice acceptor sites with the most sensitive being the sites associated with the 
generation of the small exons.   
 
 
Figure 2.3. Temperature Dependent Splicing Regulation.   
Cells were infected with the NL4-3 strain of HIV-1 and after several days the culture was divided and place at the 
indicated temperatures for the last 6 hours.  Whole cell RNA was extracted and viral RNA assessed for splicing.  The 
histogram shows the ratio of the percentage of each 1.8 kb transcript type relative to the 37o sample (always at a 1:1 
ratio with itself). Splice variants are grouped by direct splice to final acceptor or small exon inclusion.  Stars indicate 
splices to A1 that make vif transcripts or to A2 that make vpr.    X-axis labels show the splice donors and acceptors 
used and the protein product of the transcript.   
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Changes in secondary structure can affect splicing 
HIV-1 RNA has regions of highly conserved secondary structure and many of these structures 
have functional relevance (22, 28, 29, 31-35).  These include the TAR binding site in the 5’ UTR which 
binds the viral Tat protein and is required for processive transcriptional elongation (36). The major splice 
donor D1 is also in this region as well as a structure that regulates genome packaging (32), and the 
dimerization sequence.  The Rev Response (binding) Element, RRE, located in the env intron, also has 
features of highly conserved secondary structure (37).  Some splicing elements are contained in, or are in 
close proximity to, conserved structural elements, and some of these structures are well characterized 
(22, 28, 30, 34).  This raises important questions about the role of RNA structural elements in controlling 
splicing during viral infection, and the importance of such structures for correct splicing.  
A previous comparison of RNA secondary structure between HIV-1 NL4-3 and SIVmac239 
revealed regions of highly conserved structure (22) one of which was a stem-loop structure termed 
SLSA1 that contains the vif splice acceptor site A1 in the loop. We previously engineered two silent point 
mutations to disrupt the SLSA1 stem without changing the A1 splice acceptor sequence or nearby 
reported splice regulatory sequences and noted a change in downstream splicing using an older, PCR 
product size-based assay (22). We have re-evaluated this mutant with the new deep sequencing assay 
and confirm an effect on splicing but can now identify it as an effect on the proximal vif A1 splice acceptor 
site.  RNA from CEMx174 cells infected with the SLSA1 mutant virus was processed in parallel with the 
RNA from cells infected with the wild-type/parental NL4-3 strain.  These two point mutations resulted in an 
approximately 10-fold decrease in the utilization of A1 relative to the control, which was reflected in the 
decrease of the direct splice to create vif mRNA and in RNAs containing the first small exon from A1 to 
D2 (Figure 2.4).  Thus the conserved SLSA1 stem loop structure containing the A1 splice site plays an 
important role in regulating the utilization of that site. 
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Figure 2.4. Effect of SLSA1 Structural Mutations on Splicing.   
Y-axis is a log scale of the fold change of splice type abundance of SLSA1 mutant relative to WT NL4-3. X-axis 
shows the pattern of splice donors and acceptors and the transcript type in the 4 kb and 1.8 kb class with that pattern.  
A missing bar indicates that splice type did not occur in the SLSA1 mutant. 
 
Combined effects of temperature and structure 
 We next reasoned that the temperature sensitivity of A1 might be related to the melting of the 
proximal conserved stem-loop structure (SLSA1).  This would predict that the SLSA1 mutant would not be 
temperature sensitive for splicing to A1.  To test this we compared splicing across the temperature range 
in the SLSA1 mutant to WT NL4-3, using the same strategy as in the temperature gradient experiment.  
We saw that the effects of temperature and the SLSA1 mutations were additive when compared to the 
wild type virus at 37 C, reducing splicing to A1 to very low levels (Figure 2.5A).  When we focused on the 
effect of the different temperatures within the context of reduced splicing of the SLSA1 mutant we saw 
that the pattern of increases and decreases of splice site usage as a function of temperature were the 
same as seen with wild type virus (Figure 2.5B).  This suggests that there are two separate mechanisms 
giving rise to the SLSA1 and temperature sensitive phenotypes for splicing to A1.  We have also noted 
enhanced accumulation of APOBEC3 G/F mutations in the deep sequencing data set with the SLSA1 
mutant, consistent with reduced vif mRNA resulting in reduced levels of Vif (data not shown). 
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Figure 2.5. Combined Effects of Temperature and SLSA1 Mutation.  
A) The histogram shows the ratio of the percentage of each 1.8 kb transcript that utilizes A1 relative to the 37˚C WT 
sample.  B)  Ratio of the percentage of all 1.8 kb transcripts from SLSA1 mutant samples relative to 37˚ C SLSA1 
mutant sample. 
 
Splicing in transfected cells 
 The comparison between the SLSA1 mutant and WT NL4-3 was repeated using transfected 293T 
cells, and essentially identical splicing patterns were observed (data not shown). This and other 
experiments showed that the splicing quantification assay for HIV-1 gives similar results in comparing 
asynchronous viral replication in CEMx174 cells or after transfection of 293T cells.  Performing the assay 
in transfected cells has the potential to allow splicing analysis of mutant viral genomes that are incapable 
of infection and replication in a permissive cell line.  
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Comparison of splicing in transmitted/founder viruses 
Most HIV-1 splicing studies have used the NL4-3 strain, a subtype B chimeric virus and a 
laboratory strain (21).  We asked if splicing in HIV-1NL4-3 is representative of splicing in clinical isolates, 
and if conserved splicing is critical for infection and spread of HIV-1.  To address these questions we 
analyzed splicing in a panel of subtype B T/F viruses (17-20).  We found that overall splicing patterns 
were similar among all of the isolates in that the same splice site acceptors and donors were used, 
including for the small exons, but with examples of surprising ranges of variability.  In these analyses we 
used values obtained from three different experiments with the NL4-3 strain to account for experimental 
variability. 
 The range of A1 usage in the T/F viruses is comparable to NL4-3, while splicing from D1 to A2 
varies from near zero to about sixty percent of total transcripts (Figure 2.6A). D2 and D3 are utilized in 
proportions comparable to NL4-3, and in percentages that correlate closely with the use of upstream A1 
or A2.  Thus the high frequency use of D3 results in most of the high A2 utilization turning into 
downstream transcripts, with the level of residual vpr transcripts showing only modest variability in spite of 
the variability in the use of A2 (Figure 2.6B). 
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Figure 2.6. Splicing in Transmitted/Founder Viruses.  
A) Ranges of A1, A2, and small exon usage in eight transmitted/founder viruses compared to NL4-3. SX1 = small 
exon 1, SX2 = small exon 2.   NL4-3 samples are from three separate experiments, the red dot indicates the sample 
run in the transmitted/founder experiment.  Results shown are for 1.8 kb transcripts.  Red arrow indicates sample 
#42, which has a mutated D3 sequence.  B) vpr transcripts in transmitted/founder C-E) Usage of A3, A5, and A4 
variants in transmitted/founder virus, 1.8 kb transcript class. 
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 One isolate, sample 42 indicated by the red arrow in Figure 2.6A, has a G-to-A transition at the 
donor site D3 that disrupts the donor consensus sequence. It would be expected that with the knockdown 
of D3 usage, transcripts spliced to A2 would accumulate resulting in increased vpr transcripts and very 
few transcripts with small exon 2.  However, this was not the case.  The change to D3 corresponded with 
greatly decreased splicing to A2 (Figure 2.6A).  There are no obvious sequence changes in this virus that 
would explain reduced use of A2.  This suggests either that there is a connection between the recognition 
of D3 as a splice donor and the use of A2 as a splice acceptor, as predicted by the concept of exon 
definition, or that some unrecognized sequence change has independently down regulated A2 use in this 
isolate.  Thus in spite of a mutated D3 site and low usage of A2 in this virus, vpr transcript levels are near 
a normal level (Figure 2.6B). 
 Splicing to A3/tat spanned a range from less than 1% to greater than 11% (Figure 2.6C). There 
are four A4 splice acceptors, named A4a to A4d (Figure 2.6D).  There was greater variety in A4 usage 
than in any other acceptor, and different viruses showed different A4 splice site preferences.  There was 
also a higher degree of sequence variability around these acceptors.  The differences in use were partly 
compensatory in that total A4 usage varied only around 3-fold while the use of any one site varied up to 
10-fold.  The relative usage of the two A5 acceptors (A5 much greater than A5b) was similar between the 
different strains, with A5 always being the predominant splice acceptor but varying from less than 60% to 
more than 80% (Figure 2.6E). Thus the relative amounts of the mRNAs for the different viral proteins 
were generally similar, with the RNAs for Tat and Rev showing the greatest variability.  These results 
confirm that there is a core set of just over 50 major spliced RNA products that define the conserved HIV-
1 RNA expression program. 
Detection of cryptic/rare splicing events 
 While the main donor and acceptor sites are well defined, we identified mis-splicing, particularly 
to the nearby bases around all of the major donor and acceptor sites.  In addition, there was a low-level 
background of rarely used acceptor sites across the genome, interspersed with hotspots. It has been 
reported previously that blocking a canonical splice acceptor or donor site leads to activation of cryptic 
sites (2, 38, 39).  While we did not test this phenomenon directly, we will note that the virus with the 
defective D3 donor site (sample 42) did not activate a substitute donor site for D3 or an alternative 
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acceptor for A2.  Even the T/F viruses in the extremes of low or high acceptor usage did not activate 
significant cryptic donor or acceptor sites.  A scan for rarely used acceptor sites in all of the T/F viruses 
identified sites used at various frequencies, and the proportion of proximal alternative acceptor sites 
compared to use of the canonical acceptor sites for the each of the transcripts for viral proteins are shown 
in Figure 2.7.  Rare acceptors within the normally unspliced gag/pro/pol (GPP) sequence were also 
compared to total transcripts.  Transcripts with rare splice sites made up a very small proportion (less 
than 1%) of total transcripts in both NL4-3 and in this panel of T/F viruses.  
 
Figure 2.7. Cryptic Acceptor Usage as a Percentage of Major Acceptor Usage in 
Transmitted/Founder Viruses and NL4-3.  
Transcripts with cryptic acceptor sites are shown as a percentage of non-cryptic transcripts using the comparable 
major acceptor site with the same open reading frame.  Cryptic acceptors in the gag/pro/pol (GPP) sequence are 
compared to total transcripts.   
 
 An unusual set of rare splicing events was observed in both HIV-1NL4-3 and all T/F viruses in 
which the apparent order of splicing was reversed.  Splicing from D2 to A1 and from D3 to A1 or A2 was 
observed, as well as from D4 to all upstream acceptors. This out-of-order acceptor use suggests trans-
splicing, where a donor from one transcript splices to an acceptor in a different transcript.  In the 1.8 kb 
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size class of the NL4-3 isolate, trans-splicing to A1 made up 0.006% of total transcripts, and 0.3% of all 
reads had a D4 trans-splice to an upstream acceptor.  Acceptor usage in these D4 trans-splices was 
similar to acceptor usage from D1, as shown in Figure 2.2A.  In these cases the region between A5 and 
D4 becomes yet another small exon.  These additional small exons skew towards the 1.8 kb transcript 
class, at a frequency six times greater than that of the 4 kb transcripts for trans-splices from D2 or D3 to 
A1, and three times greater for trans-splices from D4.  Remarkably, consecutive trans-splicing events can 
also be detected in rare transcripts such as D4 to A2 followed by D3 to A2. 
It has been observed that reverse transcriptase and/or PCR template switching can create trans-
splicing artifacts between regions of sequence identity (40, 41).  We do not believe this is the cause of the 
trans-splices we have observed between these canonical splice sites.  We looked for evidence of 
artifactual apparent trans-splicing.  There are regions of exact identity to portions of several canonical 
acceptor and donor sites in some of the T/F viruses.  Isolates 43 and 47 have a duplicate post-A1 
sequence 166 nucleotides upstream of the actual A1 site.  In addition, isolate 42 has a duplicate pre-D2 
sequence 24 nucleotides upstream.  All have 10 nucleotides of exact sequence identity and yet they were 
never found in combination with a canonical splice donor or acceptor.  Thus the trans-splicing is linked to 
the functional donor and acceptor sites and not regions sharing sequence identity with these sites.  
Additionally, we reasoned that if template switching were random in regions of sequence similarity, we 
should see a high proportion of other random events near the trans-spliced sites; however, when we 
scanned for nearby trans-splices we found none.  Taken together, this leads us to conclude that the 
trans-splicing we observed is not artifactual but rather a measure of errors in splicing by the host cell 
machinery. 
 We asked if trans-splicing occurs only in cis, i.e. between transcripts in close proximity as they 
are consecutively transcribed from a single provirus, or if it could occur in trans between transcripts from 
proviruses at different integration sites.  To address this question we pseudotyped HIV-1 subtype C ∆env 
particles with the VSV G envelope protein and used this virus to infect 8E5 cells.  8E5 cells have a single 
stably integrated HIV-1 subtype B genome.  8E5 and the subtype C virus generated from pZM247Fv2 
have sequence dissimilarities that can identify a change from a donor of one viral RNA to an acceptor of 
another viral RNA.  We harvested total cellular RNA from the dually infected 8E5 cells and used it in the 
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splicing assay, with forward and reverse primers specific for 8E5 and pZM247Fv2.  Our results found 
trans-splicing from both the 8E5 virus to the pZM247Fv2 virus and vice versa, suggesting that trans-trans-
splicing between transcripts from different proviruses is possible. 
Splicing in subtype C 
 We adapted the assay to quantify splicing in this subtype C strain and found that splicing for virus 
generated from the pZM247Fv2 clone is very similar to virus generated from the pNL4-3 clone (subtype 
B).  Donor and acceptor sites were precisely conserved.  The relative abundance of splice acceptor 
usage is also very similar (Figure 2.8) as is usage of the small exons.  The splicing differences seen 
between the 4 kb and 1.8 kb sizes in NL4-3 are also seen in pZM247Fv2.  A previous study found high 
variation in A4 splice site usage among subtypes and samples (16, 42).  In this single sample, we did not 
see any new splice site usage, although the pZM247Fv2 sequence has a point mutation that completely 
inactivates A4d.   
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Figure 2.8. Quantification of Splicing in Subtype C Strain pZM247Fv2.  
A) Acceptor usage from D1 in the two size classes.  Circles represent all transcripts in size class.  B) Circles 
represent the total splices from D1 to A1. Shown are proportions that splice again at D2 and those that remain vif 
transcripts. C) Circles represent the total splices to A2, and the proportions that splice again at D3 compared to those 
that remain vpr transcripts.  D) Circles represent all transcripts in size class.  Shown are proportions of transcripts that 
contain either one, both, or no small exons.  SX1 = small exon 1, SX2 = small exon 2.   
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Splicing quantification in in SIVmac239 
We next adapted the assay to quantify splicing in SIVmac239.  SIVmac239 has a more 
complicated splicing pattern than HIV-1 (Figure 2.9).  Though generally very similar to HIV-1, SIVmac239 
includes an expanded 5’ untranslated region (UTR) with an optional intron upstream of D1, here called 
small exon 0 (SX0).  We began by using a random reverse primer to find the splice junctions, then 
designed primers that would pick up the 1.8 and 4 kb size class equivalents, as in the HIV-1 assay.  Like 
the HIV-1 assay, the SIVmac239 assay uses Primer ID-tagged reverse primers specific to each size class 
and a forward primer 5’ of D1, which is also the major splice donor.  Additionally, a second forward primer 
5’ of D0 was used in separate reactions with each reverse primer to quantify splicing from D0. 
 
Figure 2.9. SIVmac239 Splice Patterns and Primer Locations.  
Light Blue = D0 forward primer. Blue = D1 forward primer.  Red = 1.8 kb class Primer ID tagged reverse primer.  
Green = 4 kb class Primer ID tagged reverse primer.  Grey boxes are small exons or sequences that may or may not 
be present in the respective transcripts.  Not drawn to scale but relative locations are correct. 
 
 Most SIVmac239 acceptors and donors align with and act analogously to HIV-1 acceptors and 
donors (Figure 2.10).  Relative acceptor usage is mostly similar to HIV-1, except that in SIVmac239 A5 
was used even more frequently in both size classes, such that most spliced transcripts use A5 as the final 
acceptor, whether by direct splicing from D1 or by including the small exons (Figure 2.10B). 
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Figure 2.10. Quantification of Splicing in SIVmac239.  
A) Acceptor usage from D0 in the two size classes.  Yellow represents the proportion of transcripts that splice from 
D0 to A0, black represents the proportion of transcripts that splice directly from D0 to an acceptor other than A0, 
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orange represents the transcripts that do not splice from D0 to A0.  B) Acceptor usage from D1 in the two size 
classes.  Circles represent all transcripts in size class.  C) Circles represent the total splices from D1 to A1. Shown 
are proportions that splice again at D2 and those that remain vif transcripts. D) Circles represent the total splices to 
A2, and the proportions that splice again at D3 compared to those that remain vpx transcripts.  E)  Circles represent 
the total splices to A6411.  Shown are proportions that splice again at D6551 compared to those that remain vpr 
transcripts.  F) Circles represent all transcripts in size class.  Shown are proportions of transcripts that contain any 
small exons compared to those that splice directly to the final acceptor. 
 
 The two small exons, SX1 and SX2 are conserved, though in SIVmac239 additional donors and 
acceptors create a third small exon (called here SX3) due to the presence of the extra gene vpx.  Two of 
these small exons overlap with SX1 (using A1 and either D2 or a donor at 5514) and SX2 (using either A2 
or an acceptor at 6018 and D3).  The third small exon spans 6411 to 6551.  Thus an SIVmac239 
transcript can have up to three of these small exons, and all possible combinations of the three small 
exons are observed.  In SIVmac239, A2 (and SX2) are linked to vpx, a gene not present in HIV-1 and 
placed between vif and vpr.  An additional splice acceptor site, A6411, is used to make vpr transcripts 
and this splicing event activates D6551 to make SX3.  In both SIVmac239 and HIV-1 a greater fraction of 
splices to the vpr acceptor remain as vpr transcripts in the 4 kb class, while in the 1.8 kb size class use of 
A6411 more often activates D6551 to make SX3; however, in contrast to the high use of D3 to make SX2 
in HIV-1, in SIVmac239 SX3 is seldom made even in the 1.8 kb class – most splices to A6411 remain vpr 
transcripts (compare Figure 2.10E and Figure 2.2C).  It is worth noting that splicing to vpx is similar to the 
upstream vif and not the downstream vpr in the high use of the proximal donor site (D3) in both size 
classes leaving little vpx mRNA (Figure 2.10C, D). 
 There is no splicing analog to SX0 in HIV-1. In contrast to the creation of the small exons SX1 
and SX2, which are generated after splicing to A1 or A2 followed by splicing from D2 and D3 
(respectively), inclusion of SX0 results from not splicing.  Quantification using the primer upstream of D0 
shows that the 85 nucleotide long D0-A0 intron is retained in most transcripts – 73.6 % in the 1.8 kb class 
and 84.6 % in the 4 kb class (Figure 2.10A).  Although D0 can splice to acceptors other than A0 it only 
rarely does so (0.51 % in the 1.8 kb class, 0.075% in the 4 kb class).  This suggests that activation of D0, 
unlike D1, is tightly coupled to the use of the proximal splice acceptor A0. 
 There are some quantification limitations in the SIVmac239 splicing assay due to the limited read 
length using the MiSeq platform. Although quantification of splicing from D1 is similar in HIV-1 and 
SIVmac239 with most splice variants identifiable, the increased length of SIVmac239 between donors 
and acceptors makes some spliced variants too long to fully catalog, so some long transcripts (A3 with 
 60 
small exons) are grouped together.  Measuring splicing from D0 has additional limitations in that the 
length of the forward read just reaches to D1, so all splicing from D1 must be quantified in the reverse 
read and this is not sufficient to separate splices from D1 to A1, A2, and A3.  Spliced RNAs quantified 
from D0 must either splice from D0 directly to some downstream acceptor other than A0 or must also 
splice at D1 to be short enough to be sequenced.  It is possible that there are transcripts that splice from 
D0 to A0 but then remain full-length downstream, an RNA variant that would not be detected using the 
current approach. 
Discussion 
 We have developed a new HIV-1 splicing assay that utilizes the MiSeq deep sequencing platform 
and Primer ID technology to efficiently and accurately quantify HIV-1 splicing.  The depth of sequencing 
data combined with template indexing (Primer ID) make it possible to identify and quantify even low 
abundance variants.  This assay is unique in its ability to simultaneously quantify multiple splicing events 
in HIV-1 RNA transcripts in the context of viral infection with a total of just three primers.  It is noteworthy 
that this assay also works in transfected 293T cells, allowing quantification of mutated viral genomes that 
are incapable of productive infection.  The assay has been used to measure splicing in infected primary T 
cells and dendritic cells, and the results were comparable to the splicing seen in CEMx174 cells (C. Miller, 
R. Gummuluru, A.E., R.S. in preparation), validating the cell line model.   This is a moderate throughput 
assay – 24 samples can be multiplexed in a single deep sequencing reaction – that will allow it to be used 
to screen and compare the activity of mutations or compounds for their effects on splicing. 
 It is useful to compare this new assay using the MiSeq platform to previously described assays.  
Given the complexity of HIV-1 splicing we will limit this comparison to assays that are capable of 
capturing most of that complexity, specifically the original RT-PCR/gel sizing assay of Purcell and Martin 
(2), and the more recent use of the PacBio next gen sequencing platform described by Bushman and 
colleagues (3).  While the RT-PCR/gel sizing assay is the simplest it relies on size for the identification of 
the splicing events, some of which can co-migrate, and has limited sensitivity to detect minor variants.  
Also, the number of mRNA templates queried is not known making the procedure prone to PCR skewing.  
For these reasons, next gen sequencing platforms offer the opportunity to capture much more information 
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about splicing and represent a natural evolution where new technology allows re-examination of 
longstanding questions to gain a greater depth of understanding.  
 The MiSeq assay and the PacBio assay share the features of an initial cDNA synthesis reaction 
followed by amplification and sequence analysis.  MiSeq sequencing is sufficiently accurate to allow the 
use of Primer ID which allows correction for PCR skewing and quantifies the number of mRNA templates 
actually sequenced.  PacBio is not yet amenable to Primer ID due to its higher level of error and therefore 
it is necessary to do end-point dilution PCR of isolated templates (in droplets) to avoid PCR skewing but 
this system cannot account for the number of mRNA templates that are sequenced which results in PCR 
resampling during sequencing.  Both systems suffer from the low processivity of RT which results in an 
under-estimation of splicing events that are detected based on a longer cDNA; in our assay cDNA 
products range from about 300 to 1100 nucleotides.  We have focused our assay on the large majority of 
splicing events which we detected with just three primers; the PacBio assay included the use of more 
primers which included the detection of an unusual 1 kb size class of spliced RNAs (discussed below).  
Within the individual 1.8 and 4 kb size classes, relative transcript abundance is similar in both 
assays but both assays share two important weaknesses - the inability to quantify the 1.8 kb transcript 
class relative to the 4 kb transcript class, or to quantify spliced transcripts versus unspliced transcripts. 
Size class quantification is a complicated problem as there are no sequences in the 4 kb class of 
transcripts that are not also present in either the 1.8 kb class and/or unspliced transcripts.  Given the 
inherent, but different, limitations of the MiSeq and PacBio platforms it has been necessary to add a 
complementary assay to each data set to obtain a more complete view of viral populations.  The PacBio 
approach has been linked to an RNAseq data set where oligo dT-primed cDNAs of whole-cell RNA are 
analyzed by short reads over their entire length (3, 43). A feature of using RNAseq is that the lack of 
processivity in the cDNA synthesis step by reverse transcriptase requires a correction of observed to 
calculated frequency of the longer cDNAs (up to 9 kb) making it difficult to measure small differences with 
confidence.  To complement the use of the MiSeq platform we have explored the use of a random cDNA 
primer linked to amplification with the same upstream primer just 5' to D1.  This allows a comparison of all 
transcripts, spliced or unspliced.  In this analysis we estimate that about 22% of the spliced transcripts are 
in the 1.8 kb size class with 78% in the 4 kb size class (unpublished observation).  Estimation of the ratio 
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of unspliced to spliced viral RNA appears to be confounded in this system by abortive or incompletely 
transcribed and processed reads (44, 45), giving a higher-than-expected size of the unspliced population.  
It is likely that the estimation of the ratio of different size classes and spliced to unspliced will be sensitive 
to the bias of whatever method is used in which case it will be important to compare several methods or 
to focus on the use a sensitive and reproducible method that allows the detection of differences as 
experimental conditions are changed. 
In its current form the MiSeq assay relies on just three primers; we have chosen not to include 
another primer to detect either the direct splice from D1 to A7/nef or to look for the 1 kb spliced RNA size 
class, although additional primers could be included to capture these events.  Regarding direct splicing 
from D1 to A7/nef, these are splicing events that are part of the canonical splicing program but that occur 
at a low percentage. Our data using the random reverse primer suggests that D1 to A7 splices represent 
only about 0.4 percent of all spliced transcripts.  Therefore, we conclude that while not exhaustively 
inclusive, this new MiSeq assay captures virtually all essential canonical splicing events and can be used 
to sensitively measure changes in splicing. 
Similarly, we have chosen not to use an additional primer to probe for the 1 kb spliced RNA.  
These smaller RNAs have been previously described (46, 47) and were seen with the HIV-189.6 isolate but 
generally thought not to be conserved among isolates (3).  We did not detect similar spliced RNAs in 
either the NL4-3 isolate or in the SIVmac239 isolate using the random reverse primer approach.  For this 
reason we have chosen not to include another primer (which would require a separate amplification) to 
detect what appear to be poorly conserved splicing events outside of the canonical splicing program.  
However, the existence of the previously uncharacterized 1 kb RNAs does suggest that using an 
approach like the random reverse primers with the transmitted/founder virus set of isolates would allow a 
more systematic examination of the question of any as yet undetected conserved splicing events, which 
must exist at a low level if at all.   
 Using our assay we quantified splicing patterns in the NL4-3 laboratory strain and observed that 
usage of splice acceptors A1 and A2 is temperature sensitive.  We linked a specific RNA secondary 
structure, SLSA1, to the efficiency of splicing at its proximal acceptor site (A1).  Finally, we used this new 
assay to analyze splicing in a panel of subtype B transmitted/founder viruses, a subtype C isolate, and an 
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SIVmac isolate, and found that splice donor and acceptor sites are well conserved, though frequency of 
use varied.  Following we discuss observations and issues raised given these very precise measures, 
based not on the total number of sequence reads but rather on the actual number of mRNA templates 
sequenced, of relative splice site usage. 
 We quantified splice acceptor site usage in NL4-3 and found that of the two small exons made by 
using D2 or D3, D2 usage was consistent in both transcript size classes but D3 (D6551 in SIVmac239) 
was not – in the 1.8 kb size class most splices to A2 activate splicing from the adjacent D3, but in the 4 kb 
size class about half of the D1-A2 spliced RNAs remain as vpr transcripts without activating D3 (Figure 
2.2).   In contrast splicing to A1/vif activates D2 most of the time in both RNA size classes.  This suggests 
a link between D3 usage and downstream D4 usage, which has not yet been explored.  This difference is 
even greater in SIVmac239 where splicing to A2/vpx activates D3 in both size classes similar to what 
happens with splicing to A1/vif, but splicing to the new downstream A6411/vpr acceptor activates the 
adjacent D6551 donor in only a minority of cases and hardly at all in the 4 kb size class.  Thus there is a 
strong gradient effect of linked donor activation across the center of the viral RNA.  Nonsense mediated 
decay (48) could play a role in degrading 1.8 kb vpr transcripts thus leaving mostly 4 kb vpr transcripts, 
but this raises the question of why the same rules don't apply to 1.8 kb and 4 kb vif and vpx transcripts.  
Alternatively, the mechanism that suppresses splicing from D4 (allowing the formation of the 4 kb size 
class) may also influence the use of the proximal upstream donor site in both HIV-1 and SIV.  There are 
several other examples where splicing is differentially suppressed in the 4 kb size class that support this 
notion (see below). 
 The purpose of the conserved small exons remains to be clearly elucidated.  They are conserved 
across subtypes and in SIVmac239 (including for the additional vpx gene) (49, 50) (Figure 2.1 and 2.9), 
as well as in the T/F viruses analyzed (Figure 2.6), consistent with strong selective pressure for their 
presence.  Previously cited studies to define their functional importance are, as mentioned, inconclusive 
(1, 6-9).  It is not clear whether donors D2 and D3 exist to down-regulate the amount of vif and vpr 
mRNAs or if D2 and D3 are required for exon definition (51) to activate A1 and A2 respectively.  The 
transmitted/founder virus isolate 42 with the mutant D3 argues for exon definition, i.e. knockdown of D3 
reduced A2 usage, a result that has also seen in model systems (10, 14, 52); however, in another study 
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with a different HIV-1 isolate we saw that a reduction in D3 usage led to accumulation of vpr transcripts 
(data not shown).  Viruses that differ dramatically in their use of vpr/A2 still produce similar levels of vpr 
mRNA (Figure 2.5A), consistent with the idea that splicing regulation can be accomplished by different 
mechanisms even for the same site.  More work is needed to clarify the roles of D2 and D3 and the 
purpose of the small exons given their conservation across clades and in at least some nonhuman 
primate lentiviruses. 
 There are 62 spliced mRNA species that are well conserved among the different isolates.  Given 
the conservation of these alternative splicing pathways for HIV-1 we were interested in using temperature 
shifts to probe features of their control and found that the use of A1 and A2 are each, but differentially, 
sensitive to temperature changes.  The differential response to temperature in the use of A1 and A2 are 
consistent with suboptimal interactions of these splice acceptor sites with the host cell splicing machinery, 
but in different ways.  It is worth noting that these same two splice sites are indirectly down-regulated with 
the high frequency use of D2 and D3, suggesting the use of A1 and A2 have been selected to be 
suboptimal for interactions near the point of instability.  A secondary structure proximal to A1 was seen to 
be critical to splicing based on the observation that two mutations designed to decrease its structural 
stability reduced splicing in a way that was additive with the effect of temperature (Figure 2.5).  These 
data do not rule out the possibility that the mutations affect other features of splicing, such as binding by 
an unknown factor, and further work is required to fully understand the role of this hairpin in regulating A1 
usage.  It would be also be interesting to use deep sequencing technologies to see if temperature shifts 
reveal similar changes among alternative splicing pathways of cellular RNAs.   
 Our data suggest that the SLSA1 structure is important to A1 usage, and other splice acceptors 
and splice control elements are also located in or near structural features and many of these regions have 
been studied for their ability to bind cellular splice factors (53, 54). It will be informative to continue to 
characterize the role these and other structures play in splicing regulation by creating mutations that alter 
either structure or cellular factor binding sites.  One such study has involved the knockdown of the cellular 
factor hnRNP H1 with the observation that splicing to A1/vif is most affected by limiting this factor (S. 
Kutluay, P. Bieniasz, A.E., R.S., in preparation). 
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 As most previous HIV-1 splicing studies have used HIV-1NL4-3 as a model, it is significant that we 
observed HIV-1NL4-3 splicing to be comparable to the mean splicing patterns seen in the T/F virus panel 
and in a subtype C isolate (Figure 2.6 and 2.8).  This finding validates use of HIV-1NL4-3 in other studies of 
splicing regulation.  In addition, some general conclusions can be drawn from the T/F virus splicing data.  
Overall, splicing patterns are the same.  Acceptors and donors remain constant, but there is surprisingly 
high variability in their usage.  In addition, there are examples of splicing events within a strain that are 
not conserved between strains, with some examples being the reported 1 kb size class in the 89.6 strain 
(3), the SX0 exon in the SIVmac239 strain, and greater than 50% tat transcripts in the NDK strain (data 
not shown).  The idea that splicing is a tightly regulated and carefully balanced process (1) needs 
reexamination.  The variance in transcripts in these different strains of virus suggests that if a virus meets 
a threshold level for each transcript type, it can be transmitted and continue to replicate.  
 Previous studies suggested that cryptic splicing will be activated if/when usage of a regular 
acceptor is changed or blocked (1, 2, 38, 39).  Our data do not support this concept.  Cryptic splicing 
remained negligible across the entire panel of T/F viruses, in spite of functionally important changes in 
acceptor and donor consensus sequences.  In no case was a cryptic donor or acceptor substitute 
activated above background levels.  HIV-1 acceptors have been classified as weak (55, 56) and clearly 
they diverge from the cellular splicing consensus sequence and branch point rules (1, 57, 58); however, 
they are still consistently recognized as major splice sites above the background noise.  This suggests 
that many as yet unexplained factors contribute to HIV-1 splicing regulation. 
 We found evidence of trans-splicing in NL4-3 and all of the transmitted/founder viruses.  Our 
assay can detect trans-splicing up to a maximum length of four small exons so the full extent of trans-
splicing may be greater than what we have seen.  The overall frequency of trans-splicing was surprisingly 
high.  At a frequency of 0.3% in the 1.8 kb class, total trans-splicing occurred more often than several of 
the canonical spliced transcript types.   Trans-splicing in HIV-1 has been previously reported (59, 60), 
though not between HIV-1 RNAs, which we infer must have occurred given the altered order of the exon 
segments and between transcripts of different proviruses.  Whether the cryptic splicing we observed here 
has biological significance or is merely a stochastic occurrence between two viral transcripts in close 
proximity is unknown.  By observing trans-splicing between transcripts from two different proviruses we 
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were able to show that this phenomenon occurs beyond a flurry of co-transcriptional splicing between 
adjacent transcripts.  Also, the greater level of trans-splicing in the 1.8 kb class compared to the 4 kb 
class provides yet another example of where splicing is partially suppressed in the context of retaining the 
D4/A7 intron.  The effects on suppressing the use of these viral splice donor sequences is reminiscent of 
the observation that there is a general suppression of splicing (i.e. intron retention) in cellular transcripts 
during HIV-1 infection (43).  One model to explain these phenomena is that binding of the RNA by Rev to 
move the RNA to the Crm1 export pathway may suppress proximal splice donor activation, and that Rev 
may fortuitously bind to some cellular pre-RNAs. 
 In conclusion, developments in deep sequencing technology now make it possible to quantify the 
complexity of HIV-1 splicing in depth and to study effectors of splicing with greater precision than 
previously possible.  Here we report some examples of its utility and suggest potential uses in further 
studies. 
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CHAPTER 3: GLOBAL SYNONYMOUS MUTAGENESIS IDENTIFIES CIS-ACTING RNA ELEMENTS 
THAT REGULATE HIV-1 SPLICING AND REPLICATION2 
Overview 
 The ~9.5 kilobase HIV-1 genome contains RNA sequences and structures that control many 
aspects of viral replication, including transcription, splicing, nuclear export, translation, packaging and 
reverse transcription. Nonetheless, chemical probing and other approaches suggest that the HIV-1 
genome may contain many more RNA secondary structures of unknown importance and function. To 
determine whether there are additional, undiscovered cis-acting RNA elements in the HIV-1 genome that 
are important for viral replication, we undertook a global silent mutagenesis experiment. Sixteen mutant 
proviruses containing clusters of ~50 to ~200 synonymous mutations covering nearly the entire HIV-1 
protein coding sequence were designed and synthesized. Analyses of these mutant viruses resulted in 
their division into three phenotypic groups. Group 1 mutants exhibited near wild-type replication, Group 2 
mutants exhibited replication defects accompanied by perturbed RNA splicing, and Group 3 mutants had 
replication defects in the absence of obvious splicing perturbation. The three phenotypes were caused by 
mutations that exhibited a clear regional bias in their distribution along the viral genome, and those that 
caused replication defects all caused reductions in the level of unspliced RNA. We characterized in detail 
the underlying defects for Group 2 mutants. Second-site revertants that enabled viral replication could be 
derived for Group 2 mutants, and generally contained point mutations that reduced the utilization of 
proximal splice sites. Mapping of the changes responsible for splicing perturbations in Group 2 viruses 
revealed the presence of several novel splicing inhibitory RNA signals that suppressed the use of cryptic 
or canonical splice sites. Some sequences that regulated splicing were diffusely distributed, while others 
could be mapped to discrete elements, proximal or distal to the affected splice site(s). Overall, our data 
indicate complex negative regulation of HIV-1 splicing by RNA elements in various regions of the HIV-1 
genome that enable balanced splicing and viral replication. 
                                                     
2 This chapter is under revision at Plos Pathogens with the above title and the following authors: Matthew 
Takata, Steven Soll, Ann Emery, Daniel Blanco-Melo, Ronald Swanstrom and Paul D. Bieniasz. 
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Introduction 
 The HIV-1 genome contains a variety of RNA elements that have important cis-acting functions 
(1, 2). Some of these RNA sequences are multi-functional in that they lie in open reading frames and 
therefore encode proteins as well as performing functions as RNA that are critical during viral replication.  
Known cis-acting RNA elements in the HIV-1 genome that lie within protein-coding sequences include 
splice donors, acceptors, and branch points (3), splicing regulatory elements that enhance or inhibit the 
use of proximal splice sites (4), the Rev-responsive element (5, 6), the central polypurine tract and 
termination sequence (7), the Gag-Pro-Pol ribosomal frameshift regulatory element (8) and components 
of the viral genome packaging signal (9, 10). It is not known whether the aforementioned represent a 
complete catalogue of cis-acting RNA elements, or whether additional RNA-based functionality exists in 
the HIV-1 genome. That additional RNA sequences function in cis may exist in the HIV-1 genome is 
suggested by studies employing chemical probing approaches. For example, SHAPE experiments 
indicate that individual nucleotides in HIV-1 RNA have widely divergent tendencies to be base-paired (11-
13). These findings, along with phylogeny-based approaches, strongly suggest that secondary structures 
form in HIV-1 RNA that are conserved between strains, and might therefore serve a useful function in 
HIV-1 replication (11, 13). One example of a recently suggested function for HIV-1 RNA secondary 
structure is the regulation of translational rate, whereby translation is periodically slowed to enable folding 
of one protein domain of the multidomain HIV-1 Gag protein before synthesis of the next (11). However, 
no evidence for such a phenomenon was found in an analysis of SIVmac (14). 
 Despite the suggestion that novel RNA secondary structures may be important for HIV-1 
replication, targeted mutagenesis of putatively important individual stem loops has not generally yielded 
evidence that is strongly supportive of a role for these potential structures in HIV-1 replication (15). 
Conversely, some studies in which portions of the HIV-1 genome were synonymously mutated have 
suggested a role for RNA (as opposed to protein) sequence or structure in HIV-1 replication (16, 17). 
However, the precise nature of defects induced by synonymous mutations are unclear, and possibly 
pleiotropic.  
 RNA sequence and structure must play a key role in a particular aspect of HIV-1 replication, 
namely alternative splicing. Indeed SHAPE analysis revealed a novel stem loop that influences splicing 
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(14, 18). Nevertheless, the regulatory mechanisms controlling alternative splicing are incompletely 
understood (4, 19). HIV-1 employs four salient splice donors (D1, D2, D3, D4) and eight acceptors (A1, 
A2, A3, A4a, b, c, A5 and A7) to generate a large number of mRNAs that enable expression of nine viral 
open reading frames in a temporally biphasic manner (20). HIV-1 splicing is, by necessity, inefficient as a 
substantial fraction of the viral transcripts must remain unspliced so as to provide viral genomes and Gag-
Pol mRNA (19, 21). Splice-site utilization is regulated by deviation from consensus splicing signals as well 
as regulatory elements consisting of exonic and intronic splicing silencer (ESS and ISS) elements, and 
exonic splicing enhancer (ESE) elements (4, 19, 21-30). All HIV-1 splicing involves D1, while splice 
acceptor sites 5’ to each initiation codon are used to generate mRNAs encoding the HIV-1 proteins Vif 
(A1), Vpr (A2), Tat (A3) Rev (A4a, b, c), Vpu/Env (A4a, b, c and A5) and Nef (A5 and A7) (Figure 3.1) (3, 
4). In addition, some HIV-1 mRNAs include short noncoding exons (SX1 (A1-D2)) and (SX2 (A2-D3)) 5’ to 
the expressed open reading frame. The relative frequencies that the various splice sites are used, which 
can be measured using next-generation sequencing approaches (18, 31), have a profound impact on the 
levels of viral proteins that are synthesized and thus on viral replication. 
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Figure 3.1. Design and analysis of panel of synonymously mutated HIV-1 viruses.  
(A) Schematic of HIV-1 proviral DNA, indicating open reading frames, splice sites, and blocks of nucleotides that 
were synonymously mutated in the 16 proviral plasmids (A-P) (B) Single-cycle infectious titers (measured using MT4 
cells) 48h following transfection of 293T cells with each of the WT(HIV-1NHG) and mutant (A-P) proviral plasmids, 
mean,+/-sd. (n=3). (C) Western blot analysis of protein expression and virion release 48h after transfection of 293T 
cells with each of the WT (HIV-1NHG) and mutant (A-P) proviral plasmids. 
 
 To identify and catalog regions of the HIV-1 genome that contain critical but unidentified cis-
acting RNA elements that impact splicing and other functions, we employed a global synonymous 
mutagenesis strategy. Sixteen mutant proviruses, each containing blocks of synonymous mutations 
covering nearly the entire HIV-1 protein coding sequence, were examined. Despite encoding identical 
proteins, and despite the fact that all known cis-acting sequences were maintained in an intact form, 
some viruses were completely incapable of a spreading infection. Other mutants displayed apparently 
normal fitness. Some defective mutants, termed Group 3 mutants, displayed near normal splicing but 
were defective in spreading replication assays. In these cases, second site revertants could not be 
recovered. In this study we focused on Group 2 mutants that displayed aberrant splicing. We found that 
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replication competence could be recovered by second-site revertant point mutations that were often, but 
not always, proximal to splice sites. Sequences responsible for aberrant splicing were sometimes 
diffusely distributed, but sometimes could be mapped to discrete elements of 20- 120 nucleotides and 
suggest the existence of novel forms of splicing-suppressive RNA signals. Overall, this study 
demonstrates that novel elements in the HIV-1 genome determine the fate and splicing of HIV-1 RNA and 
thus the ability of HIV-1 to replicate. 
Results 
Design and synthesis of synonymously mutated HIV-1 strains 
 To determine whether there are important, undiscovered cis-acting elements in the HIV-1 
genome, a mutant HIV-1 sequence was designed that contained a maximum number of synonymous 
mutations in the open reading frames while leaving known RNA elements that are important for virus 
replication intact. Mutations were designed so as to maximize the probability of disrupting base pairing in 
which a given nucleotide might participate. Thus, where multiple synonymous mutation possibilities were 
available, transversion mutations (purine to pyrimidine or vice versa) were preferred over transition 
mutations. To avoid the creation of new splice acceptors and donors, no new AG or GU dinucleotides 
were introduced. Moreover, sequences encoding overlapping open reading frames were not altered, and 
all known RNA elements that control HIV-1 splicing, gene expression and reverse transcription remained 
intact in the mutant viral genome.  
 This designed HIV-1 sequence contained 1,976 synonymous mutations and was divided into 150-
500 nucleotide blocks that were synthesized separately. Each synthetic mutated fragment was introduced 
into a replication competent HIV-1 proviral plasmid (HIV-1NHG) (32) that carried GFP in place of the 
nonessential gene nef. Thus, sixteen different mutated proviral plasmids, designated A through P, with 
each carrying a mean of ~125 synonymous mutations were generated (Figure 3.1A). 
Protein expression and replication properties of synonymously mutated HIV-1 mutants 
 Each of the synonymously mutated HIV-1NHG proviral plasmids was transfected into 293T cells 
and the infectious virion yield was determined in a single-cycle infection assay in MT4 cells (Figure 3.1B). 
Many of the mutants yielded WT, or close to WT, levels of infectious virions in this transfection/titration 
assay format. However, mutants A, B, I, and J yielded between 5-fold and 1000-fold fewer infectious 
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virions (Figure 3.1B). Western blot analysis of the transfected 293T cells and extracellular virions showed 
that mutants A and B expressed additional Gag protein species of unexpected sizes, and mutant B 
displayed a particle release defect, possibly a consequence of the expression of the aberrant Gag protein 
(Figure 3.1C). Mutants I and J displayed reduced Gag, Pol, Env and Vif protein, and slightly elevated 
GFP levels. Mutant J also grossly overexpressed the Vpr protein (Figure 3.1C). 
 We next examined whether each of the mutants could replicate in MT4 and CEM T-cell lines 
(Figure 3.2). Seven of the mutants (D, E, F, G, H, N and P) replicated with WT, or close to WT, kinetics 
while eight other mutants, (A, B, I, J, K, L, M, and O) were replication defective, or highly impaired, in both 
cell lines (Figure 3.2). Mutant C was somewhat impaired in MT4 cells, but replicated with close to WT 
kinetics in CEM cells. Thus, an apparent discrepancy was evident in the ability of some of the mutants to 
generate infectious virions in 293T cells, versus their ability to generate a spreading infection in T-cell 
lines. 
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Figure 3.2. Spreading replication properties of mutant viruses.  
(A-P) MT4 cells were infected with the indicated virus (harvested from the supernatant of 293T cells transfected with 
each of the WT (HIV-1NHG) mutant (A-P) proviral plasmids at an MOI of 0.002. Aliquots of infected cells were 
withdrawn each day, fixed in 4% PFA and the proportion of infected cells determined by FACS analysis of GFP 
expression. 
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Assays for splicing perturbations in replication-defective HIV-1 mutants 
 The viral mutants were designed to avoid altering RNA sequences in the HIV-1 genome that are 
known to be important for replication, including those that participate in or regulate splicing. Nevertheless, 
the aberrant pattern of viral protein expression in two of the synonymously mutated viruses (I, J), and the 
appearance of novel Gag-related protein species in two others (A, B), suggested that HIV-1 splicing might 
have been perturbed in at least some of the mutant viruses. Therefore, we next used two approaches to 
determine whether the mutations affected splicing in each of the mutant viruses. We used a recently 
described Primer ID-based deep sequencing approach (18) to globally quantify the relative utilization of 
the various splice donors and acceptors in the mutant viruses (Figure 3.3A-E). We also used a 
fluorescent primer-based PCR-PAGE assay to more conveniently, albeit less quantitatively, track the 
generation of the major mRNA species in the canonical spliced 1.8 kb class of HIV-1 mRNAs. These two 
assays yielded results that were in good agreement (see below). Of the canonical splice acceptors in the 
central portion of the genome (A1, A2, A3 A4a, b, c, and A5, Figure 3.3A), the WT HIV-1NHG most 
frequently spliced to A5, with lower levels of splicing to A1, A2, A3, A4a, b, c (Figure 3.3A, C, F). 
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Figure 3.3. Analysis of HIV-1 splicing in WT and synonymously mutated HIV-1.  
(A) Schematic of segments of HIV-1 proviral DNA focused on mutants exhibiting perturbed splicing. Canonical splice 
sites (black) and cryptic splice sites (red) are indicated, as are blocks of nucleotides that were synonymously mutated 
in the viruses exhibiting perturbed splicing. (B-D) Nextgen sequencing analysis of HIV-1 splicing, heatmaps indicate 
relative proportion of sequencing reads that indicate splicing at the sites indicated at the bottom of the heatmaps (B, 
C), or inclusion of the short exons (SX1 and/or SX2) indicated at the bottom of the heatmaps (D). For panel (C) only 
direct splicing to the indicated acceptor sites is indicated in the heatmaps Alternatively, the relative abundance of the 
various 1.8 kb mRNA species is indicated (E). (F) Fluorescent primer PCR analysis of HIV-1 splicing. 293T cells were 
transfected with the indicated proviruses, RNA extracted and cDNA synthesized. A sense PCR primer situated 5’ to 
the major splice donor, was used along with an antisense primer positioned either 3’ to A7 or 3’ to D4 (labelled with 
IRDye 800) was used to amplify cDNAs derived from the 1.8 kb (top) or 4 kb (bottom) classes of spliced HIV-1 
mRNAs respectively. PCR products were subjected to PAGE and a LI-COR Odyssey scanner was used to detect 
fluorescent signals directly from the gels. 
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Activation of cryptic splice sites in mutants A and B (Group 2a) 
 A splicing defect was observed for mutants A and B, which contained synonymous changes 
toward the 5’ end of the HIV-1. For each of these mutants, the relative levels of canonical splice site 
utilization was only marginally perturbed, but the Primer ID-based sequencing assay revealed that cryptic 
splice sites near the 5’ end of the genome were activated (Figure 3.3B, C). These mutants were 
designated Group 2a. For mutant A, a cryptic splice acceptor at position 955 (A955) and a donor at 
position 1169 (D1169) were activated, neither of which was used at a measurable level in WT HIV-1NHG 
(Figure 3.3A, B). While A955 was used rarely (~1% of 1.8 kb mRNAs) in mutant A, ~14% of the 1.8 kb 
mRNAs were spliced using D1169. (Figure 3.3B). For unknown reasons, splicing events involving D1169 
were selective with respect to which of the downstream acceptors were used: A3, A4, or A5, were used 
as acceptors for D1169 but A1 or A2 were not (AE, unpublished observations).  
 For mutant B, the major perturbation was activation of a cryptic splice acceptor at position 1321 
(A1321, Figure 3.3B). This splicing event, involving ~12% of mRNAs in the 1.8 kb class, appeared to 
enable a cascade of further alternative splicing events involving several downstream cryptic splice sites 
(AE unpublished observations). However, the most obvious outcome of the aberrant splicing event was 
the generation of a truncated ~40 kD Gag protein (Figure 3.2B). This protein would be the expected 
translation product of an mRNA in which a D1- A1321 splice (and no further splicing) had occurred. 
Specifically, translation initiation at the second Met codon in the gag gene would generate a truncated 
~40 kD Gag protein lacking MA, that likely accounts for the aberrant band on the cell-associated Gag 
western blot as well as the reduced particle yield from cells transfected with the B mutant proviral plasmid 
(Figure 3.1C). 
Overuse of canonical splice acceptor sites in mutants I, J and K (Group 2b) 
 Viruses containing mutations in the central portion of the genome, specifically mutants I, J and K, 
exhibited a different type of splicing defect, and were designated Group 2b. Specifically, mutants I, J and 
K exhibited increased direct splicing to A1, A2 and A3 respectively, at the expense of direct splicing to 
downstream (3’) acceptors (Figure 3.3C). In the case of mutant I, increased use of A1 was accompanied 
by increased use of the proximal downstream splice donor (D2) as well as a downstream acceptor–donor 
pair (A2 and D3) and thus the abundant inclusion of short exons (SX) 1 and 2 (SX1= (A1-D2) and SX2 = 
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(A2-D3)) into spliced viral mRNAs (Figure 3.3D). For mutant J, overuse of A2 (which is positioned 3’ to 
SX1) was accompanied by overuse of proximal downstream splice donor D3 and thus overrepresentation 
of SX2 = (A2-D3) into spliced viral mRNAs (Figure 3.3D). For mutant K, overuse of A3 (which is 
positioned 3’ to SX1 and SX2) did not result in the more frequent inclusion of these short exons (Figure 
3.3D). Overall therefore, it appeared that one consequence of the overuse of a given splice acceptor (A1 
or A2), was a resultant overuse of the proximal downstream splice donor (D2 or D3), consistent with an 
‘exon definition’ model of splicing control. 
 This overuse of canonical splice acceptors in I, J and K resulted in aberrant representation of 
particular viral mRNAs. Among the 1.8 kb class of mRNAs, for WT HIV-1, nef2 was the dominant mRNA 
species (Figure 3.3E). Conversely, in mutant I, nef5 was the dominant mRNA, while in mutant J, nef4, 
tat3 and vpr1 were overrepresented (Figure 3.3E). These changes were likely responsible for the 
overexpression of GFP (in the nef position) and/or Vpr in these mutants (Figure 3.1C). For mutant K, tat1 
mRNA was over-represented (Figure 3.3E), but the overall levels of protein expression were not greatly 
affected in transfected cells. 
Viruses with blocks of synonymous mutations with three different phenotypes that map to distinct regions 
of the HIV-1 genome  
 For other replication defective mutants (L, M, and O) that we termed Group 3 the relative uses of 
splice sites appeared normal, despite obvious replication defects (Figure 3.2, Figure 3.3B-E). These 
viruses appeared to express a normal complement of viral proteins in transfected cells (Figure 3.1C), thus 
the underlying basis for their replication defect was initially unexplained. Overall, therefore, analyses of 
viral replication and RNA splicing led to the classification of the synonymously mutated viruses into three 
groups (Figure 3.4A): Group 1 mutants exhibited near WT fitness, Group 2 mutants exhibited replication 
defects accompanied by perturbed RNA splicing, while Group 3 mutants had profound replication defects 
in the absence of obvious splicing perturbation. The three phenotypes were caused by mutations that 
exhibited a clear regional bias with respect to their distribution along the viral genome (Figure 3.4A). 
Specifically, Group 1 viruses carried mutations throughout the pro (D) and pol (E to H) genes or in the 3’ 
portion of the env gene (N, P), and replicated indistinguishably from HIV-1NHG. Conversely, Group 2 
viruses with obvious splicing defects carried mutations in two distinct genomic regions: Group 2a viruses 
(A, B) carried mutations toward the 5’ end of the genome, within the Gag ORF, while Group 2b viruses (I, 
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J, K) carried mutations or in the central portions of the genome, within the accessory genes (Figure 3.4A). 
Group 3 viruses (L, M, O) that were defective but exhibited near-normal splicing carried mutations in the 
env gene (Figure 3.4A).  
 
Figure 3.4. Phenotypes of synonymously mutated HIV-1 viruses. 
(A) Summary of the properties of HIV-1 viruses carrying blocks of nucleotides that were synonymously mutated (A-P), 
assessed in transfection (perturbations of splicing), single-cycle replication (unspliced RNA levels and infectious virus 
yield) and spreading replication (replication competence) assays. (B) Infectious virion yield measured in the 
supernatant of MT4 cells, infected with each of the mutant viruses at an MOI of 1.0, and harvested 2 days post 
infection. (C) Levels of unspliced HIV-1 genomes in RNA extracted from MT4 cells, infected with each of the mutant 
viruses at an MOI of 1.0, and harvested 2 days post infection.  
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Single-cycle replication assays suggest that reduced levels of unspliced viral RNA underlie replication 
defects in synonymously mutated HIV-1 
 We next explored the discrepancy in the abilities of certain mutant viruses to yield infectious 
virions after transfection of 293T cells, but were unable to spread in MT4 cells (Figure 3.2). We examined 
this discrepancy by carrying out experiments that analyzed a single cycle of replication in MT4 cells. 
Specifically, we infected cells with each of the mutant viruses at an MOI of 1 and quantified infectious 
virion release (Figure 3.4B) as well as levels of full length unspliced viral mRNA, during the first cycle of 
infection (Figure 3.4C). These experiments revealed significant deficiencies in infectious virion yield from 
infected cells for mutants A, B, K, L and M, that were not evident or less evident when virions were 
generated after transfection of 293T cells with a plasmid containing full length viral DNA (Figure 3.4B, 
Figure 3.1B). Moreover, these deficiencies, and the inability of each mutant virus to support a spreading 
infection, correlated with reduced levels of unspliced HIV-1 RNA in infected cells (Figure 3.4A, C). These 
observations suggest that the underlying defect in each of the replication defective mutants is a deficit in 
maintaining the level of unspliced RNA. This deficiency could result from excessive or aberrant splicing 
for Group 2 mutants or via unknown mechanisms for Group 3 mutants. It therefore appears likely that the 
deficit in unspliced RNA can be overcome, for some mutants, through the overexpression that results 
from transient viral DNA transfection in 293T cells. However, each of the mutants with reduced levels of 
unspliced RNA in single cycle-infected cells was profoundly defective in a spreading replication assay 
(Figure 3.4A). For Group 3 viruses, attempts to generate replication competent second-site revertants 
were unsuccessful, even after long term passage. Moreover, attempts to map discrete elements within 
the mutated blocks responsible for replication were also unsuccessful for Group 3 viruses. 
Mapping elements responsible for splicing perturbations in Group 2 viruses  
 To determine the sequence elements responsible for the perturbations in splicing in Group 2a 
and Group 2b viruses we took two approaches. First, we attempted to derive second-site revertant 
viruses through passage of each viral mutant in MT4 cells. Second, we applied a mapping approach, in 
which each block of mutations in mutants A, B, I, J and K was divided into roughly equally sized 
component segments, and the splicing properties of each secondary mutant re-examined. Through an 
iterative process, sometimes combining mapping and second-site revertant derivation, we could 
 85 
determine the nature of the defects in each Group 2 mutant and map the responsible cis-acting 
sequences. 
Redundant HIV-1 RNA sequences mediate suppression of cryptic splice sites that are activated in Group 
2a mutant viruses 
 For mutants A and B in which cryptic splice sites within the gag gene were activated by the silent 
mutations, we first attempted to derive revertant viruses by passage in MT4 cells. For both mutants A and 
B, passage quickly yielded viruses that replicated more rapidly than the parental mutant viruses (Figure 
3.5A, B). In the case of mutant A, passage in MT4 cells yielded a revertant virus that replicated well and 
contained two nucleotide substitutions relative to the A mutant parent, one of which (C819T) was 
responsible for the revertant replication phenotype (Figure 3.5A). The C819T mutation was synonymous, 
and while it occurred at a position that differs from the WT in mutant A, the reversion was not to the WT 
sequence (WT=G819, mutant A=C819, revertant=T819). Thus, if position G819 in the WT virus was 
involved in a hypothetical RNA secondary structure that was perturbed or induced in mutant A (C819), 
then the C to T substitution in the revertant would not be expected to affect the perturbation of that 
secondary structure. The C819T revertant largely corrected the predominant splicing defect in mutant A, 
reducing the use of the cryptic splice acceptor (A955) from ~ 1% to ~0.1% and the cryptic splice donor 
(D1169) from ~14% to <1% (Figure 3.5C). Since the reversion mutation C819 was distal to the cryptic 
splice sites (~140 and ~350 nucleotides 5’ to A955 and D1169, respectively, Figure 3.5D) the mechanism by 
which it exerts its effect was unclear. Notably, the revertant mutation occurred within a few nucleotides of 
the reported secondary structure that includes the HIV-1 packaging sequence, and D1 (which is at 
position 743). Thus, it may be that the revertant mutation acts through D1, rather than on the cryptic D1169 
that was activated in mutant A. 
 For mutant B, passage in MT4 or CEM cells yielded two different replicating revertant viruses 
each of which contained a single nucleotide substitution relative to the B mutant (G1326A in MT4 cells 
and T1311C in CEM cells) (Figure 3.5B) Both revertant mutations were synonymous, at positions that 
differed in WT and mutant B viruses, both mutations were proximal to the cryptic splice acceptor (A1321) 
that was activated by the B mutations (Figure 3.5E). Analysis of the G1326A revertant in the NGS splicing 
assay indicated reduced use of the cryptic acceptor A1321 (from 12% to <1%, Figure 3.5C), and both 
revertants exhibited reduced expression of the truncated Gag protein and increased virion release (not 
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shown). Given the proximity of the reversion mutations to the silenced cryptic splice site, it is likely that 
these mutations act directly to reduce splicing factor binding, and thereby reduce the use of the cryptic 
D1169. Conversely, the G1326 and T1311 mutations (and maybe others) in mutant B virus may have 
created or revealed a splicing factor binding site that was otherwise limiting for the use of the cryptic 
D1169. 
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Figure 3.5. Activation of cryptic splice sites by synonymous mutations in Gag. 
(A, B) MT4 cells were infected with the indicated virus (harvested from the supernatant of 293T cells transfected 
proviral plasmids representing each of the WT (HIV-1NHG), mutant (A, B and revertants thereof) at an MOI of 0.002. 
Aliquots of infected cells were withdrawn each day and the proportion of infected cells determined by FACS analysis 
of GFP expression. (C) Next gen sequencing analysis of HIV-1 splicing. The heatmap indicates relative proportion of  
sequencing reads that used the cryptic splice sites indicated at the bottom of the heatmap.(D, E) Schematic 
representation of the mutant blocks of nucleotides in HIV-1 mutants A (D) and B (F), indicating positions of mutant 
derivatives (AA, AB, BA, BB) etc., and the positions of cryptic splice sites and revertant mutant sites. Blocks colored 
blue are those that conferred overt splicing perturbations when mutated. (F) Fluorescent primer PCR analysis of HIV-
1 splicing in mutant A. A sense PCR primer situated 5’ to the cryptic donor D1169, was used along with an antisense 
primer positioned 3’ to A7 (labelled with IRD800) was used to amplify cDNAs derived from the 1.8 kb class of spliced 
HIV-1 mRNAs respectively. (G) Fluorescent primer PCR analysis of HIV-1 splicing in mutant B. A sense PCR primer 
situated 5’ to D1, was used along with an antisense primer positioned 3’ to the mutant B block (labelled with IRD800) 
was used to amplify cDNAs derived HIV-1 mRNAs. For panels (F) and (G) PCR products were subjected to PAGE 
and a LI-COR Odyssey scanner was used to detect fluorescent signals directly from the gels. 
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 To map mutations in A and B that were responsible for activating cryptic splice sites D1169 and 
A1321 respectively, we generated a set of mutant viruses (AA, AB, AC, AD, AE and BA, BB, BC, BD, BE) 
that contained subsets of the synonymous mutations present in mutants A and B (Figure 3.5D, E). We 
also designed a fluorescent primer-based PCR-PAGE assay in which a PCR primers were positioned to 
conveniently and specifically monitor the major aberrant splicing event in mutants A and B which, as 
expected, yielded PCR product consistent with splicing at the respective cryptic splice sites (D1169 and 
A1321, respectively) (Figure 3.5F, G). Surprisingly, none of the secondary mutants containing subsets of 
the A and B mutations recapitulated the effects of the A and B mutations (Figure 3.5F, G). Thus, the 
activation of the cryptic splice sites by the Group 2a mutants A and B was the result of multiple 
synonymous changes in those mutant viruses, though reversion of the effect could be observed with 
single mutations. 
Multiple novel cis-acting RNA elements suppress HIV-1 splicing at A1 and A2 
 For mutant I, which exhibits overuse of A1 and A2 (and the corresponding 3’ donors D2 and D3), 
we failed to obtain revertant replication competent viruses, even after extended passage. Therefore, we 
divided the I segment into 5’ and 3’ halves and generated two derivative mutant viruses (IA and IB) each 
of which had approximately half the of the synonymous mutations that were present in I (Figure 3.6A). 
Both IA and IB mutants also exhibited splicing defects primarily manifested as overuse of A1, but these 
defects were less complete, in that some degree of direct splicing to downstream acceptors was present 
in both IA and IB (Figure 3.6B). Notably, IA exhibited direct oversplicing to A1 only while IB exhibited 
direct oversplicing to both A1 and (to some degree) to A2 (Figure 3.6B). Both IA and IB could replicate 
with delayed kinetics compared to HIV-1NHG, and extended passage of IA and IB yielded point mutation 
revertants that could replicate with kinetics close to those of HIV-1NHG (Figure 3.6C, D). In the case of IA, 
a T4904A mutation occurred in the A1 polypyrimidine tract (Figure 3.6A, C). This caused a profound 
reduction of splicing to A1, and likely as a consequence, reduction of the inclusion of SX1 (A1-D2) in 
spliced RNAs (Figure 3.6B). In fact, other than underuse of A1 and reduced inclusion of SX1 (A1-D2), the 
IAT4904A revertant had a near normal splicing pattern. For IB the situation was more complex; a revertant 
(G4912A) was recovered after passage, precisely at the A1 acceptor and abolished the use of A1, and 
consequently the inclusion of SX1 (A1-D2) into spliced mRNA (Figure 3.6A, B, D). However, significant 
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overuse of A2, and consequent inclusion of SX2 (A2-D3) remained evident in the IBG4912A revertant 
(Figure 3.6B). Indeed, overuse of A2 was more prominent in the IBG4912A revertant than in IB, perhaps 
because of the functional removal of A1 (Figure 3.6B).  It was therefore apparent that elements within IA 
suppress splicing at A1, while elements within IB suppress splicing at both A1 and A2. 
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Figure 3.6. Activation of canonical splice acceptor sites (A1 and A2) by synonymous mutations in 
mutant I. 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant I, indicating positions of mutant 
derivatives (IA, IB, IC…etc.), and the positions of splice sites and revertant mutant sites (blue arrows). Blocks colored 
blue are those that conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis of HIV-1 
splicing in transfected 293T cells. The heatmap indicates relative proportion of sequencing reads that indicate direct 
splicing to the acceptors or inclusion of the short exons (SX1 and/or SX2) indicated at the bottom of the heatmap. 
(C, D) MT4 cells were infected with the indicated virus (harvested from the supernatant of 293T cells transfected 
proviral plasmids representing each of the WT (HIV-1NHG), mutant or revertant viruses at an MOI of 0.002. Aliquots of 
infected cells were withdrawn each day and the proportion of infected cells determined by FACS analysis of GFP 
expression. (E, F) Fluorescent primer PCR analysis of HIV-1 splicing. 293T cells were transfected with the indicated 
WT and mutant proviruses, RNA extracted and cDNA synthesized. A sense PCR primers situated 5’ to the major 
splice donor, was used along with an antisense primer positioned either 3’ to A7 (labelled with IRD800) to amplify 
cDNAs derived from the 1.8 kb class of spliced HIV-1 mRNAs. PCR products were subjected to PAGE and a LI-COR 
Odyssey scanner was used to detect fluorescent signals directly from the gels.  
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 To map elements within IA and IB that control splicing at A1 and A2, we used the fluorescent 
PCR-based assay to analyze the pattern of splicing for viruses containing subsets of the IA and IB 
mutations. For IA, analysis of viruses containing smaller component mutant elements (IC and ID, Figure 
3.6A) revealed that aberrant splicing was conferred by the ID element (Figure 3.6E). Thereafter, when ID 
was subdivided into ID1 and ID2, it was evident that the controlling element resided primarily within ID2 
(Figure 3.6E). Thus, this analysis revealed a ~48 nucleotide sequence that contains a novel ESS element 
that suppresses splicing at A1. 
 For IB the situation was more complex, as mutations in this segment control splicing at both A1 
and A2. Nevertheless, subdivision of the IB mutations into components IE and IF (Figure 3.6A), revealed 
that the majority the effect of IB mutations were conferred by mutations in IF. However, IF did not exhibit 
as prominent a degree of perturbation as IB (Figure 3.6E). Thus even though the splicing of IE appeared 
normal (Figure 3.6E), mutations in IE made some contribution to the defects present in IB. Subdivision of 
IF into IF1 and IF2 yielded viruses with a normal pattern of splicing (Figure 3.6F). Thus, it was evident that 
multiple elements acting together in IB, distributed over IE, IF1 and IF2 regulate splicing at A1 and A2 and 
their overall contributions could not be mapped to a small (<100 nucleotide) ESS element. 
 For mutant J, which exhibited overuse of A2 and D3 we also failed to obtain revertant replication 
competent viruses, even after extended passage. Therefore, we divided the J segment into 5’ and 3’ 
halves and generated two derivative mutant viruses (JA and JB, Figure 3.7A). Although there was some 
degree of splicing perturbation in JB (Figure 3.7B), this perturbation was modest compared to J and JA. 
Moreover, JB was only marginally delayed in spreading replication assays compared to HIV-1NHG. (Figure 
3.7C). Therefore, we did not attempt to select JB revertants. Conversely, JA recapitulated the splicing 
perturbation observed in J, and was replication defective (Figure 3.7B, D). Extended passage of mutant 
JA yielded a revertant mutation (G5463A) that enabled replication (Figure 3.7D). Notably, the reversion 
mutation was precisely at, and inactivated donor D3 (Figure 3.7A), but also abolished splicing to A2 
(Figure 3.7B). Thus, D3 appears to be required for splicing to A2, even though only a fraction of RNAs 
that are spliced to A2 are also spliced at D3. It was notable that the JB mutants as well as the 
JA(G5463A) revertant exhibited some oversplicing to A1 (and therefore elevated inclusion of SX1) even 
though the mutant J mutant sequences were distal (~440 to 890 nucleotides) to A1 (Figure 3.7A, B). 
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Figure 3.7. Activation of canonical splice acceptor site A2 by synonymous mutations in mutant J. 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant J, indicating positions of mutant 
derivatives (JA, JB, JC….etc.), and the positions of splice sites and revertant mutant sites (blue arrows). Blocks 
colored blue are those that conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis of 
HIV-1 splicing in transfected 293T cells. The heatmap indicates relative proportion of sequencing reads that indicate 
direct splicing to the acceptors or inclusion of the short exons (SX1 and/or SX2) indicated at the bottom of the 
heatmap. (C, D) MT4 cells were infected with the indicated virus (harvested from the supernatant of 293T cells 
transfected proviral plasmids representing each of the WT (HIV-1NHG), mutant or revertant viruses at an MOI of 0.002. 
Aliquots of infected cells were withdrawn each day and the proportion of infected cells determined by FACS analysis 
of GFP expression. (E, F) Fluorescent primer PCR analysis of HIV-1 splicing. 293T cells were transfected with the 
indicated WT (HIV-1NHG) and mutant proviruses, RNA extracted and cDNA synthesized. A sense PCR primer situated 
5’ to the major splice donor, was used along with an antisense primer positioned either 3’ to A7 (labeled with IRD800) 
to amplify cDNAs derived from the 1.8 kb class of spliced HIV-1 mRNAs. PCR products were subjected to PAGE and 
a LI-COR Odyssey scanner was used to detect fluorescent signals directly from the gels.  
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 To map elements within JA that control splicing, we used the fluorescent PCR-based assay for 
the 1.8 kb HIV-1 mRNAs to analyze viruses containing subsets of the JA mutations. We divided the JA 
mutant segment into 5’ and 3’ halves in two derivative mutant viruses (JC and JD, Figure 3.7A) which 
both exhibited some degree of perturbed splicing (Figure 3.7E). Further subdivision of JC into JC1, JC2 
and JC3 clearly suggested that the 20 nucleotide JC2 segment contained an ESS element whose 
mutation was primarily responsible for the perturbed splicing in JC (Figure 3.7E), but further division of 20 
nucleotide JC2 yielded two mutant segments (JC2A and JC2B) both of which cause perturbed splicing to 
nearly the same degree as the J, JA, JC and JC2 mutant segments from which they were derived (Figure 
3.7F). Division of the JD segment into JD1 and JD2 clearly revealed another ESS element within the 46 
nucleotide JD1 segment, that when mutated yielded a splicing pattern similar to that of the J mutant virus 
(Figure 3.7E). Thus, multiple mutations within the JA fragment, contained within the segments JC2 and 
JD1 were capable of causing splicing defects similar to those observed in the J mutant. 
A novel cis-acting RNA element inhibits HIV-1 splicing at A3 
 For mutant K (Figure 3.8A), which exhibits overuse of A3 (Figure 3.8B), it proved straightforward 
to recover a revertant mutant virus through passage that corrected the splicing defect and replicated well 
(Figure 3.8B, C). This revertant contained two mutations, one of which (C5774T) was sufficient to restore 
replication to near WT kinetics (Figure 3.8C). This functional reversion mutation was 3 nucleotides from 
the A3. Notably the KC5774T revertant not only corrected overuse of A3 but exhibited a splicing pattern that 
was nearly indistinguishable from that of HIV-1NHG (Figure 3.8B). To map sequences within K that were 
responsible for causing oversplicing, we divided the K mutant segment into two halves (KA and KB, 
Figure 3.8A) and analyzed the pattern of 1.8 kb mRNAs using the fluorescent primer PCR assay. This 
analysis revealed that mutations responsible for A3 overuse resided in KA (Figure 3.8D). Then, further 
subdivision of KA (into KC and KD) revealed that KD contained the controlling element (Figure 3.8D). 
Finally, subdivision of KD (into KD1 and KD2) showed that KD2 contained the ESS element (Figure 
3.8E), but further subdivision of KD2 (into KD2A and KD2B) showed that mutations in both of these KD2 
components contributed its effect (Figure 3.8F). Thus a 23-nucleotide element (KD2) contained a novel 
ESS element responsible for inhibiting splicing at A3.  
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Figure 3.8. Activation of canonical splice acceptor site A3 by synonymous mutations in mutant K. 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant K, indicating positions of mutant 
derivatives (KA, KB, KC….etc.), and the positions of splice sites and revertant mutant sites (blue arrows). Blocks 
colored blue are those that conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis of 
HIV-1 splicing in transfected 293T cells. The heatmap indicates relative proportion of sequencing reads that indicate 
direct splicing to the acceptors or inclusion of the short exons (SX1 and/or SX2) indicated at the bottom of the 
heatmap. (C) MT4 cells were infected with the indicated virus (harvested from the supernatant of 293T cells 
transfected proviral plasmids representing each of the WT (HIV-1NHG), mutant or revertant viruses at an MOI of 0.002. 
Aliquots of infected cells were withdrawn each day and the proportion of infected cells determined by FACS analysis 
of GFP expression. (D, E, F) Fluorescent primer PCR analysis of HIV-1 splicing. 293T cells were transfected with the 
indicated WT (HIV-1NHG) and mutant proviruses, RNA extracted and cDNA synthesized. A sense PCR primer situated 
5’ to the major splice donor, was used along with an antisense primer positioned either 3’ to A7 (labeled with IRD800) 
to amplify cDNAs derived from the 1.8 kb class of spliced HIV-1 mRNAs. PCR products were subjected to PAGE and 
a LI-COR Odyssey scanner was used to detect fluorescent signals directly from the gels.  
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Discussion 
 Through a global synonymous mutagenesis experiment we found that extensive portions of the 
HIV-1 genome could be synonymously mutated without major effects on viral replication (Group 1 
mutants). In particular, synonymous mutations throughout the majority of the pol gene had a minimal or 
no effect on viral fitness, such that their effect was not measurable in our assays. Given the extent of the 
mutations that were introduced, and the improbability that most RNA secondary structures would be 
preserved in our mutants, it seems unlikely that undiscovered specific RNA secondary structures 
essential for replication exist in portions of the viral genome covered by Group 1 mutants. Even among 
mutants that were replication defective, Group 2 mutants could be restored to replication competence 
through single nucleotide reversion mutations that suppressed the utilization of cryptic or canonical splice 
sites, whose use was enabled or elevated in the global mutagenesis experiment. Again, this argues 
against the notion that undiscovered, specific RNA structures exist in Group 2 mutants that are essential 
for replication (however, see discussion of splicing regulation below). 
 An important caveat to this conclusion is that replication was measured in permissive cell lines in 
the absence of competition. It is possible, even likely, that mutants or revertants with WT or near WT 
replication dynamics, have modest fitness deficits that would be evident in a more stringent environment 
or a competitive replication assay. For example, some of the HIV-1 accessory genes are important in 
vivo, but non-essential in vitro, therefore defects in their expression would be expected to have minimal 
effects on replication in our assays. Thus, while we can reasonably conclude that RNA secondary 
structures in Group 1 and Group 2 revertant mutants are non-essential for replication per se, it is 
nevertheless possible that RNA structures play an accessory role in regulating or fine-tuning the levels of 
mRNAs encoding certain accessory proteins.  
 Nevertheless, synonymous mutations in some portions of the HIV-1 genome caused profound, 
near-lethal defects in these highly permissive T-cell lines (Group 2 and Group 3 mutants). These 
mutations therefore targeted essential, non-coding features of the HIV-1 nucleotide sequence. One 
noncoding feature of the HIV-1 genome that appeared important for replication that was uncovered by our 
Group 2a mutants was suppression of cryptic splice sites near the 5’ end of the RNA genome. Potential 
mechanisms by which cryptic splice sites were activated in Group 2a mutants are not obvious because 
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discrete elements that led to cryptic splice site suppression or activation could not be mapped. Simply 
reducing the magnitude of the deviation from WT sequence by subdividing the mutant sequence blocks 
into two mutant blocks approximately equal lengths (e.g. mutants AA, AB and BA, BB) reverted the 
mutant splicing phenotype. This finding suggests that activation of the existing cryptic splice sites resulted 
from the cumulative effect of multiple perturbations to the gag nucleotide sequence. Moreover, in the case 
of mutant A, a single nucleotide revertant mutation that occurred distal to the activated cryptic splice site 
corrected the splicing defect. These findings might be best explained by the existence of multiple 
elements in the gag gene (secondary structures or protein binding sites) that act redundantly to suppress 
cryptic splice site utilization. The fact that the revertant mutation for mutant A occurred at a position 
proximal to an existing RNA structure that includes D1 (33), may suggest a role for an extended 
secondary structure involving the 5’ leader and the gag gene in suppressing the utilization of potential 
cryptic splice sites in gag. Clearly further work will be required to understand how the WT noncoding 
sequence avoids utilization of cryptic splice sites. 
 A detailed analysis of Group 2b mutants, that targeted the central portion of the genome, 
revealed several previously unidentified elements that apparently act as splicing regulatory signals to 
inhibit utilization of the canonical splice acceptors A1, A2, and A3. When combined with existing 
knowledge of splicing regulation at these sites (4, 19, 21-30), these and previous findings indicate a 
complex regulatory network of functional inputs that govern alternative splicing of the HIV-1 genome 
(Figure 3.9). 
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Figure 3.9. Summary of splicing control in HIV-1. 
A schematic representation of the central portion of the HIV-1 genome with the positions of canonical splice sites 
indicated. Previously identified splicing control elements are indicated with grey bars and the splice sites on whose 
they inhibit and enhance are indicated with grey and green arrows, respectively. Newly identified splicing inhibitor 
sequences are indicated with red lines and the splice acceptors on which they act are indicated with red arrows. The 
sequences of the newly identified splicing inhibitory sequences (upper line = WT sequence, lower line = oversplicing 
mutant sequence) are shown in the lower part of the diagram. 
 
 The phenotypes of some mutant and revertant viruses (i.e. viruses with perturbed splicing whose 
replication was recovered by splice site mutations) is consistent with the notion that exon definition 
(coordinated recognition of a 5’ splice acceptor and a 3’ splice donor by the splicing machinery (34)) plays 
a key role in the regulation of HIV-1 alternative splicing.  For example, in a mutant (IA) that exhibits 
elevated use of A1 and D2, the revertant (IA(4904)) occurs at A1 and exhibits reduced utilization of both 
A1 and D2. Similarly, in IB, that has elevated use of both A1 and A2, both D3 and D2 are also overused, 
the revertant mutation (IB(G4912A)) at A1 causes abolition of splicing at both A1 and D2 (no SX1 
inclusion) while splicing at A2 and D3 (SX2 inclusion) remains elevated. Consistent with this notion, 
previous work has also shown that the efficiency with which D2 is recognized can affect the frequency of 
splicing at A1 (35). Strikingly, in the case of a mutant (JA) that exhibited profound oversplicing at A2, a 
reversion mutation that occurred at splice site D3 caused abolition of splicing at A2 (as well as D3). 
Because not all splices at A2 lead to splicing at D3, this observation suggests that recognition of D3 by 
the splicing machinery is required for splicing at A2 even when D3 is not utilized, as has previously been 
suggested (21). The notion that splice acceptor sites compete with each other is also consistent with our 
data, with ‘cascading’ effects based on exon definition. For example, in a mutant (JA) that underutilizes 
A1 and over utilizes A2, the revertant (JA(G54653A)) occurs at D3, abolishes use of A2, and 
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overutilization of A1 results. In an apparently reciprocal example of A1-A2 competition, abolition of A1 
utilization in the revertant IB(G4912A), was accompanied by increased splicing at A2. In another example 
of apparent acceptor competition, the mutant K, exhibited oversplicing at A3 at the expense of splicing at 
A1, A2, A4b and A5, but the reversion mutation at A3 in K(C5774T) led to restoration of WT splicing 
frequency at all other sites in the central portion of the HIV-1 genome. 
 Overall therefore, a key regulator of the use of a particular splice site is the presence and 
utilization of other splice sites, through coordinated recognition of acceptor and donor sites, along with 
competition between acceptor sites. Thus, disruption of the splicing regulatory signals identified herein 
can have complex effects on overall splicing, through the propagation of their effects from one splice site 
to another. Clearly the effect of these perturbations is best appreciated in the nextgen sequencing assay 
with all splice sites represented in a viral construct. 
 That being the case, the sequence elements that we have identified to inhibit splicing at the 
various splice acceptors (Figure 3.9) could work directly or indirectly. Specifically, they could act to 
directly inhibit access of the splicing machinery to the affected splice sites or indirectly through splice 
donors, inhibiting splicing by blocking exon definition. Existing splicing regulatory sequences have been 
reported to exert their effect through binding of hnRNP or SR proteins, or through the formation of RNA 
secondary structures (36). The sequences that we have identified are of varying sizes; some elements 
that had major effects on splicing appear sufficiently small (e.g. JC2 and KD2) to constitute specific 
protein binding sites. However, these elements did not appear to be enriched in canonical hnRNP binding 
motifs, as might be expected for splicing silencers (36). Some of the effects on splicing that we found in 
our mutants, particularly within the I and J fragments, appeared complex and not easily mapped to small 
discrete elements. Perhaps these effects are the result of combinatorial inputs from multiple binding sites 
or secondary structures that could act to occlude splice sites, or spatially separate 5’ donors from 3’ 
acceptors thereby inhibiting exon definition. Further work will be required to determine precisely how 
these elements inhibit HIV-1 splicing. 
 We note that perturbation of balanced splicing did not always lead to abolition of HIV-1 
replication. For example, the mutants JB and JA(5463A) had perturbed splicing (overuse of A1 for JA, 
and abolition of SX2 utilization for JB) but their replication was only slightly delayed compared to WT. 
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Similarly the IB (G4912A) revertant virus had near WT replication but completely lacked splicing to A1 
and therefore abolished inclusion of SX1. We note that these perturbations would be expected to lead to 
under expression or overexpression of Vif and Vpr, neither of which are essential for replication in this 
particular cell type. Thus, the requirement for a particular balance of HIV-1 mRNAs could be highly 
context dependent. In our experiments, replication defects that resulted from oversplicing were likely the 
result of depletion of the pool of unspliced RNA, thus leading to lower levels of synthesis of Gag, Pro, Pol, 
and other viral proteins, and lower levels of viral genomes for packaging. Thus, a key role of splicing 
inhibitory signals in the HIV-1 genome is to maintain the unspliced RNA pool.  
 In the case of another set of replication-defective mutants, that we termed ‘Group 3’ and had 
synonymous mutations in the env gene, we could not detect significant splicing defects. Nevertheless, 
reduced levels of unspliced RNA were present in Group 3 virus-infected cells, and reduced levels of 
infectious particles were generated in single cycle replication assays. It is possible that that some form of 
splicing perturbation that was not detected in our splicing assays occurred in Group 3 mutants. However, 
the fact that we could not recover replication competent revertants from Group 3 viruses, while other 
replication defective mutants with clear splicing defects (Group 2) readily yielded replication revertants, 
suggests some other defect is responsible for the loss of replication competence in Group 3 mutants. The 
precise nature of the defect in Group 3 mutants is currently under investigation. 
 Overall, our global synonymous mutagenesis experiment has revealed several cis-acting RNA 
sequences that have essential functions in HIV-1 replication. In particular, we have identified several 
novel signals in the HIV-1 genome that appear to act through suppression of canonical splice sites to 
regulate alternative splicing and maintain unspliced transcript levels. Additionally, our analysis revealed 
that some as yet unidentified property of RNA sequences in the gag gene suppresses utilization of cryptic 
splice sites. Understanding how these regulatory signals work in the context of HIV-1 may give insights 
into the general mechanisms by which alternative splicing is regulated and how splicing regulation 
evolves, as well as opportunities to intervene therapeutically in HIV-1 infection. 
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Material and Methods 
Cell lines, viruses and infections 
 293T cells (ATCC) were grown in DMEM with 10% fetal bovine serum (Sigma). MT4 cells (NIH 
AIDS Reagent Repository) were cultured in RPMI supplemented with 10% fetal bovine serum. HIV-1NHG 
and mutant derivatives containing a reporter GFP in place of nef were produced by transfection of 293T 
cells with the proviral plasmid using PEI. Virus titers were determined by FACS analysis of target MT4 
cells. Dextran sulfate was added to inhibit reinfection at 18 hours post infection and the number of 
infected cells determined by FACS analysis of GFP expression 2 days post infection.  
 For spreading replication infections, 2x105 MT4 cells in 2 mL of media were infected at an MOI of 
0.002. Aliquots of infected cells were withdrawn each day, fixed in 4% PFA and the proportion of infected 
cells determined by FACS analysis of GFP expression.  For single cycle infections, cells were infected 
with HIV-1NHG or mutants thereof, at an MOI of 1.0, and harvested 2 days post infection for western blot 
and qPCR analysis. Serial passage of mutant viruses was started by infecting a culture of 5x105 MT4 
cells at an MOI of 0.002 and time points were fixed in 4% PFA. Upon infection of the entire culture, 200 
μL of cell free supernatant was filtered and used to inoculate a new culture of 5x105 MT4 cells. After the 
final passage, the cells were collected and the DNA was extracted (Qiagen Tissue Mini Kit), then the 
mutated region was sequenced to determine the revertant mutation that had occurred.  
Construction of mutant proviral plasmids 
 The mutated regions of the HIV-1 genome were synthesized (Genewiz) and cloned into HIV-1NHG 
using restriction digest sites that were proximal to the mutated regions (Supplemental Table 1). Division 
of the original mutant blocks into two new derivative mutants was achieved using overlap extension PCR 
based approaches with mutant and WT templates. Revertant mutations acquired through passage of the 
virus were reconstituted into the original mutant provirus from which they arose through site directed 
mutagenesis and overlap extension PCR.  
PCR quantification of unspliced HIV-1 RNA  
 RNA was extracted from infected cells using Trizol and reverse transcribed using the SuperScript 
III reverse transcriptase (ThermoFisher). The resulting cDNA was used as a temple for quantitative real-
time PCR using the ABI Fast RT-PCR system along with the Fast Start TaqMan Probe master mix. 
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Unspliced viral RNA was detected using a forward primer: 5’-GGACTTGAAAGCGAAAGGGA-3’, a 
reverse primer: 5’-TCTCTCTCCTTCTAGCCTCCG-3’ and a TaqMan probe 5’-
GGGCGGCGACTGGTGAGT-3’ targeting the major splice donor D1. Serial tenfold dilutions of known 
copy numbers of HIV-1NHG plasmid was used to generate a standard curve.  
Antibodies and western blotting  
 Cells were normalized for cell number, lysed in SDS sample buffer, separated by electrophoresis 
on NuPage 4-12% Bis-Tris gels (Novex) and blotted onto nitrocellulose membranes (GE Healthcare). 
Blots were probed with an HIV-1 anti-capsid antibody (183-H12-5C) obtained from the NIH AIDS reagent 
repository, a GFP antibody (G1546, Sigma), and HIV-1 anti-Env gp120 antibody (12-6205-1, American 
Research Products).  
Analysis of HIV-1 splicing with fluorescent primer PCR 
 RNA from 293T cells transfected with mutant provirus was extracted using the Nucleospin RNA 
extraction kit (Machery Nagel). RNA was reverse transcribed using SuperScript III reverse transcriptase 
(ThermoFisher) with gene specific primers for either fully spliced (8483R: 5’-
CCGCAGATCGTCCCAGATAAG-3' and partially spliced (6223R: 5'-CAAGTGCTGATATTTCTCCTTCAC 
-3') mRNA classes. The cDNA templates were then used in a 10μL PCR reaction with fluorescent reverse 
primers specific to the splice class (labelled at their 5’ ends with IRD800) and a forward primer position 5’ 
to the major splice donor (499F: 5' -CTGAGCCTGGGAGCTCTCTGGC-3') and run for 25 cycles with an 
annealing temperature of 54°C. Alternatively, to determine use of the activated cryptic splice site in 
mutant A, a forward primer, positioned 5’ to the mutations (763F 5’- 
TGACTAGCGGAGGCTAGAAGGAGAGAG -3’) and the fluorescent reverse primer for the fully spliced 
class (8483R) were used in a PCR reaction with the cDNA templates. To determine use of the activated 
cryptic splice site in mutant B, the forward primer 499F and a fluorescent reverse primer 5’ to the 
mutations in B (1557R 5’- GATAGGTGGATTATGTGTCATCC -3’) were used in a PCR reaction with the 
cDNA template. Then, 10μL of 2x TBE-Urea sample buffer was added to the PCR reaction which was 
then run on a 6% TBE-Urea gel for 90 minutes at 180V (Novex). A LI-COR Odyssey scanner was used to 
detect fluorescent signals directly from the gels. 
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Analysis of HIV-1 splicing using Primer ID-based deep sequencing 
 Determination of splice site utilization using the Primer ID-based deep sequencing assay was 
done substantially as described with minor modifications (18). Briefly, RNA was extracted from cells 
transfected with HIV-1NHG or mutants thereof using the RNeasy Plus minikit (Qiagen). Primers used for 
cDNA synthesis were 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNCAGTTCGGGATTGGGAGG
TGGGTTGC for 1.8 kb spliced transcripts and 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNGCTACTATTGCTATTTGTA
TAGGTTGCATTACATG for 4 kb spliced transcripts. Indexed primers were obtained from Integrated DNA 
Technologies Custom Oligos. Total cell RNA (8 μg) was subjected to cDNA synthesis, purification and 
cleanup and an initial PCR amplification. An aliquot of the product from this first PCR was used as the 
template for the second PCR to add the Illumina adapter and bar codes to allow multiplexing in the 
Illumina sequencing reaction. PCR products were visualized on a 2% agarose gel and then cleaned. 
Libraries were mixed/multiplexed and sequenced using the 300-base paired-end read for the Illumina 
Miseq platform. Reads were sorted using the Illumina bcl2fastq pipeline (v.1.8.4) to separate the 
multiplexed samples. Subsequent Data analysis and splicing quantification were done using the 
previously described in-house pipeline (18) written in Ruby and adapted to accommodate the mutated 
sequences.  This program uses the combined sequence information from the paired-end reads to identify 
splice site usage and transcript type.  Reads are condensed by Primer ID to prevent skewing in the PCR 
steps. Cryptic alternative donor and acceptor splice sites were identified using a program that compares 
data reads to a reference sequence and identifies the base where a splice discontinuity occurs and the 
base it splices to. 
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CHAPTER 4: CLIP-SEQ REVEALS A KEY ROLE FOR hnRNP H1 IN REGULATION OF HIV-1 
ALTERNATIVE mRNA SPLICING3 
Overview 
 Alternative splicing of HIV-1 mRNAs is a complex process that regulates transcript abundance, 
increases the coding potential of the compact viral genome and allows temporal regulation of viral gene 
expression. This process is in part regulated by the host heterogeneous nuclear ribonucleoproteins 
(hnRNPs) that bind to poorly defined sequences on HIV-1 RNAs and subsequently repress alternative 
splicing at nearby regulatory elements. In this study, we employed crosslinking immunoprecipitation 
coupled with next-generation sequencing (CLIP-seq) to identify the direct binding sites of several hnRNPs 
on viral RNAs in cells. We show that hnRNP A1, hnRNP A2 and hnRNP B1 proteins bind promiscuously 
throughout viral RNAs and require the presence of ‘AGG’ motifs for binding. In contrast, hnRNP H1 
binding took place at well-defined purine-rich sequences comprised of four or more consecutive 
guanosines that are often surrounded by A-rich elements. Reassuringly, the sequence specificities of 
hnRNPs on viral RNAs largely mirrored those on cellular introns. In support of these findings, isolated 
RNA-binding domains of hnRNP H1 exhibited a clear preference for G-rich sequences in vitro. Notably, 
modulation of hnRNP H1 levels by RNAi and mutations within the most prominent hnRNP H1 binding site 
on viral RNAs decreased usage of splice acceptor A1 as revealed by an unbiased high throughput 
sequencing-based assay. Overall, our studies reveal novel cis-regulatory elements of HIV-1 splicing and 
provide the highly needed experimental framework to study an essential step of HIV-1 replication in 
greater detail. 
                                                     
3 This chapter is ready for submission for publication pending the addition of some final experimental 
results.  The authors are Sebla B. Kutluay, Ann Emery, Srinivas Penumutchu, Dana Townsend, Michaela 
Madison, Amanda Stukenbroeker, Chelsea Powell, David Jannain, Blanton S. Tolbert, Ron Swanstrom, 
and Paul D. Bieniasz. 
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Introduction 
Following its integration into the host genome, genesis of new HIV-1 particles is initiated by the 
host RNA polymerase II-mediated transcription of a single primary polycistronic viral transcript that 
undergoes various levels alternative splicing. This process gives rise to over fifty alternative splice 
isoforms (1, 2), which are classified with respect to their sizes. The completely spliced 1.8 kb class of 
transcripts encode for Tat, Rev and Nef proteins, the incompletely spliced 4 kb class code for Vif, Vpr, 
Env, Vpu and a truncated form of Tat, and the incompletely spliced primary transcripts code for Gag and 
Gag-Pol proteins, and serve as the genomic RNA that is packaged into progeny virions. A novel 1kb class 
of transcripts was identified in a recent next-generation sequencing-based study (3); however, no 
functionality has been assigned to this class of transcripts yet. While completely spliced transcripts are 
easily exported out from the nucleus by canonical cellular pathways, export of incompletely spliced and 
unspliced transcripts is mediated by the viral Rev protein. Rev binds to a highly structured RNA element 
referred to as the Rev-responsive element (RRE) on viral RNAs and mediates their export by bridging 
between viral transcripts and the host karyopherin Crm1 (4). This mode of regulation allows temporal viral 
gene expression and provides sufficient time for the genesis of infectious virus particles (5). 
Alternative HIV-1 splice isoforms are generated by the utilization of at least four splice donor (D1, 
D2, D3, D4) and eight acceptor sites (A1, A2, A3, A4c, A4a, A4b, A5 and A7) (1, 6). Recent deep-
sequencing-based studies have revealed the existence of several other splice donor and acceptor sites 
that are generally utilized at lower frequencies (3). The intrinsic strengths of the donor and acceptor sites 
are thought to be governed by the extent of their homology to the consensus donor and acceptor 
sequences (2). For example, D1 is 100% homologous to the consensus sequence and is the most 
frequently utilized 5’ splice site. In fact, all downstream splicing events involve the usage of D1. In 
contrast, many of the other donor and acceptor sites are suboptimal and as such their utilization is 
thought to be regulated by other nearby cis-acting elements. Exonic splicing enhancers (ESEs) and 
exonic splicing silencers (ESSs) are such cis-acting elements that are bound by members of the serine–
arginine-rich protein (SR protein) and heterogeneous nuclear ribonucleoprotein (hnRNP) families, which 
are generally thought to enhance or repress the usage of nearby splice sites, respectively.  
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Based primarily on in vitro binding and genetic assays, few members of the hnRNP protein family 
have been proposed to regulate HIV-1 alternative splicing. Among these, members of the hnRNP A/B 
family have been studied most extensively and were shown to bind to distinct sequences on viral RNAs, 
including the exonic splice silencer (ESS) ESS2 within tat exon 2 (7, 8), ESS3 located within tat/rev exon 
3 (9, 10), ESSV located in the vif-coding exon (11) and an intronic splice silencer element within tat intron 
(10, 12, 13). Similarly, hnRNP H1 has been suggested to bind to ESS2p (14), a cryptic exon within the 
Env ORF (15, 16), a G-rich motif within tat exon 2 (17) and intron 3 (18). In addition, isolated studies have 
proposed that hnRNP D (19), hnRNP E (20) and hnRNP K (21) can regulate HIV-1 splicing. However, in 
many of these studies, regulation of HIV-1 splicing has been studied using in vitro and in vivo splicing 
reporters wherein viral sub-genomic fragments were moved to foreign genetic environments so as to 
determine how they influence the distribution of spliced reporter products. In addition, binding of a given 
hnRNP was assessed largely by in vitro binding assays using defined targets. Whether the presumed 
target sites can be bound by hnRNPs in infected cells and whether other binding sites on viral RNAs exist 
is unknown.  
HnRNPs are modular proteins, a common feature of which is the presence of two or more RNA 
binding domains. Most hnRNPs also contain RGG boxes (Arg-Gly-Gly repeats) and auxiliary domains 
with distinct amino acid composition (i.e. glycine-rich, acidic or proline-rich domains) that are believed to 
be responsible for protein-protein, RNA-protein, and single-stranded DNA-protein interactions (22). As 
such, most hnRNPs can form homophilic interactions and heterophilic interactions with other hnRNPs.   
Crosslinking-immunoprecipitation followed by deep sequencing (CLIP-seq) has emerged as a 
powerful method to identify the RNA targets of RNA-binding proteins at near-nucleotide resolution in 
physiological settings. Here we adapted the CLIP-seq methodology to determine viral RNA binding sites 
of some of the previously studied hnRNP proteins in physiological settings, and determine the effects of 
these interactions directly on viral splicing using next-generation sequencing-based methods. Our studies 
reveal that unlike previously suggested, hnRNP A/B group of proteins do not bind to distinct elements but 
rather bind promiscuously throughout viral RNAs and require the presence of ‘AGG’ motifs within binding 
sites. In contrast, hnRNP H1 was bound to well defined purine-rich sequences comprised of four or more 
consecutive guanosines frequently surrounded by A-rich elements. In support of these findings, 
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biochemical experiments revealed a clear preference for G-rich sequences in isolated RNA-binding 
domains of hnRNP H1. Overall, the binding specificities of hnRNPs on viral RNAs largely mirrored those 
on cellular introns. Notably, modulation of hnRNP H1 levels by RNAi and mutations within hnRNP H1 
binding sites on viral RNAs decreased usage of splice acceptor A1 as revealed by an unbiased high 
throughput sequencing-based assay.  Overall, our studies reveal novel cis-regulatory elements of HIV-1 
splicing and provide the much needed experimental framework to study an essential step of HIV-1 
replication in much greater detail. 
Results 
Generation of 3xHA-tagged hnRNP variants   
 To determine the binding sites of hnRNP A1, A2, B1, H1 and K proteins on HIV-1 RNAs, we first 
generated HEK293T-derived cell lines that stably express 3xHA-tagged versions of these proteins at 
lower than endogenous levels (Figure 4.1A). Importantly, these modifications did not affect HIV-1 Gag 
expression in cells (Figure 4.1B), particle release (Figure 4.1B) or infectivity (Figure 4.1C). We next 
determined whether hnRNP-RNA complexes that form in these cells can be isolated by a previously 
established CLIP-seq protocol (23). To this end, cells were grown in the presence of 4-thiouridine (4-SU) 
and UV-crosslinked to induce protein-RNA crosslinking at 4-SU-modified nucleotides. hnRNP-RNA 
adducts were immunoprecipitated, the bound RNA was end-labeled and complexes were visualized by 
autoradiography following separation by SDS-PAGE and transfer to nitrocellulose membranes. 
Reassuringly, all tagged hnRNPs were efficiently immunoprecipitated in complex with cellular RNAs 
(Figure 4.1D). To identify the binding sites of hnRNPs on viral RNAs, similar experiments were conducted 
in cells transfected with full-length HIV-1NL4-3 (subtype B). To account for subtype-specific differences on 
hnRNP binding, parallel experiments were conducted on cells transfected with HIV-1NDK (subtype D) 
proviral plasmids. HnRNP-RNA complexes were isolated as above, and bound RNA molecules were 
further purified and the resulting libraries were subjected to high throughput sequencing. Following 
trimming of 5’ and 3’ adapters, the CLIP-seq reads were sequentially mapped to the human and viral 
genomes. Two independent libraries for each hnRNP and each virus were generated and are 
represented in Figure 4.1E. In general, the majority of sequencing reads mapped to the human genome 
and only a small fraction (~1% or less) were derived from viral RNAs (Figure 4.1E). Importantly, these 
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numbers reflect the relative abundance of viral and cellular mRNAs in similar settings (23), suggesting 
that hnRNPs bind with similar affinity to viral and cellular RNAs.  
 
Figure 4.1. Generation of cell lines stably expressing HA-tagged hnRNPs and summary of CLIP-
seq. 
(A) Western blot analysis of HA-tagged and endogenous hnRNP proteins. (B, C) 293T cells expressing 3xHA-tagged 
hnRNPs were transfected with HIV-1NL4-3. Western blot analysis of cell lysates and virions using an anti-CA antibody 
(B). Infectious virion yield was determined using MT4-GFP-reporter cells (C). Data is normalized to vector only control 
and represents the average of two independent experiments. (D) Immunoprecipitated and end-labeled hnRNP-RNA 
adducts from 4SU-treated cells is visualized by autoradiography (upper). Western blot analysis of the same 
membranes (lower). (E) Proportion of raw CLIP-seq reads that map to the human (cellular) and viral genomes 
obtained from experiments conducted with NL4-3 and NDK viruses. Data represents four independent CLIP-seq 
experiments (two NL4-3 and two NDK). 
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Binding sites of hnRNPs on viral RNAs  
 Analysis of the hnRNP binding sites on viral RNAs revealed unexpected and remarkable 
differences between the binding patterns of hnRNPs. Although HnRNP A1, A2 and B1 proteins were 
previously proposed to bind to distinct sequences on viral RNAs as detailed above, CLIP-seq analysis 
revealed multiple binding sites throughout the viral genome (Figure 4.2A-C). Nevertheless, regions 
overlapping with splice acceptor A7 (~nt 7860) and downstream from it (~nt 8300) were more frequently 
bound for both HIV-1NL4-3 and HIV-1NDK (Figure 4.2A-C). This pattern of binding may reflect the spreading 
of hnRNP A1 in 5’ and 3’ direction through oligomerization following its initial binding to a high affinity 
binding site (24). Importantly the binding patterns of the highly related hnRNP A1, A2 and B1 proteins 
were largely similar for both HIV-1NL4-3 and HIV-1NDK. We noted that hnRNP B1 binding took place at more 
distinct locations (Figure 4.2C), which can be explained by the presence of an extended N-terminal 
domain in hnRNP B1 that contains several basic amino acids that may alter its RNA binding affinity and 
specificity. In contrast to the promiscuous binding pattern of hnRNP A/B proteins, hnRNP H1 was bound 
to distinct well-defined sequences on viral RNAs (Figure 4.2D). While the majority of the binding sites 
were conserved between HIV-1NL4-3 and HIV-1NDK, the most frequently bound site within HIV-1NL4-3 (~nt 
5800) was not present in HIV-1NDK (Figure 4.2D). Importantly, although a previous study indicated a role 
for hnRNP K in regulation of HIV-1 splicing (21), hnRNP K binding on the viral genome was at 
background levels (Figure 4.2E) as also apparent in the fairly low percentage of CLIP-seq reads that map 
to the viral genome as compared to other hnRNPs (Figure 4.1E). 
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Figure 4.2. CLIP-seq of hnRNPs reveal their binding sites on viral RNAs.  
293T cells stably expressing 3xHA-tagged hnRNPs were transfected with full-length HIV-1NL4-3  and HIV-1NDK proviral 
plasmids prior to CLIP-seq. Frequency distribution of nucleotide occurrence (read density) of reads mapping to NL4-3 
and NDK genomes are shown for hnRNP A1 (A), hnRNP A2 (B), hnRNP B1 (C), hnRNP H1 (D) and hnRNP K (E). A 
schematic diagram of HIV-1 genome features shown above is co-linear. 
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HnRNPs bind primarily to intronic sequences on cellular RNAs 
 We next determined the properties of the cellular RNAs bound by hnRNPs to gain further insight 
into whether the binding specificities of hnRNPs on viral RNAs are similar to those on cellular RNAs. 
Reassuringly, the majority of binding events for all hnRNPs took place within the transcripts of known 
genes (Figure 4.3A). Of these, a large fraction of CLIP-seq reads were derived from introns (Figure 4.3B), 
as also observed previously (25). To identify the sequence motifs within mRNAs and introns bound by 
hnRNPs, we applied the cERMIT algorithm (26). Representative sequence motifs and the cumulative 
frequencies of their occurrence are depicted in (Figure 4.3C). For hnRNP A1, A2 and B1 the predicted 
UNAGG motif resembles the well-characterized UAGG motif within the hnRNP A1 binding site (27, 28). 
HnRNP H1 binding took place at highly G-rich sequences similar to the previously known binding 
specificity for GGGA motif (29). Although hnRNP K has been proposed to bind short C-rich tracks as 
inferred from a SELEX study (30), CLIP-seq revealed the presence of ‘CGAU’ and ‘CCAUAGA’ motifs 
within a subset of cellular binding sites. Overall, the binding specificities of hnRNPs on viral RNAs 
mirrored those on cellular RNAs (see below). 
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Figure 4.3. Classification of hnRNP-bound cellular RNAs and the binding motifs identified within 
them. 
(A) hnRNP CLIP-seq derived sequencing reads were mapped to the human genome, clustered and classified based 
on whether they map to RNA-coding genes (genic) or intergenic regions. (B) Further classification of “genic” clusters 
is detailed below. Total number of sequencing reads in each group is represented below the pie charts. (C) Binding 
motifs within these clusters and the cumulative percentages of their occurrence within clusters. 
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Direct effect of hnRNP RNAi on HIV-1 splicing  
 We next tested how the RNAi-mediated knock down of hnRNPs may alter the global landscape of 
HIV-1 alternative splicing events as well as viral gene expression and infectivity. To this end, following the 
transfection of siRNA duplexes targeting hnRNP A1, A2/B1 and H1, cells were infected with HIV-1NL4-
3/VSV-G and HIV-1NDK/VSV-G for two days. As expected, expression level of all hnRNPs, in particular 
hnRNP A2/B1 and hnRNP H1 was largely reduced upon siRNA transfection (Figure 4.4A). Next, we 
determined the direct effects of hnRNP RNAi on HIV-1 alternative splicing in cells by employing a high-
throughput sequencing-based assay. While RNAi of all hnRNPs modestly increased the usage of splice 
acceptor A3 and decreased the usage of A4 for both 1.8 kb (Figure 4.4B) and 4 kb (Figure 4.4C) classes 
of transcripts, utilization of A1 was reduced upon RNAi of hnRNP A2/B1 and hnRNP H1 (Figure 4.4B, C). 
In addition, hnRNP H1 RNAi decreased the usage of splice acceptor A2 for both 1.8 kb and 4 kb classes 
of HIV-1 mRNAs (Fig, 4E, F). Analysis of cell lysates and cell culture supernatants revealed that RNAi of 
hnRNP H1 has consistently reduced NL4-3 (Figure 4.4D) and NDK Gag (Figure 4.4E) expression in cells, 
resulting in a proportional decrease in the relative number of infectious virus particles in cell culture 
supernatants (Figure 4.4D-F). In general, RNAi of hnRNP A1 and hnRNP A2/B1 modestly affected Gag 
expression and particle release/infectivity (Figure 4.4D-F), despite altering viral splicing. This in part can 
be explained by the opposing effects of hnRNP A1 and A2/B1 knock down on tat (increase in A3 usage) 
and rev (decrease in A4 usage) expression (Figure 4.4B). Overall, RNAi of each hnRNP had a distinct 
outcome on viral splicing but relatively modest effects on Gag expression with the exception of hnRNP 
H1.  
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Figure 4.4. RNAi of hnRNP H1 decreases Gag expression and alters viral splicing in cells.  
HEK293T cells were transfected with siRNAs targeting the indicated hnRNPs, infected with HIVNL4-3/VSV-G or 
HIVNDK/VSV-G one day post-transfection, and cells and viruses were harvested two days post-infection for further 
analysis. (A) Expression of targeted hnRNPs was determined by immunoblotting against the indicated hnRNPs. (B, 
C) Western blot analysis of cells lysates and virions using an anti-CA antibody is shown for HIVNL4-3 (B) or HIVNDK (C)-
infected cells. (D) Virus titers in cell culture supernatants was determined on MT4-GFP indicator cells. Data is 
normalized to non-targeting siRNA-transfected cells and shows the average of two independent experiments. Error 
bars represent the range. (E, F) Analysis of splicing events that occur at acceptors A1-A5b products for 1.8 kb (E) 
and 4 kb (F) classes of viral RNAs. 
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hnRNP H1 binds to purine-rich sequences on viral RNAs   
 Given that hnRNP H1 was bound to distinct sequences on viral RNAs (Figure 4.2D) and its RNAi 
had the most prominent effect on Gag expression (Figure 4.4D, E), we next aimed to determine how 
hnRNP H1 binding on viral RNAs directly affect HIV-1 alternative mRNA splicing. Analysis of the eight 
most frequently bound sites on the HIV-1 genome revealed that the majority of them consisted of one or 
more copies of G-rich tracks (four or more guanosines) surrounded by A-rich sequences (Figure 4.5A). 
Given this preference for G-rich sequences, we conducted hnRNP H1 CLIP-seq experiments in cells 
grown in the presence of 6SG to avoid any bias towards G-rich sequence elements with nearby uridines. 
While the overall binding pattern of hnRNP H1 was similar, we noticed that the relative frequencies of 
binding were different within certain sites. In particular, binding sites near ~3000 nt (site 4) and ~5800 nt 
(site 6) were relatively less frequently bound in 6SG-based CLIP-seq experiments (Figure 4.5B). Other 
sites, including site 5, which encompasses the central polypurine track remained as one of the most 
frequently bound sites (Figure 4.5B). We then tested whether the highly related hnRNP F protein binds to 
similar sites on viral RNAs by CLIP-seq. Although the majority of the binding sites, including sites 2, 5 and 
6, overlapped, many other putative lower-frequency binding sites were observed (Figure 4.5C), 
suggesting that these highly similar proteins potentially have both overlapping and distinct functions in 
regulation of HIV-1 splicing. We then tested whether mutations within hnRNP H1 binding sites blocked 
hnRNP H1 binding on viral RNAs. To this end, mutations within the eight most predominant hnRNP H1 
binding sites were introduced such that no more than two consecutive A or G nucleotides remained within 
the hnRNP H1 binding site. Reassuringly, these mutations abolished hnRNP H1 binding on viral RNAs 
and did not lead to the emergence of other high frequency binding sites (Figure 4.5D). Overall, these 
findings corroborate the aforementioned CLIP-seq studies with hnRNP H1 (Figure 4.2D) and support the 
presence of several high-specificity binding sites for hnRNP H1 on HIV-1 RNAs. 
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Figure 4.5. HnRNP H1 binds to purine-rich sequences on the viral genome. 
(A) Sequence alignment of the eight most frequently hnRNP H1-bound sites as derived from CLIP-seq analysis 
shown in Figure 4.2. (B-D) Comparison of the frequency distribution of nucleotide occurrence (read density) of reads 
mapping to the NL4-3 genome derived from CLIP-seq experiments conducted on 4SU vs. 6-SG-treated cells (B), 
hnRNP H vs. hnRNP F-expressing cell lines (C), and in hnRNP H1-expressing cells transfected with WT vs. hnRNP 
H1-binding site mutant proviral clones (D). 
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Calorimetric and NMR titrations validate hnRNP H1 RNA binding preferences 
 To gain a quantitative description of how hnRNP H1 binds purine rich sequences, we carried out 
calorimetric and NMR titrations using its RNA binding domains. Human hnRNP H1 consists of three 
quasi-RNA Recognition Motifs (qRRMs) and two glycine-rich domains (Figure 4.6A). At its N-terminus, 
qRRM1 and qRRM2 are connected through a ~20 amino acid linker (qRRM12), whereas qRRM3 is 
embedded between the glycine-rich domains at its C-terminus. While members of the hnRNP H/F family 
are known to bind G-rich sequences, our CLIP-seq experiments reveal an obvious poly-A preference 
surrounding these sequences. To quantitatively determine the RNA sequence contribution to hnRNP H1 
in recognition of HIV-1 RNAs, we performed calorimetric titrations of its qRRM12 domain with an RNA 
oligonucleotide that has the same composition as site 5 (Figure 4.6B). The titration showed that qRRM12 
binds site 5 with moderate affinity (Kd = 0.62 μM) and with a stoichiometry >2, likely as result of the 
presence of three G-tracts that are 4-6 nts long within site 5. The poly-A region did not appear to 
contribute to binding affinity since titrations of qRRM12 with a 5’-AAAAA-3’ oligonucleotide showed no 
binding (Figure 4.6B). Furthermore, titrations with 5’-AGGAC-3’ revealed that binding requires more than 
2 consecutive guanosines (Figure 4.6B). 
 
 
Figure 4.6. HnRNP H1 exhibits specificity for G-rich sequences in vitro.  
(A) Schematic diagram of the domain architecture of hnRNP H1. ITC experiments conducted with (B) hnRNP H1-
qRRM12 and RNA fragments consisting of Site 5 within the viral genome, ‘AAAAA’, and ‘AGGAC’, (C) hnRNP H1-
qRRM12 and RNA fragments ‘AGGGG’, ‘AGGGA’, ‘AGGGU’ and ‘AGGGC’. (D) ITC experiments were conducted 
using individual RNA binding domains of hnRNP H1, qRRM1-3 and ‘AGGGU’. (E) HSQC titrations were performed 
with 15N-labled qRRM12 and unlabeled ‘AGGGU’.  
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 Having established that qRRM12 does not bind poly-A and minimally requires >2 consecutive 
guanosines, we next performed calorimetric titrations with model RNA oligonucleotides: 5’-AGGGG-3’, 5’-
AGGGA-3’, 5-AGGGU-3’ and 5’-AGGGC-3’ (Fig 6C). qRRM12 bound all four oligonucleotides with 
moderate affinities (Kd = 0.08-1.7 uM) but it bound 5’-AGGGG-3’ the tightest (Fig 6B). The binding 
stoichiometry for the qRRM12-(5’-AGGGG-3’) complex is <0.5, which we determined by NMR (not 
shown) to be a result of a preexisting single-strand to G-quadruplex equilibrium of 5’-AGGGG-3’. The 
stoichiometric ratios for all other complexes are consistent with 1:1 binding, indicating that these 
oligonucleotides predominantly adopt a single-strand conformation under the solution conditions. Given 
that qRRM12 binds G-tracts with 1:1 stoichiometry, we sought to determine if the isolated qRRMs retain a 
similar mode of interaction. Figure 4.6D shows that all three qRRMs bound 5’-AGGGU-3’ with nearly 
identical affinity and as a 1:1 complex. To further identify the binding interface of qRRM12 with G-tract 
RNA, we performed HSQC titrations, wherein uniformly 15N-labled qRRM12 was titrated with unlabeled 5’-
AGGGU-3’ (Fig 6E). The differential line broadening of the NMR signals for qRRM12 in complex with 5’-
AGGGU-3’ clearly indicate binding specificity through both qRRM1 and qRRM2 domains. Thus, the 
combined calorimetric and NMR titrations reveal that each qRRM binds G-tract sequences equally well 
and that the tandem qRRM12 domain does not appear to bind G-tracts cooperatively.  However, these 
results shed light on why Site 5, which contains three consecutive G-rich tracts constitutes the primary 
hnRNP H1 binding site on viral RNAs.  
Effect of mutations within the hnRNP H1 binding sites 
 We then tested whether individual mutations within hnRNP H1 binding sites can recapitulate the 
observed effects of hnRNP H1 RNAi on HIV-1 alternative mRNA splicing (Figure 4.4B, C). To this end, 
mutations within hnRNP H1 binding site were introduced as above. Note that although the majority of 
these mutations were silent, conserved amino acid substitutions (i.e. lysine to arginine) were introduced 
within hnRNP H1 binding sites when necessary. Reassuringly, transfection of HEK293T cells with proviral 
plasmids yielded similar levels of infectious virus for the majority of the mutants (Figure 4.7A), with the 
exception of mutation within the eighth binding site that encompasses the 3’ polypurine tract. To test the 
effects of hnRNP H1 mutations on viral splicing, HEK293T cells were transfected with NL4-3-derived 
proviral plasmids that bear the individual hnRNP H1 binding site mutations as well as a mutant plasmid in 
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which all mutations were combined. Total RNA was analyzed as in Figure 4.4 by deep-sequencing. While 
the majority of mutations had relatively modest effects on HIV-1 splicing, mutation of the 5th binding site 
reduced the usage of splice acceptor A1 at levels similar to hnRNP H1 knock down (Figure 4.7C). Note 
that this site has consistently constituted the most predominant hnRNP H1 binding site in all CLIP-seq 
experiments and is localized near splice acceptor A1 (Figure 4.7D). Importantly, amongst all of the 
hnRNP H1 binding sites, site 5 exhibited the strongest splicing silencer activity in a reporter assay system 
(31) (Figure 4.7E). Combination of all mutations similarly led to a further reduction in A1 usage, 
suggesting the contribution of other hnRNP H1 binding sites to regulation of A1 usage. Next, we 
determined whether these changes in viral splicing would affect viral gene expression. To this end, 
HEK293T cells were infected with VSV-G pseudotyped WT and mutant viruses at equivalent MOIs, and 
Gag and Vif expression in cell lysates was analyzed two days post infection. While the mutations within 
sites 1-3 and 5 had no major effect on Gag expression, mutations 4 and 6-8 reduced Gag expression 
significantly (Figure 4.7F). Note that similar experiments conducted in the presence of reverse 
transcriptase inhibitor, Nevirapine, did not reveal any Gag signal in western blots, suggesting that the Gag 
detected in this setting is synthesized de novo and does not represent the input viruses. Most notably, 
while mutation 5 did not affect Gag expression, it led to a significant reduction in Vif expression (Figure 
4.7F), in line with the observed reduction in A1 usage that controls Vif expression (Figure 4.7C). Overall, 
these experiments revealed a novel cis-acting element that regulates splice acceptor A1 usage and 
subsequent Vif expression.  
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Figure 4.7. Mutation of hnRNP H1 binding sites alters HIV-1 replication and alternative splicing. 
(A) Viral titers for individual hnRNP H1 mutant clones transfected into 293T cells (B, C) Splice acceptor usage for the 
1.8 kb and 4 kb class of HIV-1 RNAs is shown for virus growing in cells where hnRNP H1 was knocked down with 
siRNA (first column), and in which one or all of the hnRNP H1 binding sites were mutated. (D) Schematic diagram of 
the HIV-1 genome features and the locations of the mutated hnRNP H1-binding sites. (E) Splicing activity of the 
hnRNP binding sites in a reporter assay. (F) Gag expression of the hnRNP H1 binding site mutants, with and without 
the reverse transcriptase inhibitor Nevirapine. 
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Discussion 
Alternative splicing of HIV-1 mRNAs has traditionally been studied in artificial settings whereby a 
fragment of the viral genome with presumed regulatory activity was taken out of the context of the viral 
genome. These elements and the trans-acting factors (i.e. hnRNPs or SR proteins) that bind to them 
were typically analyzed by employing in vitro or transfection-based splicing reporter assays. These 
approaches were typically combined with RT-PCR/gel sizing assays (6) to capture how mutation of a 
regulatory element alters viral splicing. However, as this method relies on size-separation of viral mRNA 
isoforms following PCR, it cannot accurately identify differences in co-migrating variants, has limited 
sensitivity to detect minor variants, and is prone to skewing in the relative quantities of splice isoforms 
due to PCR artifacts. As such, these approaches are greatly limited in their ability to reveal the 
physiologically relevant splicing regulatory events. 
In this study, we employed next-generation sequencing-based approaches to identify the targets 
of several hnRNP proteins on HIV-1 RNAs in cells and how these binding events directly affect viral 
alternative mRNA splicing. In contrast to previous studies, which suggested that members of the hnRNP 
A/B family bind to distinct sequences on viral RNAs, CLIP-seq experiments revealed that these proteins 
bind rather promiscuously throughout viral RNAs and require the presence of ‘AGG’ motifs within binding 
sites. In contrast, hnRNP H1 binding took place at distinct G-rich sequence elements, which often 
consisted of two or more copies of ‘GGGG’ nucleotides. As such, it is probabilistically expected that the 
viral genome contains significantly more binding sites for hnRNP A/B than hnRNP H1. Reassuringly, the 
most predominant hnRNP H1 binding site near splice acceptor A1 exhibited splice enhancer activity, i.e. 
mutation of this site led to a significant decrease in the usage of A1 and Vif expression. While hnRNPs 
are generally thought to repress splicing at nearby elements, it is important to note that many act in a 
context dependent manner and can exhibit splice enhancer or silencer activities (32). 
hnRNPs can repress the assembly of spliceosomes through multimerization along exons (33). 
Therefore, the promiscuous binding pattern of hnRNP A1 and A2/B1 proteins on viral RNAs can be 
explained by their initial interaction with high affinity binding sites and their subsequent oligomerization 
throughout viral RNAs. Another possible explanation is that not all binding events identified by CLIP-seq 
are relevant to splicing regulation, but reflect other metabolic roles of hnRNPs throughout the cell. Note 
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that the CLIP-seq experiments in this study were conducted on total cell lysates suggesting this 
possibility. For example, hnRNP proteins have known regulatory roles in retention of unspliced viral 
genomic RNA in the nucleus (34, 35), nuclear export of viral/cellular RNAs (36), mRNA translation, 
storage, degradation and stress responses (36-40). While at steady state the majority of hnRNP/SR 
proteins are localized in the nucleus, many hnRNP/SR proteins shuttle between the nucleus and the 
cytosol (41, 42).  
RNAi of hnRNPs have been widely utilized in the field to determine their roles in HIV-1 splicing 
regulation. However, we noticed that RNAi of hnRNP A1 and A2/B1 did not affect Gag expression or 
particle infectivity. This may indicate the functional redundancy between these proteins, as also supported 
by the CLIP-seq data. However, it is noteworthy that the RNAi of hnRNP A1 and A2/B1 altered the 
utilization of several splice acceptors, including A3, which controls tat expression, and A4, which controls 
rev expression. As such, the opposing effects of hnRNP A1 and A2/B1 RNAi on tat and rev expression 
can also, in principle, explain the lack of effect on Gag expression. In contrast, while RNAi of hnRNP H1 
decreased A4 usage (and hence likely decreased rev expression), it did not cause a corresponding 
increase in A3 usage (i.e. tat expression), which may explain the Gag expression defect.  
Several previous studies have identified hnRNP H1 binding sites on viral RNAs. Notably, none of 
these sites are bound at high levels by hnRNP H1 in the CLIP-seq setting. For example, the proposed 
hnRNP H1 binding sites within tat exon 2 (14) and tev-specific exon 6D in certain HIV-1 isolates (15) 
consists of only one ‘GGG’ element and no surrounding A-rich sequences. Notably, detailed in vitro 
binding experiments previously revealed a key preference for the presence of multiple copies of three or 
more G-rich sequences interspersed with other nucleotides for high affinity binding for all members of the 
hnRNP H family (17). We have observed that the affinity of hnRNP H1-RRM12 towards the CLIP-seq-
derived binding site 5, which contains three high affinity binding sites for hnRNP H1, was similar to 
isolated G-rich sequence elements in vitro. This perhaps suggests that the ability of hnRNP H to bind to 
target sequences is not only driven by the affinity of individual RRMs, but also by avidity, which would 
explain why site 5 within the viral genome constitutes the primary binding site for hnRNP H1. Future 
structural studies will be crucial in determining how G-rich repeats affect RNA structure and how hnRNPs 
gain specificity for target sequences given the apparent low-modest affinity of binding in vitro. 
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Although Site 5 exhibited strong splicing silencer activity in a reporter-based assay, our results 
indicate that it acts to enhance splicing to acceptor A1 within the context of the viral genome. While this 
reiterates the importance of studying a splicing regulatory element within its natural context, it is also 
noteworthy that no other cryptic sites were activated either near A1 or in other locations across the 
genome by mutations to hnRNP H1 binding sites. 
Although we have identified several distinct hnRNP H1 binding sites by CLIP-seq, mutations 
introduced within the majority of hnRNP H1 binding sites only modestly affected splicing. One explanation 
for this phenomenon is the other known roles of hnRNPs in RNA metabolism as detailed above, which 
also is in line with the result that mutation of some hnRNP H1 binding sites led to decreased Gag 
expression in cells. A further explanation is that these binding sites work in a combinatorial fashion with 
other hnRNP H1 binding sites. In fact, we noted that mutation of all hnRNP H1 binding sites led to a more 
significant decrease in splice acceptor usage (Figure 4.7D, E). This would also be in line with the model 
that hnRNPs can loop out entire exons (43), which would require a minimum of two binding sites 
surrounding exons. 
 Overall, our studies reveal precisely where on viral RNAs the hnRNPs bind to but also how these 
binding events directly regulate HIV-1 splicing. Finally, these studies also provide the key framework to 
further investigate the poorly understood process of HIV-1 splicing.  
Materials and Methods 
Cell culture, transfection and infections 
 HeLa-derived TZM-bl cells (NIH AIDS Reagents) and HEK 293T cells (ATCC CRL-11268) were 
maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Full-
length HIV-1 proviral clones, NL4-3 (NIH AIDS Reagents, (44)), NDK (45), and derivatives thereof were 
transfected to HEK293T cells either alone or together with a VSV-G expression vector at ratio of 4:1 using 
polyethylenimine (PolySciences). To generate HEK293T cells stably expressing hnRNPs, cells were 
transduced with VSV-G pseudotyped viruses that were produced by transfection of 293T cells with 
plasmids expressing MLV Gag-Pol, LHCX-derived hnRNP expression plasmids and VSV-G at a ratio of 
5∶5∶1, respectively, using polyethylenimine. Following selection in cell culture media supplemented with 
50 μg/ml hygromycin, single cell clones were isolated and propagated. For CLIP-seq experiments, 
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HEK293T cells stably expressing 3xHA-tagged hnRNPs were grown in 15-cm dishes and transfected with 
30 μg of the indicated proviral plasmids using polyethylenimine (PolySciences). In other experiments, 
293T cells grown in 24-well cell culture dishes were transfected with siRNA duplexes against hnRNPs 
using Lipofectamine RNAimax reagent (Life Technologies) according the manufacturer’s instructions. 
One day post siRNA transfection, cells were infected with VSV-G-pseudotyped HIVNL4-3 or HIV-1NDK, and 
viral gene expression was analyzed two days later. 
Antibodies 
 Antibodies used in CLIP-seq and western blot assays were as follows: mouse monoclonal anti-
HA (HA.11 Covance), mouse monoclonal anti-hnRNP A1 (SC-32301, Santa Cruz), mouse monoclonal 
anti-hnRNP A2/B1 (SC-374053, Santa Cruz), goat polyclonal anti-hnRNP H (SC-10042, Santa Cruz), 
mouse monoclonal hnRNP K (SC-28380, Santa Cruz), and mouse monoclonal anti-HIV-1 p24CA (183-
H12-5C, NIH AIDS Reagent Program). 
Plasmids 
 Full-length proviral plasmids pNL4-3 (NIH AIDS Reagents) and pNDK were described before (44, 
46). N- and C-terminally 3xHA-tagged hnRNPs were cloned into the pCR3.1 and pLHCX (Clontech) 
vector backbones by conventional molecular biology tools. HnRNPH1 binding site mutations were 
generated on the NL4-3 proviral backbone by overlap PCR using the following primer pairs containing the 
mutations: 
356-414 (F): 5’ ATT AAG CGG CGG AGA ATT AGA TAA GTT CGA CAA GAT TCG GTT AAG GCC 
AGG CGG CAA GA 3’ 
356-414 (R): 5’ TCT TGC CGC CTG GCC TTA ACC GAA TCT TGT CGA ACT TAT CTA ATT CTC CGC 
CGC TTA AT 3’ 
1373-1424 (F): 5’ GAT GAC AGC ATG TCA AGG CGT CGG CGG CCC CGG CCA TAA GGC AAG AGT 
TTT G 3’ 
1373-1424 (R): 5’ CAA AAC TCT TGC CTT ATG GCC GGG GCC GCC GAC GCC TTG ACA TGC TGT 
CAT C 3’ 
1918-1961 (F): 5’ GAA GAT GGA AGC CCA AGA TGA TAG GCG GCA TTG GAG GTT TTA TC 3’ 
1918-1961 (R): 5’ GAT AAA ACC TCC AAT GCC GCC TAT CAT CTT GGG CTT CCA TCT TC 3’ 
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2961-2909 (F): 5’ GAC ATA CAG AAG TTA GTC GGC AAG CTC AAT TTC GCA AGT CAG ATT TAT G 
3’ 
2961-2909 (R): 5’ CAT AAA TCT GAC TTG CGA AAT TGA GCT TGC CGA CTA ACT TCT GTA TGT C 
3’ 
4322-4381 (F): 5’ CAC AAT TTT AAG AGG AAG GGC GGC ATT GGC GGC TAC AGT GCA GGC GAG 
AGA ATA GTA GAC 3’ 
4322-4381 (R): 5’ GTC TAC TAT TCT CTC GCC TGC ACT GTA GCC GCC AAT GCC GCC CTT CCT 
CTT AAA ATT GTG 3’ 
4322-4381 (F): 5’ CAC AAT TTT CGA CGC CGC GGC GGC ATT GGC GGC TAC AGT GCA GGC GAG 
AGA ATA GTA GAC 3’ 
4322-4381 (R): 5’ GTC TAC TAT TCT CTC GCC TGC ACT GTA GCC GCC AAT GCC GCC GCG GCG 
TCG AAA ATT GTG 3’ 
5785-5836 (F): 5’ TAT CAG CAC TTG TGG AGA TTC GGC TGG CGC TTC GGC ACC ATG CTC CTT 
GGG A 3’  
5785-5836 (R): 5’ TCC CAA GGA GCA TGG TGC CGA AGC GCC AGC CGA ATC TCC ACA AGT GCT 
GAT A 3’  
7524-7575 (F): 5’ GGA TCA ACA GCT CCT CGG CAT TTT CGG TTG CTC TGG CAA GCT CAT TTG 
CAC C 3’  
7524-7575 (F): 5’ GGT GCA AAT GAG CTT GCC AGA GCA ACC GAA AAT GCC GAG GAG CTG TTG 
ATC C 3’  
8587-8645 (F): 5’ AGA TCT TAG CCA CTT TCT CCG CGA GCG CGG CGG ACT GGA AGG CCT AAT 
TCA CTC CCA AA 3’ 
8587-8645 (R): 5’ TTT GGG AGT GAA TTA GGC CTT CCA GTC CGC CGC GCT CGC GGA GAA AGT 
GGC TAA GAT CT 3’ 
 A GFP-based splicing silencer reporter plasmid, pZW4, was published before (31). The following 
oligonucleotides encompassing the hnRNP H1 binding sites and containing 5’ XhoI- 3’ Apa I restriction 
sites were annealed in vitro cloned into the pZW4 vector. The resulting constructs were transfected into 
HEK293T cells and GFP expression was analyzed two-days post-transfection by FACS. 
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362-402 (F): 5’ TCGAGCGGGGGAGAATTAGATAAATGGGAAAAAATTCGGTTAAGGC GGGCC 3’ 
362-402 (R): 5’ CGCCTTAACCGAATTTTTTCCCATTTATCTAATTCTCCCCCGC 3’ 
1386-1406 (F): 5’ TCGAG CAGGGAGTGGGGGGACCCGGCGGGCC 3’ 
1386-1406 (R): 5’ CGCCGGGTCCCCCCACTCCCTGC 3’ 
1925- 1958 (F): 5’ TCGAGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTAGGGCC 3’ 
1925-1958 (R): 5’ CTAAAACCTCCAATTCCCCCTATCATTTTTGGTTTC 3’ 
2867-2899 (F): 5’ TCGAGCAGAAATTAGTGGGAAAATTGAATTGGGCAAGTGGGCC 3’ 
2867-2899 (R): 5’ CACTTGCCCAATTCAATTTTCCCACTAATTTCTGC 3’ 
4325-4371 (F): 5’ 
TCGAGAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGGGGCC 3’ 
4325-4371 (R): 5’ CCTTTCCCCTGCACTGTACCCCCCAATCCCCCCTTTTCTTTTAAAATTC 
3’ 
5789-5822 (F): 5’ TCGAGAGCACTTGTGGAGATGGGGGTGGAAATGGGGCACGGGCC 3’ 
5789-5822 (R): 5’ CGTGCCCCATTTCCACCCCCATCTCCACAAGTGCTC 3’ 
7536-7564 (F): 5’ TCGAGCCTGGGGATTTGGGGTTGCTCTGGAAAACGGGCC 3’ 
7536-7564 (R): 5’ CGTTTTCCAGAGCAACCCCAAATCCCCAGGC 3’ 
8604-8631 (F): 5’ TCGAGTAAAAGAAAAGGGGGGACTGGAAGGGCTGGGCC 3’ 
8604-8631 (R): 5’ CAGCCCTTCCAGTCCCCCCTTTTCTTTTAC 3’ 
CLIP-seq experiments  
 CLIP-seq experiments were conducted as explained before (23). Briefly, 293T cells stably 
expressing 3xHA-tagged hnRNPs and transfected with proviral plasmids were grown in the presence of 
4-thiouridine. Cells were washed in 1x phosphate buffered saline and UV-crosslinked at 365nm 
wavelength. Following lysis, hnRNP-RNA complexes were immunoprecipitated using monoclonal 
antibodies against the HA-tag. Bound RNA was end-labeled with γ-32P-ATP and T4 polynucleotide 
kinase. The isolated protein-RNA complexes were separated by SDS-PAGE, transferred to nitrocellulose 
membranes and exposed to autoradiography films. Protein-RNA adducts were excised from membranes 
and RNA was purified by proteinase K digestion. RNA was sequentially ligated to 3’ and 5’ adapters, 
reverse-transcribed, PCR-amplified and the resulting DNA library was subjected to sequencing by 
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Illumina platforms. The remainder of the data analysis was followed as detailed before (23), using 
FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit), Bowtie (47), PARalyzer (48), with the exception of 
applying a more stringent T-to-C substitution-based cutoff for defining IN-binding sites (PARpipe). Briefly, 
sequencing reads were first trimmed off of the 3’ adapter, reads shorter than 15 nucleotides were filtered 
out and the library was demultiplexed based on the 5’ adapter sequences using the FASTX toolkit. 
Sequences were then collapsed into unique reads followed by trimming off the 5’ adapter using the 
FASTX toolkit. The resulting reads were mapped to the human genome (hg19) or viral genome (pNL4-3) 
containing a single repeat (R) region using the Bowtie algorithm by allowing two mismatches (-v 2 -m 10 -
-best strata). Reads that map to the human genome were further processed and clustered by PARalyzer 
and PARpipe pipelines using default settings 
Nucleic acid isolation, reverse transcription, Q-PCR  
 Total cellular RNA was isolated by Trizol extraction (Life Technologies) and the resulting RNA 
was reverse-transcribed using the Improm-II Reverse Transcription System (Promega) following the 
manufacturers’ instructions. In some experiments, cytosolic and nuclear extracts were isolated using the 
NE-PER kit (Thermo-Fisher), and RNA and DNA were isolated subsequently by phenol:chloroform 
extraction. Q-PCR analysis of unspliced and spliced RNAs was conducted using the previously published 
primer pairs (23). 
Splicing assays   
 A next-generation-sequencing splicing assay was conducted as detailed in Chapter 2. Briefly, 
total RNA from HEK293T cells transfected with proviral plasmids or infected with the corresponding VSV-
G pseudotyped viruses was isolated by Trizol. The resulting RNA was subjected to the previously 
described library generation protocol (Chapter 2) and sequenced using the 300 base paired-end read 
Illumina MiSeq platform with samples loaded at 8 pM plus 15 % PhiX double-stranded DNA fragments to 
maximize cluster separation. Sample reads were demultiplexed using the Illumina bcl2fastq v.1.8.4 
pipeline.  
Splicing data analysis was done using a customized Ruby program which combines splicing data 
from the forward and reverse reads to identify and quantify specific transcript types.  As previously 
described, all reads are tagged with a unique Primer ID sequence identifier attached in the cDNA step.  
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All sequencing reads with the same Primer ID are combined to prevent skewing from PCR resampling. 
Alternative acceptor splice sites are also identified and quantified. Programs used are available at 
https://github.com/SwanstromLab/SPLICING. 
Protein expression and purification   
 We cloned HIS6 tag qRRM1, qRRM2, qRRM3 and qRRM12 domains into pMCSG7 vector. The 
recombinant proteins were overexpressed in E. coli strain BL21 (DE3).  The BL21 (DE3) cells were grown 
to an optical density of 0.8 at 37°C with 220 rpm and through induction at 20°C with 1mM IPTG for 16 
hours. Cells were harvested in lysis buffer containing 20 mM Na2HPO4, 20 mM imidazole, 500 mM NaCl, 
4mM TCEP at pH 8.0 by sonication at 4°C and collected by centrifugation. The cleared lysate was then 
applied to Ni-NTA agarose and washed with lysis buffer and lysis buffer containing 40mM imidazole, and 
eluted with buffer containing 300mM imidazole. The elution fractions were concentrated and buffer 
exchanged into lysis buffer. The HIS6 tag of the proteins were removed by incubating with TEV Protease 
at 25°C for 16 hours. The proteins were purified by size exclusion chromatography with NMR buffer 
containing 20mM sodium phosphate, 20 mM NaCl, 4mM TCEP at pH 6.2. The purity of the proteins was 
analyzed and estimated > 95% by SDS page analysis.  
Isothermal titration calorimetry  
 The binding affinities of qRRM1, qRRM2, qRRM3 and qRRM12 with the G-tract RNA 
oligonucleotides were characterized by measuring heat changes on titrating protein domains into each G-
tract RNA oligonucleotide solution using a Microcal VP-ITC calorimeter. Protein and RNA solutions were 
buffer exchanged to 20mM sodium phosphate, 20 mM NaCl, 4mM TCEP at pH 6.2, centrifuged and 
degassed under vacuum before use. All titrations were performed at 25°C and the data were analyzed 
using Origin software (Microcal). 
NMR experiments  
 The NMR experiments were performed on a Bruker 800 MHz spectrometer at 32°C equipped with 
a cryprobe. The 15N-labeled and 15N/13C-labeled samples for NMR experiments were prepared in a buffer 
containing 20mM sodium phosphate, 20 mM NaCl, 4mM TCEP and 10 % D2O at pH 6.2. Backbone 
assignments of qRRM12 were obtained from HNCA, HNCACB, HNCO, and HN(CA)CO. For NMR 
titrations, the uniformed 15N- in 
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20mM sodium phosphate, 20 mM NaCl, 4mM TCEP and 10 % D2O at pH 6.2. The unlabeled 5’-AGGGC-
3’ oligonucleotide was added to uniformly 15N-labeled qRRM12 at molar ratio of 1:0:33, 1:0:66, 1:1, 1:2. 
All Spectra were processed with NMRPipe/DRAW and analyzed using Sparky. 
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CHAPTER 5: USING APOBEC3G AS A MUTAGEN TO PROBE HIV-1 SPLICING SIGNALS 
Background 
 HIV-1 RNA is spliced to produce more than 40 different transcripts, and regulated splicing is 
required to produce sufficient amounts of each mRNA to make the viral proteins.  Full-length genomic 
RNA is the primary product of transcription, and it may remain unspliced as genomic RNAs or as the gag 
and gag/pro/pol mRNAs.  All other viral mRNAs are made by splicing of this full-length transcript (1-3).  All 
spliced transcripts first use splice donor D1 to splice to one of the downstream acceptors.  A second 
splicing event may remove the env intron by splicing between D4 and A7.  Transcripts that retain the env 
intron are called incompletely spliced or 4 kb transcripts, and those that splice out the env intron are 
called completely spliced or 2 kb transcripts.  
 The HIV-1 Vif protein is made by a splice from the 5’ donor D1 to the 3’ acceptor A1 without any 
further splicing at D2(1-3). Vif prevents the mutagenic effects of cellular APOBEC3G (A3G) on viral DNA 
by targeting A3G for ubiquitination and proteosomal degradation (4-6).  In the absence of Vif, A3G is 
incorporated into progeny virions and causes C to T mutations on the newly synthesized negative strand 
of viral DNA during reverse transcription (7).  It is therefore critical that the virus makes enough Vif to 
counter A3G hypermutation, but not too much Vif since overexpression would be at the expense of 
expression of other viral proteins.  The jury is still out on the question of the toxicity of too much Vif 
protein per se.  While some researchers have reported that high levels of Vif reduce Gag processing (8, 
9), another group showed that the high levels of Vif are the result of mutations that cause oversplicing, 
and the excessive number of spliced vif transcripts reduces the number of unspliced gag transcripts (10).  
A third group finds that in naturally occurring variations, the level of vif transcripts does not affect other 
transcripts but high or low Vif has a fitness cost (11). Either way, the number of vif transcripts must be 
kept within certain parameters for optimal viral fitness.  Because HIV-1 splicing is highly suppressed and 
inherently inefficient, cis-acting splicing regulatory elements (SRE) are required to control splicing and 
splice acceptor usage.  Many studies have found, characterized, and tested the effects of SREs acting on 
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HIV-1 splice acceptor A1 (12-16). Although even low levels of Vif provide enough protection from A3G to 
allow a near-normal degree of replication, Vif-minus viruses are completely replication defective in cells 
that express A3G (13).   
 Structure also plays an important role in the regulation of vif transcripts.  The stem-loop structure 
containing splice acceptor A1 (SLSA1) is highly conserved (17), and naturally occurring variations in the 
structure result in varied levels of Vif (11).  We have previously found that silent mutations that disrupt the 
SLSA1 structure caused a 10-fold reduction in vif transcripts (3).  This loss in vif transcripts caused a 
barely noticeable replication defect (17), as is typical for mutations that partially down-regulate Vif (13). 
 Considering the lack of fitness loss, we asked if the SLSA1 mutant virus had a higher mutation 
rate than the WT NL4-3, based on our previous splicing data (3).  We used Primer ID technology to 
accurately identify mutations and mutation rates.  Primer ID is a random sequence tag in the cDNA 
primer, which is incorporated in the cDNA synthesis step and all PCR products subsequently made from 
that tagged cDNA (18). Each cDNA gets a unique Primer ID and after sequencing, the PCR products can 
be sorted by their Primer IDs. No matter how many times any one Primer ID occurs, each Primer ID 
sequence is counted only once, and skewing in the PCR steps is filtered out. Additionally, a consensus 
sequence is made from the multiple reads with the same Primer ID, making it possible to filter out PCR 
and sequencing errors and identify valid mutations.  
 For this analysis of mutation rates, we looked at a sequence between splice acceptor A5 and 
splice donor D4 (Figure 5.1).  This is a sixty-one nucleotide sequence that starts 6 bases downstream of 
A5 and ends 1 base before D4.  These boundaries excluded bases that are part of the splicing consensus 
sequences.  This region is present in all HIV-1 transcripts.  Additionally, it is located immediately adjacent 
to the Primer ID-tagged reverse primers used for cDNA synthesis and is in the early and accurate part of 
the sequencing reads, making it well suited for identifying mutations. 
 
 138 
 
Figure 5.1. Target sequence between A5 and D4.  
The sequence used to quantify mutations is in brackets and contains part of the GAR ESE element and is part of both 
the Tat and Rev ORFs. 
 
 This target sequence between A5 and D4 contains part of the ORFs for both Tat and Rev, plus a 
splicing enhancer named GAR ESE (guanine-adenine rich exonic splicing enhancer) which has been 
previously identified as necessary for the splicing of env transcripts (use of acceptors A4 or A5) (19, 20).  
Besides the GAR ESE element, the rest of the sequence between A5 and D4 was also found to be 
essential for splicing but the specific bases involved were not defined (20-22). This previous work used 
artificial splicing constructs and PCR product/gel quantification.  While such artificial constructs are useful 
for screening potential SREs, they may not represent splicing in the full-length virus.  The constructs used 
to characterize the region between A5 and D4 failed to exhibit normal HIV-1 splicing behavior and 
therefore the conclusions drawn from them must await confirmation by an in-context demonstration of 
their validity.  Our straightforward assay quantifies HIV-1 RNA splicing patterns in the context of viral 
infection.  
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 When we analyzed mutation rates, the results were unexpected.  Specific mutations collected 
differentially in the two HIV-1 size classes, suggesting that the mutations themselves impacted splicing 
behavior and thus created a genetic screen that correlates mutations in the A5 to D4 sequence with both 
upstream and downstream changes in splicing.  
Sequencing and Bioinformatics Methods 
 As previously described in Chapter 2 for the SLSA1 experiment, CEMx174 cells were infected 
with either WT NL4-3 or SLSA1 mutant viruses.  RNA was harvested after 5 days of spreading infection.  
Primer ID-tagged reverse primers specific for either the 1.8kb or 4kb splice size classes and a common 
forward primer were used to tag the 50+ HIV-1 spliced mRNAs with a Primer ID (Figure 2.1).  Following 
amplification and Illumina paired-end deep sequencing, the data files for both the WT and mutant SLSA1 
for both size classes were processed using the following algorithm.  mRNAs were quantified according to 
spliced transcript type using the splicing program described in Chapter 2.  Reads that occurred 3 or more 
times in the sequencing data (identified by their matching Primer IDs) were collapsed into consensus 
sequences spanning the A5 to D4 region shown in Figure 5.1.  Each consensus sequence was then 
aligned with the WT A5 to D4 sequence and mutations were identified and scored.  Only consensus 
sequences with two or fewer mutations were used, to filter out hypermutated or mis-primed reads.  The 
consensus sequences were sorted and quantified according to mutation type.  This information provided 
the data for calculations of total mutation rates and for specific mutation types. 
 To quantify the proportional representation of mutations in each size class, the consensus 
sequences were sorted and quantified according to mutation type.  For each mutation type we calculated 
its percentage of the total consensus sequences.  These relative proportions were then compared across 
size classes.  The rates of upstream splice acceptor usage were also tabulated for each mutation type.   
Results 
Mutations are not equally represented in the two HIV-1 spliced transcript size classes  
Figure 5.2 shows the mutation rate in the WT vs. SLSA1 mutant for both the 1.8 kb and 4 kb size 
classes.  In the 4 kb transcripts, there was no increase in mutation rate in the SLSA1 sample, but there 
was an increase in mutation rate in the 1.8 kb samples.   
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Figure 5.2. Mutation rates for WT or SLSA1 (low vif) in the 1.8 kb or 4 kb size classes. 
 
Looking only at the A3G mutations (C-to-T, or G-to-A in the positive strand), we found that they 
increased in the SLSA1 mutant in both size classes, but that the proportion of these A3G mutations in the 
1.8 kb class was about twice that in the 4 kb class (Figure 5.3).  This was puzzling because both 1.8 kb 
and 4 kb transcripts are made from the same full length starting transcripts, which come from the same 
integrated genomic DNA.  If the short transcripts are more mutated, the long ones should be mutated too 
and at the same rate, unless the mutations themselves increase splicing from D4 to A7. 
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Figure 5.3. G-to-A mutations as a proportion of total mutations. 
 
 To avoid confusion between the two strands, the data will be discussed in the positive strand 
notation, where A3G mutations appear as G-to-A mutations.  We looked at the proportional 
representation of each of the G-to-A mutations in the 1.8 kb and 4 kb size classes and found that they 
were in fact skewed toward the 1.8 kb class in both the wild type and the mutant SLSA1 samples. 
 Due to the effect of A3Gs on the G-to-A mutation rate, G-to-A mutations are present at a higher 
rate than other mutation types.  Nevertheless, the depth of sequencing was sufficient to also measure the 
skew in A-to-G mutations, which are not so overrepresented.  This indicated that all types of mutations, if 
present in sufficient amounts to allow for valid measurements, could be correlated with their effects on 
splicing.  With this data set we were able to analyze two types of potential changes in splicing.  First, if 
skewing was seen between the size classes we could find the mutations that increase or decrease the 
rate of splicing from D4 to A7.  Second, this data set also contains the upstream splicing data which 
identifies the acceptor used when splicing from D1.  With this information we could correlate specific 
mutations with upstream acceptor usage. 
 To do this extended mutational analysis we used the WT data only and not the SLSA1 mutant 
data to avoid introducing any possible additional splicing changes caused by the loss of A1 functionality.  
Reverse reads were sorted by Primer ID and reads with 3 or more occurrences were collapsed into a 
consensus sequence for the region between A5 and D4.  These consensus sequences were aligned to 
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the WT sequence and mutations were scored and tabulated along with the splicing data.   
 Only sequences with 2 or fewer mutations were considered, as we did not want the data 
confounded by possible hypermutation across the genome outside of the observed area.  Nevertheless, it 
should be noted that there may be unknown mutations outside of the A5 to D4 sequence that could affect 
splicing outcomes, but such mutations should be random and therefore unlikely to skew the results.  
Hypermutation was rare and greater than 97% of all consensus sequences were wild type NL4-3.  This 
analysis produced a list of mutations across the A5-D4 sequence and correlated the mutations to both 
upstream and downstream splicing events. 
G-to-A and A-to-G mutations are skewed in size class distribution  
 Figure 5.4 shows the ratio of proportional representation of the G-to-A mutations in the fully 
spliced 1.8 kb class compared to the partially spliced 4 kb class.  This is a log scale, so an upward bar 
shows a skew towards short 1.8 kb transcripts and a downward bar shows a skew towards long 4 kb 
transcripts.  G-to-A mutations skew strongly towards D4-A7 splicing (1.8 kb short transcripts). 
Combinations of G-to-A mutations were seen that skewed at even higher rates, though they are present 
in low numbers. 
 
Figure 5.4. Skew of G-to-A mutations.  
Y-axis is a log scale of the ratio of proportional representation of each of the mutations in the 1.8 kb size class relative 
to the 4 kb size class. The numbers on the X axis show the nucleotide position within the 61 nucleotide stretch 
between A5 and D4. 
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 In contrast to the G-to-A mutations which largely caused skewing toward the 1.8 kb size class, we 
found the opposite effect for the A-to-G mutations (Figure 5.5). These mutations were more likely to be 
represented in the partially spliced 4 kb class than in the fully spliced 1.8 kb class.  While the skew for any 
one base was less than seen with the G-to-A mutations, there are more As in this region of the genome – 
22 of the 61 bases in the analyzed sequence are As. 
 
Figure 5.5. Skew of A-to-G mutations.  
The Y-axis is a log scale of the ratio of proportional representation of each of the mutations in the 1.8 kb size class 
relative to the 4 kb size class. The numbers on the X axis show the nucleotide position within the 61 nucleotide 
stretch between A5 and D4. 
 
 After G/A transitions, C/T transitions were the next most numerous mutations in this A5 to D4 
sequence.  They did not show an obvious size class skew collectively, though some individual mutations 
have an impact on splicing (not shown).  In previous work, mutations of the A or G elements in the GAR 
ESE sequence were replaced by C or T (21) or used a C and A oligo as a neutral splicing sequence (22).  
Our data show that the type of base in the mutation as well as the location is important.  There are 
examples of single positions that have two different nucleotide substitutions with different effects on 
splicing.  This suggests that these mutations affect binding of cellular splicing proteins. 
Mutations between A5 and D4 affect A5 usage 
 In addition to splicing from D4 to A7, this data set also identifies mutations that change the choice 
of upstream acceptor sites.  There are four A4 acceptor subsites that are used in different proportions in 
different HIV-1 strains (3, 23) combined with two A5 acceptor sites.  All A4 and A5 sites are included in 
the group of acceptors defined by D4.  They have shared branch points and overlapping polypyrimidine 
tracts, both involved in splice site selection (24).  It is probable that the different A4 and A5 acceptors are 
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controlled by some of the same splicing regulatory elements. 
 The usage of A5 is up or downregulated by some of the mutations in the A5-D4 sequence as 
shown in Figure 5.6.  There are hotspots that suggest these may be binding sites for regulatory proteins, 
some of which overlap with the mutations that control splicing from D4 to A7 and these effects may 
compound.  Some of the bases have multiple mutations in the data set but with results specific to 
mutation type.  For example, the mutation at base 1 shown in Figure 5.6 is an A-to-T mutation and 
causes a large reduction in A5 usage, but another mutation at base 1 from A-to-G has a smaller effect in 
the 1.8 kb size class and no effect in the 4 kb size class.  This suggests again that these mutations 
identify sites of SR or hnRNP binding. 
 
Figure 5.6. Mutations affecting the use of acceptor A5.  
The X-axis shows the positions of the mutations within the 61 nucleotide region between A5 and D7.  The 
Y-axis is a log scale of the ratio of A5 acceptor usage in the mutant relative to WT A5 usage. 
 
Discussion 
 This analysis of the region between A5 and D4 introduces a way to identify and quantify the 
effects of mutations that affect upstream splicing to A4 and A5 and also affect downstream splicing 
between D4 and A7.  Splicing regulatory elements (SRE) in this area have previously proven difficult to 
locate due to their modest effects and the confounding results of disturbing the Tat or Rev ORFs (20, 21, 
25-27).  Studies done thus far have utilized computer algorithms to identify SR protein binding sites and 
artificial splicing constructs, both with questionable outcomes (20, 21, 28). 
The sequence from A5 and D4 is unique because it is the only region between the major splice 
donor D1 and the final splice acceptor A7 that is included in every HIV-1 transcript.  The exon ending in 
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D4 can utilize the alternative A3 or A4 acceptors instead A5 but the resulting exons still contain the A5 to 
D4 sequence.  This universal inclusion identifies the A5-D4 exon as a constitutive exon.  All other HIV-1 
exons are alternative, meaning they may or may not be included.  Splicing of this constitutive exon seems 
to require a different kind of regulation from what has been seen with other alternative HIV-1 splicing 
events.  ESE and ESS elements have been identified that control splicing to A1, A2, and A3; however, 
there are no similar control elements known for A4 or A5 (12-15, 29-39).  
 Previous work identifies the GAR ESE and E42 sequences as necessary both for splicing to A5 
and for splicing between D4 and A7.  This is an unsatisfying conclusion since GAR ESE and E42 
combined constitute the entire sequence between A5 and D4 (20, 21).  The GAR ESE is not a well-
defined sequence that controls splicing and the boundary between the GAR ESE and E42 is arbitrary.   
 Mutation of the regulatory elements that control A1, A2, and A3 have dramatic effects but 
mutations to the A5 to D4 sequence cause only modest splicing changes (see Chapter 6).  It is possible 
that the regulation of this constitutive exon needs only minimal additional control elements, in contrast to 
the suppression required for the alternative splices.  Elements in the region of A7 have been described 
that control splicing between D4 and A7 (Chapter 6) (12, 34, 40, 41).  These elements are part of 
extensive pre-mRNA secondary structures and much work has been done to characterize their 
cooperative/competitive binding to regulatory proteins.  Interestingly, like the A5-D4 sequence, effects of 
mutations to these regions is small compared to the elements controlling splicing at A1, A2, and A3 (27, 
42, 43).   
 Taken together, these modest mutational effects and the spread-out nature of the putative 
regulatory sequences suggest different mechanisms controlling splicing to A5 and from D4 to A7.  We 
hypothesize that the constitutive nature of the A5-D4 exon requires very little additional control by cis-
acting sequences.  Like most known constitutive exons, it is likely to have an enhancer element, but 
perhaps not a powerful one, and no silencer (44, 45).  It may be that although splicing to A1, A2, and A3 
is controlled and highly suppressed, splicing to A4 and A5 is the default and does not require these 
multiple layers of control.  The same is likely for splicing from D4 to A7 – splicing is the default and will 
happen unless suppressed.  We hypothesize that suppression is the result of cooperative action between 
many spread-out regulatory elements (the A5-D4 region upstream of D4 and the known splicing control 
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elements downstream of A7), each relatively weak on its own.  The SREs near A7 have already been 
shown to cooperatively bind hnRNP A1 in vitro and to propagate along the mRNA and this cooperativity 
may account for the modest splicing changes seen in mutation to any one hnRNP binding site. 
 The search for A5 to D4 control elements is complicated by the requirement for Tat and Rev. This 
A5 to D4 exon includes parts of both the Tat and Rev ORFs, each in a different reading frame, and both 
Tat and Rev are critical for splicing regulation, making it difficult to make mutations without confounding 
effects (46, 47).  
 One issue that needs to be addressed with this data set is the possibility that these size class 
effects are due to mutations in Rev.  The sequence between A5 and D4 is part of the ORF for both Tat 
and Rev.  Rev is required for nuclear export of unspliced viral RNA and of the partially spliced (4 kb size 
class) HIV-1 mRNAs (46).  Deletions to Rev shift the balance of transcripts to fully spliced (unpublished 
data).  
 We do not favor this interpretation of our data.  The sequence data used came from NL4-3 virus 
grown in CEMx174 cells over a 5-day spreading infection.  CEMx174 cells form syncytia when infected 
and we waited to harvest RNA until syncytia were clearly evident and large.  Since greater than 97% of all 
the sequences analyzed were WT NL4-3, we can expect that in multiply infected cells at least one of the 
infecting viruses was producing functional Rev.  When full-length WT and mutant Rev viral plasmids are 
co-transfected, the WT Rev is sufficient to rescue normal splicing patterns in the mutant rev transcripts 
(unpublished data).  Only a small amount of Rev is required for nuclear export, and the amount of Rev in 
an infected cell is so small that it cannot consistently be accurately measured (Sebla Kutluay- personal 
communication).  An examination of the mutations found in this screen supports the presence of 
functional Rev, as the following examples illustrate.  Some mutation pairs affect the same Rev residue, 
such as two mutations that change residue 5 from S to C or G.  The first mutation is an A-to-T mutation at 
index 1 that decreases its inclusion in the 1.8 kb class – an unlikely outcome from a Rev mutant.  The 
second mutation is an A-to-G mutation also at index one that causes an insignificant increase 1.8 kb 
inclusion (see Figure 5.5, index 1).  There are several such Rev mutations in this data set with no 
apparent correlation between mutations and size class skewing.  Additionally, some of the sequence 
mutations that skew representation in the size classes are silent in Rev.  The A5-D4 sequence under 
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analysis here has not been found to harbor critical Rev residues that could have dominant negative 
effects (48).  These facts lead us to believe that the splicing changes seen here are not due to loss of 
Rev. 
 A similar argument could be made for Tat, but is unimportant since any cells singly infected by a 
Tat-defective virus would not produce enough transcripts to skew the quantification.  The presence of 
mutant tat transcripts is additional evidence for a multiplicity of infection greater than one.    
 The region between A5 and D4 is unique in that information for both the mutations and the 
splicing behavior is in the sequencing data.   It is fortuitous that such an analysis works in this specific 
region where effects are combinatorial and modest and not likely to be identified individually.  Splicing to 
A5 and A4 and from D4 to A7 has been difficult to study due to the bi-directional nature of the proposed 
SREs.  Previous studies used splicing constructs that did not create an equivalent contextual setting to 
the full-length genome for HIV-1 splicing, and mutations were not studied in the full-length virus.  This is 
the first analysis that measures the effects of mutations between A5 and D4 in the context of viral 
infection. 
 Previous studies identified SR binding sites using a computational algorithm, ESEfinder, to locate 
SR protein binding sites (28) in the ESE GAR region (21, 22).  We question the results of this method.  
SR protein binding sites have degenerate consensus sequences (28) and many more matches to the 
consensus sequences exist than the valid SR binding sites.  We submitted HIV-1 sequences likely to be 
involved in splicing regulation to ESEfinder and found that more than 50% of the bases in the sequences 
tested scored as a hit for at least one of the four SR protein binding sites used in ESEfinder.  Randomly 
generated sequences scored equally well.  Considering the nature of the known HIV-1 enhancer 
sequences and their limited locations, it is not reasonable to believe that binding sites identified by 
ESEfinder have high specificity in that it must be calling many false positive sites. This serves to illustrate 
the difficulty of identifying precise bases of SREs and the SR or hnRNP elements that bind them in vivo.   
 G-rich elements have been shown to have a splicing suppressive function (49), and two GGGG 
elements in HIV-1 suppress an upstream acceptor (15, 36).  G-rich regions flanked/interspersed by A are 
preferred hnRNP H1 binding sites (Chapter 4).  There are no GGGG regions in the A5 to D4 sequence 
but our set of mutations for this region suggests that many of the individual G bases, though spread out, 
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act to suppress downstream D4 to A7 splicing.  Though it is not possible to nail down specific factor 
binding sites, our data identifies hot spots of suppression in regions 4 through 7 and 13 through 19. 
 While the current data set is informative, an even larger data set would more specifically identify 
the bases needed for splicing repression and activation.  Combinations of mutations skew at even higher 
rates but the numbers are too low thus far for confident calculations. In addition to information about A5 
usage, a larger data set would give sufficient depth of information to quantify A4 and A3 usage as well. 
The combinatorial nature of the mutations studied here invite a machine learning analysis on a larger data 
set. 
 This A5 to D4 location is unique in that the sequencing data contains both mutations and the 
resulting splicing behavior.  This kind of correlation is possible with one other HIV-1 sequence – the area 
just upstream of D1. Like the area controlling A5 and D4, the region upstream of D1 has been challenging 
to study (50-56) and this type of deep sequencing analysis may go beyond what has been accomplished 
using artificial constructs. 
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CHAPTER 6:  A SURVEY OF KNOWN HIV-1 SPLICE REGULATORY ELEMENTS (SRE):  A RE-
EVALUATION 
Background 
 Splicing in HIV-1 requires cis-acting sequence elements and trans-acting cellular proteins to 
define and regulate the position and usage of splice sites.  The splicing consensus sequences at the 
splice sites are not sufficient by themselves to correctly distinguish correct splice sites from pseudo splice 
sites.  Cis-acting sequences outside of the splicing consensus sequences bind cellular splicing factors to 
regulate splicing.  These sequences are called splicing regulatory elements (SRE).  There are two 
classes of SREs – splicing enhancers and splicing silencers, which are named according to their 
locations.  Enhancers found in exons are exonic splicing enhancers (ESE) and enhancers in introns are 
intronic splicing enhancers (ISE).  Likewise, silencers are exonic splicing silencers (ESS) or intronic 
splicing silencers (ISS) (1).  In general, the SR family of proteins bind to enhancers to promote the 
formation of the spliceosome, while hnRNP proteins bind to silencers to occlude spliceosome formation 
(2, 3).   
 Chapter 1 summarizes the work done to date to identify and characterize SREs in HIV-1.  This 
chapter describes mutations made to a subset of the known splicing regulatory elements (SRE) shown in 
Figure 6.1.  These sites undoubtedly represent only a subset of regulatory sites with more remaining to 
be discovered.  However, as part of our efforts to gain a fuller view of HIV-1 splicing regulation we used 
two deep sequencing approaches to characterize splicing in a set of viruses with mutations in these sites.  
In addition to the previously described splicing assay (Chapter 2), this study required the development of 
a second new deep sequencing assay to quantify changes in the relative amounts of spliced, partially 
spliced, and unspliced transcripts.  Previous work done to characterize SREs used artificial sub-genomic 
constructs, but an important feature of these new studies is that they were done in the context of the full 
length viral genome. As a result of these studies we were able to confirm the contribution of some 
elements and refute the proposed role of other elements.  We were able to quantify the loss of splicing 
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repression when ESS elements were mutated, leading to oversplicing from D1 and a loss of full-length 
viral mRNAs. 
 
Figure 6.1. Relative positions of known HIV-1 SREs. 
 
Materials and Methods 
Cells and constructs 
 Silent mutations were made to the following SREs:  ESEvif, ESEM1, ESEM2, ESSV, ESS2, 
ESS2p, and ISS.  The mutated sequences were inserted into the full-length HIV-1 genome pNL-CH.  
pNL-CH is a variant of the NL4-3 strain, adapted with two silent mutations for efficient cloning.  These full-
length constructs were used to make virus and infect CEMx174 cells followed by total cellular RNA 
extraction, as described in Chapter 2.  This RNA was used as input for the splicing assay (Chapter 2) and 
also for the Random Reverse Primer Assay (RRPA) described below.   
 A set of 12 mutations were made to the stem-loop structure of ESS3 in a ∆Rev construct.   ∆Rev 
is a modification of NL4-3 with premature stop codons early in the Rev ORF.  These ∆Rev/ESS3 
constructs were co-transfected with NL4-3 into 293T cells and total cellular RNA harvested and used as 
input for the Primer ID splicing assay (Chapter 2).  Sequence differences between the mutant and wild 
type genomes allowed the spliced RNAs generated from each genome to be distinguished. 
Sequencing and bioinformatics 
 Sequencing was done using the Ilumina Mi-Seq Platform with 300 base paired-end reads as 
described in Chapter 2.  The program used to analyze the sequence data for spliced RNAs, described in 
Chapter 2, was adapted to accommodate the silent mutations created to test the role of cis-acting 
sequences.   
 A new program was written to process the random reverse primer sequencing reads.  The reads 
were sorted according to spliced or unspliced.  If spliced, the acceptor site was identified.  Spliced reads 
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of sufficient length were identified as totally spliced or partially spliced.  The number of spliced transcripts 
was compared to the number of unspliced transcripts of equal length.  A minimum read length was used 
to allow partially spliced and totally spliced transcripts to be distinguished.  To enrich for longer 
sequences, we used the Blue Pippin size separation system to extract reads from 250 to 1500 bases.  
 For the ESS3 mutations, the ESS3 mutant sequences were separated from the NL4-3 sequences 
based on the mutations to the Rev ORF.  The separated sequence files were used as input to the random 
reverse primer program, which identifies partially spliced or fully spliced transcripts. 
The Random Reverse Primer Assay (RRPA) 
 The splicing assay described in Chapter 2 can quantify splicing within each size class but cannot 
compare the relative amounts of the two size classes or detect changes in the amount of spliced to 
unspliced transcripts.  We wanted to develop an assay that could use Primer ID to quantify these other 
types of changes (4).  This is a challenging problem, as there is no single sequence element present in 
the partially spliced transcripts that is not also present in the unspliced transcripts.  Additionally, in order 
to get reproducible results, a single Primer ID-tagged cDNA primer must be used – all transcripts must be 
picked up by the same reverse primer in the same reaction.   
 We used a random reverse primer in which the primer is the Primer ID.  The random sequence is 
14 nucleotides long, followed by the Illumina adapter sequences.  A basic schematic of the HIV-1 genome 
is shown in Figure 6.2.   D1 splices to one of the A1-A5 acceptors shown grouped together, followed by 
an optional splice from D4-A7.  The random primer anneals to and primes all along the RNA.  The 
forward primer is just upstream of D1.  If the RNA is unspliced and the random reverse primer primes 
downstream of the red bracket (top line), the forward sequencing read will show no splice at D1. If the 
RNA is spliced but not from D4-A7 (middle line), the forward read will show a splice junction from D1 to 
one of the acceptor sites, and then have some part of the sequence between D4 and A7, which did not 
get spliced out.  If the RNA is completely spliced the sequencing read will contain both the D1 to A1-5 
junction and the D4-A7 junction sequences.   cDNA synthesis and the Illumina sequencing platform are 
limited in the length of fragments they can produce.  Looking at the subset of reads at least as long as the 
red bracket gives proportions of unspliced, partially spliced, and fully spliced reads. 
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Figure 6.2. Random reverse primer outcomes. 
 
 The RRPA has some limitations.  It does not prime with equal affinity at all locations, but the 
pattern of priming is highly reproducible; therefore, ratios of the transcript classes are not absolute counts 
but the assay can measure changes in the ratios.  Additionally, though there may be 67 million possible 
random sequences in the 14-base reverse primer tube, only a small fraction of those are complementary 
to the sequence of the HIV-1 genome, and thus many of the Primer IDs are likely to be used more than 
once (Primer ID resampling).   Also, there are many repeated sequences in the HIV-1 genome that could 
potentially be tagged by the same Primer ID.  This led to development the forward tag.   
 The forward tag is another Primer ID random nucleotide sequence in the forward primer.  It is 
attached after the cDNA synthesis step in a single round of PCR, described in the processing of the 
founder/transmitted viruses (Chapter 2).  This creates a double-stranded DNA with a random sequence 
tag on both ends.  Any repetition of a reverse Primer ID can be distinguished by the Primer ID tag in the 
forward primer.  In effect, the forward primer squares the ~67 million possible Primer IDs.  In practice, the 
forward tag is usually not required as the base-pairing fidelity of the reverse primer is low.  The 
sequencing data shows that the random reverse sequence will prime at many locations that have only 
minimal complementarity to the genomic RNA at that site, and thus the random reverse primers cover the 
entire HIV-1 genome (raising some interesting issues concerning the fidelity of PCR in general).  Thus the 
forward tag is an option that can be used in conjunction with the random reverse primer to reduce Primer 
ID resampling when the sequence depth is high. 
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Results 
 Silent mutations to seven known splicing control elements shown in Figure 6.3 were made alone 
and in combinations and cloned into a complete viral genome, then splicing was quantified using both the 
Primer ID splicing assay and the RRPA.  Additionally, a panel of non-synonymous mutations was made to 
the most downstream SRE shown in Figure 6.3, ESS3.  
 
Figure 6.3. Splicing regulatory elements mutated.  
SREs are color coded to match the expected affected acceptor site.  Enhancer elements (ESE) upregulate splicing 
while suppressor elements (ESS, ISS) downregulate splicing. 
Mutations to ESEVif, ESEM1, and ESEM2 alter splicing to acceptor A1  
 Figure 6.4 shows the results of the mutations to ESEVif, M1, and M2 alone and in combination.  
The Y axis is the log of the ratio of splice acceptor A1 usage by the mutants relative to the wild type, with 
the X axis showing the value for the different mutants in a histogram format. If splicing were unchanged, 
the ratio would be 1 on the Y axis.  Bars that extend up indicate an increase in A1 usage and bars that go 
down show decreased A1 usage relative to the wild type.   For this set of regulatory elements, the only 
acceptor affected was A1 so only A1 usage is presented. Mutation of M1 or M2 caused a 6-fold or 52-fold 
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decrease respectively in the number of transcripts that spliced to A1, confirming their roles as splicing 
enhancers.  Unexpectedly, the ESEVif mutant showed a slight increase in A1 usage.  This increase was 
modest in the single mutant, but the effect was consistently seen when combined with mutations of M1, 
M2 or both.   In other words, ESEVif acted like a silencer rather than an enhancer.  This suggests that 
ESEVif was misidentified in previous studies and is actually exonic splicing silencer, i.e. ESSVif.  This fits 
with the fact that alternate exons need a silencer as well as an enhancer.   It appears as if the mutations 
that were initially used to find this regulatory element inadvertently created an hnRNP A1 binding site and 
thus increased its activity as a silencer (5).  It is also possible that the mutations we introduced could 
have created an enhancer instead of mutating a silencer.  The RRPA showed no changes in the 
percentage of unspliced transcripts and no changes in the proportions of the two spliced transcript size 
classes relative to each other (data not shown).   
 
 
Figure 6.4. Usage of acceptor A1 in mutated SREs between A1 and D2. 
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 It is probable that ESEVif is the silencer predicted to exist in the alternative exon from A1 to D2, 
and if not, the question arises as to why there might be such a high density of enhancers in this area with 
no silencer.  One possible explanation may be related to the fact that this exon is only 50 bases long.  
This is short for an exon and short exons may need extra enhancers to be included (6).  Thus it is 
possible that a silencer is not needed for exon skipping.  More work and further mutations are needed to 
definitively characterize ESEVif and its role as either an enhancer or a silencer.  ESEVif serves to 
illustrate some of the difficulties in identifying splicing regulatory elements.  The trans-acting cellular 
factors regulating splicing are generally functionally redundant, bind promiscuously and sometimes 
cooperatively, and recognize multiple motifs.  With so little known about the binding splicing regulatory 
factors, it is challenging to introduce mutations with confidence that won’t create new cis-acting regulatory 
factor binding sites. 
Mutation of ESSV activates acceptor A2 usage and also activates D1 to cause oversplicing   
 ESSV is a silencer for A2, and Figure 6.5 shows the changes in acceptor usage in splices from 
D1, again on a log scale.  We would expect mutation of ESSV to increase splicing to A2, which it does, 
and splicing to other acceptors is greatly reduced.  This greater than 10-fold increase at A2 represents 
more than 97% of spliced transcripts – essentially everything that splices now splices to A2. 
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Figure 6.5. Acceptor usage in ESSV mutant relative to WT. 
 
 Figure 6.6 shows the random reverse primer data for the ESSV mutant. The percentages of 
unspliced transcripts for the WT are on the left in yellow and the ESS2 mutant on the right in green.  In 
the WT almost 80% of all transcripts are unspliced.  In contrast, the loss of repression at A2 activates D1 
so that few transcripts are left unspliced.  There is no activation of D4, so the ratio of incompletely spliced 
transcripts to completely spliced transcripts is the same in the ESSV mutant as the WT (data not shown). 
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Figure 6.6. Percent of unspliced transcripts in the WT and the ESSV mutant. 
 
Mutation of ESS2 and ESS2p synergistically activate A3 and D1 to cause oversplicing 
 There are two suppressors that regulate splicing at A3:  ESS2 and ESS2p. This area also has an 
enhancer element but silent mutations to disrupt it were not possible and thus its role in splicing was not 
tested.  Figure 6.7 shows the changes in acceptor usage compared to the WT.   The lighter blue bars are 
with mutations in ESS2 or ESS2p alone, and the dark blue bars represent splicing when both mutations 
were combined. As expected there was a large increase in A3 usage when these two elements were 
mutated, and the effects were additive.  There was no significant change in splicing to acceptors A1 or 
A2.  This increase in A3 usage came at a loss of A4 and A5 usage, which could be because A3, A4, and 
A5 are alternate acceptors on the same exon defined by D4.  This suggests that to some degree, usage 
of A3 is in competition with A4 and A5, even though it is farther upstream and does not share the group of 
common branch points and polypyrimidine tracts (PPT) used in splicing to A4 and A5.   
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Figure 6.7. Acceptor usage for mutations to ESS2 and ESS2p. 
 
 Like mutation of ESSV, these silencer mutations also activate D1 to cause oversplicing, though 
not to the same degree, and they appear to act synergistically.  Figure 6.8 shows the percentage of 
unspliced transcripts.  The WT is in yellow on the left.  When comparing the effects of these mutations on 
unspliced transcripts, ESS2 alone looked like the unmutated WT and had no effect.  ESS2p had a 
significant effect alone, but when combined with ESS2, they created another oversplicing situation, 
though not as extreme as that seen with the ESSV mutation.  A previous study found ESS2p to have a 
weaker effect than ESS2 and that they act independently, but the results shown in Figure 6.8 suggest the 
opposite (7).  The ratio of partially spliced to completely spliced was not affected (data not shown). 
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Figure 6.8. Effects of ESS2 and ESS2p mutation on percentage of unspliced transcripts. 
 
Combined mutation of ESSV, ESS2p, and ESS2 caused oversplicing to both A2 and A3   
 Since mutations of silencers that control both A2 and A3 caused increased use of the specific 
acceptor and oversplicing, we asked what the combined effect of mutations to all three silencers would 
be.  In the triple mutant the majority of the transcripts were one of two types shown in Figure 6.9 that 
splice to both A2 and A3.  The top transcript spliced from D1 to A2, then again from D3 to A3.  The lower 
transcript spliced first to A1, then to A2, and finally to A3. The level of A1 usage was only modestly 
affected by these single or combined mutations.  This suggests that HIV splicing happens in a sequential 
manner, based on which acceptor is transcribed first.   A1 is transcribed first and there is the normal 
amount of splicing to it before A2 or A3 are made.   Once A2 is available, D1 splices directly to it.  We 
don’t see direct splicing to A3, hinting that it is not available for splicing until after A2.  This is strong 
evidence of sequential cotranscriptional splicing. 
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Figure 6.9. Two transcript types make up the majority of transcripts in the ESS2/ESS2p/ESSV 
combined mutations. 
 
ISS suppresses pseudo-splice acceptors upstream of A7  
 Only one intronic splicing silencer, ISS, has been described for HIV-1.  This ISS is located just 
upstream of A7 inside the env intron and was reported to suppress splicing to A7 though mutation of the 
element produced only weak splicing enhancement (8).  In the current set of experiments, ISS was tested 
alone and in combination with ESS2, ESS2p, and ESSV.  In each case, mutation of ISS caused no 
changes in acceptor usage or splicing patterns within either the 4 kb or 1.8 kb size classes.  In addition, 
ISS had no effect on the ratio of the size classes or the amount of unspliced transcripts.    
 Some ISS elements in cellular transcripts have been described that are adjacent to a genuine 
splice acceptor or donor and they suppress pseudo-donor and pseudo-acceptor sites to correctly define 
the correct site (9).  We looked to see if pseudo-splice acceptor sites next to A7 were used more with the 
ISS mutation and found they were.  Figure 6.10 shows the percentage of splices to the two most used off-
target acceptors near A7 (A8345 and A8363).   The unmutated control is on the far left and it and all the 
other mutations to regulators are in yellow.  The orange bar on the far right shows the individual ISS 
mutation and it mis-splices 8-fold more often to a pseudo A7 site.  This suggests a function of the ISS 
element is to define correct A7 usage by suppressing pseudo-splice sites.  The shorter orange bar is the 
ISS mutant combined with the oversplicing mutations.  The effect is less when combined with the 
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oversplicing mutations, which is an interesting example of the importance of context for splicing regulatory 
elements. 
 
Figure 6.10. ISS suppresses cryptic splicing near A7.   
Y axis shows the percentage of splices from D4 to A7 that use the pseudo acceptors A8345 or A8363. 
 
Mutations to the ESS3 stem-loop cause a small increase in splicing from D4 to A7  
 Some SREs are located in RNA secondary structures, such as the SLSA1 stem loop described in 
Chapter 2, where the structure is important for SR or hnRNP binding (10).  ESS3 is a silencer just 
downstream of A7.  Like ISS and ESE3, two other SREs in the A7 region, ESS3 is highly structured as a 
stem and loop.  This structure has control elements reported to act on D4-A7 splicing (11-15).  The 
conserved nucleotides in the loop bind co-operatively to hnRNP A1 to prevent the D4-A7 splice (16).  The 
loop of the ESS3 stem structure has been extensively studied by the Tolbert lab and the hnRNP A1 
binding structure solved (17, 18).  Figure 6.11 diagrams the bases of the ESS3 stem-loop structure, which 
contains hnRNP A1 binding sites UAGU or GAU and without C residues.  Mutations were made that 
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change one or more of the loop bases to a C or alter the stem structure.  These mutations were 
introduced into a full-length NL4-3 construct with a frame shift and a premature stop codon in the Rev 
ORF to prevent the production of Rev.  These infectious clones were then cotransfected with WT NL4-3 
into 293T cells, and splicing was analyzed using the splicing assay and the random reverse primer assay.  
The cotransfected NL4-3 produces WT Rev in sufficient amounts to rescue splicing of the Rev- mutant 
(data not shown), and also serves as an internal control for normal splicing. 
 
Figure 6.11. The ESS3 stem-loop structure located downstream of splice acceptor A7.   
Adapted from Rollins (17). 
 
 hnRNP A1 binds cooperatively to prevent D4-A7 splicing, thus mutation of binding site 
nucleotides to C may enhance splicing.  These mutations had minimal or no impact on the spliced 
transcripts in either of the two size classes (data not shown), but would be expected to alter the balance 
of the size classes in the mutant compared to NL4-3, increasing the number of transcripts in the 1.8 kb 
class relative to the 4 kb class.  The results are shown in Figure 6.12.  In all except mutant #1, the mutant 
has increased 1.8 kb transcripts (more splicing from D4 to A7).  Though consistent, this increase is 
modest when compared to the Rev-negative parental construct without cotransfected NL4-3, which 
without Rev has a 1.8 kb to 4 kb ratio of about 31 (data not shown).  It has been found that ISS and ESS3 
synergistically promote hnRNP A1 multimerization across the extended sequence spanning both 
silencers (14) so a future experiment will combine mutations to both sites. 
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Figure 6.12. Ratio of 1.8 kb transcripts to 4 kb transcripts in each ESS3 mutant and its internal 
NL4-3 control. 
 
Discussion 
 Analysis of these SRE mutations demonstrates the utility of the RRPA to measure changes in 
transcript classes using deep sequencing and in the context of a full-length viral genome.  It must be 
emphasized that these are relative measurements, unlike the splicing assay, as the random reverse 
primer has preferential but reproducible priming sites.   
 An additional capability of the random reverse primer assay is its ability to detect aborted 
transcription.  Early in infection, before the viral transcription factor Tat is present in sufficient quantity, 
many prematurely terminated HIV-1 transcripts are synthesized (19).  Though not shown in the data 
presented here, the random reverse primer assay primes most often in the region just downstream of the 
transcription start site, suggesting a large number of abortive transcripts even in late infection when Tat 
levels would be expected to be high.  For this reason, the minimum valid read lengths for identifying 
unspliced transcripts must be long enough to be out of the range of abortive transcripts.   
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 Although all of the mutations tested here have been previously characterized, advances in deep 
sequencing technology and the development of the two splicing assays presented in this thesis allow in-
context measurements of splicing patterns within and between transcript classes.  We have found 
different results from previous studies for ESEVif, ESS2p, ESS2, ISS, and ESS3, and more extensively 
quantified these known elements.  The set of mutations tested here is incomplete and an obvious future 
direction is to repeat this analysis for the other known SREs.  
 We have quantified the extent of oversplicing in the ESSV, ESS2 and ESS3p silencer mutations.  
Oversplicing results in insufficient Gag and consequent replication defects (20).  Oversplicing is the most 
lethal splicing defect we have seen to date, and suggests possible therapeutic applications (21).   
 Because ISS and ESS3 have previously been characterized as suppressors of splicing from D4 
to A7, it is surprising that the effects of mutations were so modest in the context of the full-length virus.  
This again emphasizes that SREs are context dependent.  It’s been found that ISS and ESS3 
synergistically promote hnRNP A1 multimerization (14) so a future experiment will combine mutations to 
both sites.  It may be that they act in concert, similarly to ESS2 and ESS2p, where the combined effect is 
much greater than the individual contributions. 
 Utilizing the recent developments in deep sequencing technology has made it possible to 
examine splicing regulatory elements in the context of viral infection.  These advances in quantification 
allow the roles of the various SREs to be measured individually and in combination.  Further work will 
more completely characterize SREs that control splicing in HIV-1. 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 One important goal for studying HIV-1 is to identify therapeutic targets, and the ultimate purpose 
of studying HIV-1 splicing is to determine if and how splicing can be targeted to produce a useful 
therapeutic effect.  The ability to quantify splicing is indispensable to this purpose and the work done in 
this thesis identifies aspects of splicing that are and are not likely to be useful targets. 
 There is a general assumption in the literature that “balanced” use of the HIV-1 acceptors and 
thereby a carefully balanced control of protein products is critical to viral replication (1, 2).  Tat and Rev 
are held in particular reverence in this regard (3-5).  Without sufficient Tat viral transcription aborts 
prematurely.  Without sufficient Rev, no unspliced transcripts can leave the nucleus.  Low levels of either 
of these proteins would seem to force the cell into a functional, and perhaps actual, state of latency.  If 
some splice acceptors could be made more or less efficient, the balance would be upset with a high 
fitness cost.  The splicing data for the transmitted/founder viruses (described in Chapter 2) challenge the 
idea of balanced splicing.  The data shown in Figure 2.6 show a wide range of both tat and rev transcript 
levels in cells expressing the transmitted/founder viruses.   This suggests a new paradigm – rather than 
carefully balanced splicing, some minimum threshold of each protein is all that is required for viral 
replication.  Targeting the relative proportional use of the different acceptors is not likely to have 
therapeutic value. 
 Another potential balancing target is the ratio between the two spliced transcript size classes.  
This ratio is determined by the degree of splicing from D4 to A7, once splicing from D1 has already 
occurred.  In my collective data thus far, the ratio of fully spliced to partially spliced transcripts varied from 
about 1:2 and 2:1, with this range falling within assay variability as seen in replicates under the same 
experimental conditions.  This is especially evident in the mutations made to ESS3, seen in Figure 6.11.  
Each of the eleven ESS3 mutations was co-transfected with NL4-3 to provide Rev.  The ratio of 1.8 kb to 
4 kb RNAs in the NL4-3 controls should be about the same for the different transfections but this ratio 
varied appreciably across the samples.  Although all but mutation #1 show an increase in this ratio 
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compared to their control, these increases are modest compared to the changes seen in other SRE 
mutations analyzed in Chapter 6.   Mutations to ESS3, ISS and to the GAR ESE region collectively had 
modest but consistent effects.  Thus far I have not seen any mutations that skew D4 to A7 splicing much 
beyond the range of assay variability, making the D4/A7 splice an unlikely therapeutic target unless a 
more dramatic regulatory site can be identified.  The one factor that did make a big difference in the 1.8 to 
4 kb RNA ratio was deleting Rev, which skewed the totally spliced to partially spliced ratio as high as 30 
to 1.  This suggests there is a race to see if Rev can bind the RRE once it is transcribed before A7 is also 
transcribed and the RRE gets spliced out.  The RRE and A7 could be close enough to sterically exclude 
either Rev binding or splice factor binding to A7 SREs.  Viewed in the context of cellular RNA splicing, the 
splice from D4 to A7 joins two constitutive exons.  The exon containing D4 is always included and D4 is a 
strong splice donor (6).  The layers of control seen in alternative exon splicing may not be required.  
Conceivably, splicing from D4 to A7 would always occur unless Rev intervenes.  The completely 
spliced/partially spliced balance may be a cycle controlled by Rev. Too much Rev reduces completely 
spliced transcripts, which in turn reduces the amount of Rev. Less Rev increases completely spliced 
transcripts, raising Rev levels. The oscillating levels of spliced to unspliced transcripts suggests a 
continual feedback system operating within loose parameters, regardless of the efficiency of D4-A7 
splicing.  The role of Rev in splicing is an area for continued study. 
 Another therapeutic target that appears unlikely to succeed is activation of cryptic splice sites to 
make aberrant proteins.  It has been reported and often repeated in the literature that perturbation of 
canonical splice sites activates cryptic splice sites (2).  My data suggests that cryptic splice site activation 
is not common.  It was not seen in the transmitted/founder viruses, and not it seen generally in the global 
mutations described in Chapter 3.  Some strains do exhibit altered cryptic splicing (7-10) that may give 
rise to new or combined ORFs, and production of the chimeric protein products has been documented.  
To date, no useful functionality has been ascribed to any of these hybrid proteins.  The splice sites that 
created them are not generally conserved in HIV-1 strains, but are instead the result of mutations that 
create new splicing elements rather than arising from suppression of the canonical sites to activate 
nearby cryptic sites.  The hybrid proteins produced by these cryptic sites did not prevent the viruses from 
replicating. 
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 There is one exception to the cryptic splice site issue.  Mutations downstream of D1 (Chapter 3) 
did cause cryptic splicing.  New acceptors and donors and small exons were introduced.  Even though 
this aberrant splicing was only seen in a subset of the transcripts, viruses with these mutations were 
unable to replicate effectively.  Reversion mutants abolished the cryptic sites.  While we did not test 
specifically for this effect, the fitness cost suggests that the truncated fragments of Gag protein encoded 
by these aberrant transcripts have a dominant negative effect.  This is an area for further research.  Little 
is known about regulation of D1, the major splice donor.  Studies of D1 are complicated by the density of 
other nearby sequence and structural elements.  The area upstream of D1 and splicing at D1 can be 
studied using a genetic screen like the one described in Chapter 5.  Changes in the D1 area do in fact 
give rise to cryptic splicing (2) and it will be interesting to probe the mechanism of D1 activation. 
 Suppression of splicing is an attractive target.  HIV-1 is unique in that the majority of transcripts 
retain introns, and viral infection has been shown to cause intron retention in transcripts of cellular genes 
(11), hinting that a viral protein is the cause. This suppression of splicing is unique to HIV-1 and thus a 
potential therapeutic target.  Suppression manifests in two different mechanisms.   
 First, mutations to exonic splicing silencers, explored in Chapter 6, activated the upstream 
proximal acceptor site (see Figures 6.4 through 6.6). They also lifted suppression of splicing (i.e. 
activated splicing) at the major 5’ splice donor D1 to cause oversplicing, but did not activate splice donor 
D4.  Additional disruptions of silencing were discovered by synonymous mutagenesis of the HIV-1 
genome as described in Chapter 3.  Loss of suppression caused oversplicing and a concomitant fitness 
cost due to insufficient Gag particle production.    
 Second, I have observed that the absence of Rev decreases (but does not eliminate) unspliced or 
partially spliced transcripts.  I looked for but did not find evidence of transcripts that fail to use D1 (i.e. 
retain the gag/pro/pol intron) but use D4 to splice out the env intron. Additionally, I found no transcripts 
that used D2 or D3 without first using D1, making D1 suppression a marker for suppression of all splice 
donors.  This suggests unspliced transcripts are suppressed early and completely from all splicing, long 
before the other downstream splice donors or the Rev Response Element (RRE) are transcribed.  The 
mechanisms of suppression are another area of ongoing research. 
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 One possible mechanism of splicing suppression could be the secondary structure of the D1 
region.  A previous study found that this region can fold into two structures, depending on the number of 
G’s included at the variable transcription start site (12).  This small change from 1 to 3 G’s is sufficient to 
alter the pre-mRNA secondary structure so that D1 is either presented on the loop of a stem-loop or is 
part of a double stranded RNA region.  This changed access to D1 may be a factor that suppresses 
splicing early on, before any acceptor sites are transcribed.  Blocked access could explain splicing 
suppression at D1 but not the lack of splicing from D4 to A7, which may also be prevented by 
participation in as yet unknown secondary structures.  Further work will test splicing in these alternate 
constructs.   
Too little is known about the specificities of SR and hnRNP proteins and their roles in HIV-1 
splicing to speculate about them being possible therapeutic targets.   These proteins are problematic 
because they are redundant and bind promiscuously across the entire genome.  There are multiple motifs 
reported for binding sites of these proteins, some more convincing than others.  I am skeptical of reports 
of HIV-1 enhancers found by computer algorithms based on binding site consensus sequences. Feeding 
any HIV-1 sequence that might be associated with splicing, or even randomly generated sequences, into 
ESEfinder (13) finds that about half of the bases are contained in an enhancer – which cannot be correct.  
More and better data are needed to find the actual HIV-1 binding sites of SR and hnRNP proteins and 
their effects, and more studies like those described in Chapter 3 are needed. 
 The work done in Chapter 3 raises more questions than it answers and calls into question 
previous models of splicing factor binding.  Previous studies have used SELEX to fish out the highest 
affinity binding sequences out of a pool of random oligos (14).  This method has produced degenerate 
consensus sequences, and different studies report different results.  The consensus sequences found 
using CLIP-seq are not the same (though similar) as previously reported (15, 16).  siRNA knock down of 
cellular splicing factors produced mild changes in splicing phenotypes, but the changes caused by 
hnRNP H1 knock down are not the same as the changes found by mutation of hnRNP H1 binding sites.  
This suggests that a partial knock down is not sufficient to cause severe splicing defects, either due to 
redundancy of splicing factors or a low factor concentration requirement.   
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 We may be looking at the wrong splicing factors.  siRNA knockdown was done to target the 
factors most often reported to play a role in HIV-1 splicing; however, the methods used to determine 
relevant factors are questionable.  In several cases, biotinylated oligos containing splicing regulatory 
elements were soaked in cellular extracts and they bound hnRNP A/B proteins (17-19), but CLIP-seq 
data show hnRNP A/B proteins bind promiscuously across the HIV-1 genome (Figure 4.2).  
 The high-frequency binding sites of hnRNP A/B (Figure 4.2) do not correspond to any of the HIV-
1 splicing regulatory elements claimed to bind them.  The CLIP-seq experiments in Chapter 4 have 
negative controls but not a positive control.  For this set of experiments negative controls would be the 
anti-HA Ab alone (which shouldn’t bind RNA in the absence of the HA-tagged hnRNP proteins) and the 
HA-tagged hnRNP proteins without the HA specific Ab (which would bind the RNA but should not be 
precipitated).  Without both the binding protein and the antibody there should be only a very low level of 
“noise” reads, like that seen with hnRNP K, and therefore we consider the promiscuous binding of hnRNP 
A/B valid.  This promiscuous binding supports previous findings that hnRNP A/B binds at high affinity 
sites and multimerizes along the RNA (20-22).  Nevertheless, it would be reassuring to find that the 
binding sites found in CLIP-seq actually correspond to known cellular splicing regulatory elements, which 
we do not see with hnRNP A/B.  This suggests that the hnRNP A/B proteins are not the actual factors 
involved in HIV-1 splicing, but that we have been led astray by these highly promiscuous and abundant 
splicing proteins.  Work is currently in progress to identify other splicing factors by their splicing phenotype 
rather than binding of a regulatory sequence.  In future CLIP-seq experiments, we would also hope to 
validate the connection between binding sites and splicing phenotype, as we did with hnRNP H1, but 
were unable to do with hnRNP A/B. 
 The model of a protein factor binding a specified nucleotide consensus sequence is common in 
cell biology but is too simplistic for HIV-1 splicing regulation.  The hnRNP H1 binding sites in HIV-1 are 
not a simple consensus sequence of poly-Gs, but a group of poly-Gs.  Scanning the HIV-1 genome 
reveals multiple matches to the TGGGG hnRNP H1 consensus sequence, but only the sites with multiple 
proximate poly-G tracts make an hnRNP H1 binding site.  Additionally, there are no grouped hnRNP H1 
consensus sites outside those found by the CLIP-seq data.  Mutation of any one of the hnRNP H1 binding 
sites was insufficient to produce the loss of splicing seen to A1 when all binding sites were mutated.  This 
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hints that there is an additional layer of interaction between the binding sites, as has been shown to occur 
with hnRNP A1.   
 This combined data suggests a new model (Figure 7.1) in which binding sites are composed of 
multiple single sites that collectively make a high probability (high affinity) area for binding of the hnRNP 
protein to the RNA, followed by cooperative binding between the hnRNP proteins.  In Figure 7.1, using 
hnRNP H1 as an example, the consensus sequences for hnRNP H1 binding sites shown at the top 
illustrate the multiple poly-G consensus sites grouped together.  Site 5 is boxed in pink, and the second 
row illustrates hypothesized interactions between the hnRNP H1 proteins at site 5.  The eight hnRNP H1 
binding sites are shown in red on the third line of Figure 7.1, and in this proposed model the individual 
sites then interact with each other, looping out the intervening sequences.  Additional work on binding 
proteins and their binding sites is underway. 
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Figure 7.1. A Proposed Model for hnRNP Binding.  
Using hnRNP H1 as an example, row 1 shows multiple proximate consensus sites in each binding site.  Row 2 
illustrates hypothesized interactions between hnRNP proteins to stabilize binding and define the binding site.  Row 3 
shows the binding sites spread across the genome and row 4 the hypothesized tertiary interactions between the 
binding sites. 
 
 Splicing is essentially the same in infected T cell lines (CEMx174, Jurkat, H1) and transfected 
293 T cells.  I also found that splicing was the same in T cells and dendritic cells (part of the work done in 
Miller et al., see appendix) and this validates the use of cell lines and transfection to study splicing.  The 
next step is to quantify splicing in macrophages.  Macrophages are reported to have low levels of Tat and 
slow viral growth, making them long-term viral reservoirs. Splicing patterns in macrophages are also 
reported to be different following HIV-1 infection (23).  Since the virus can adapt to growth in 
macrophages late in infection it will be important to determine if adjustments in the splicing program are 
part of this adaptive process. 
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 In Chapter 6, ISS was found to block mis-splicing to pseudo-acceptors upstream of A7.   There 
are other pseudo-splice sites, several of which are detected by the splicing assay.  Some come in pairs 
and can make a small exon but most work together with a canonical acceptor or donor.  It’s likely that 
other intronic splicing silencers exist to keep these in check.  Elements that control an infrequently used 
donor site downstream of D2 were recently characterized (19).  Elements that suppress other pseudo-
sites remain to be found. 
 Finally, the purpose of the small exons created by donors D2 and D3 remains a mystery.  They 
are highly conserved yet have no clear function.  It has been suggested that they are necessary for exon 
definition to ensure adequate Vif and Vpr expression (24-26), but the data from the transmitted/founder 
viruses showed little change in vpr even when the second small exon was knocked down (Figure 2.6).  
Also, viruses with low levels of Vif due to reduced splicing to A1 show no fitness costs unless APOBECs 
are over-expressed (26).  This suggests that the small exons aren’t critical for Vif and Vpr.  They didn’t 
change protein production or transcript stability (24, 27).  The reason for their high degree of conservation 
remains unsolved.  
 Since the discovery of splicing in adenovirus in 1977, the mechanisms of splicing in cellular 
genes has been well studied.  Although HIV-1 uses the cellular splicing machinery and proteins, it must 
suppress and control alternative splicing to appropriately express all the viral transcripts from a single 9 
kilobase transcript.  There are evidently several different regulatory mechanisms at work, some coming 
into focus while others remain mysterious.  Differences in cellular and HIV-1 splicing suggest several 
areas where the virus may be vulnerable.  The advent of successful splicing therapy to treat genetic 
diseases is creating new technologies that may someday translate knowledge about HIV-1 splicing into 
clinical usefulness.  To understand splicing, it must be quantifiable, and this is made possible by the rapid 
expansion of sequencing technology and bioinformatics tools.  These developing technologies provide 
opportunities to probe the mechanisms of HIV-1 splicing regulation. 
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APPENDIX: VIRION ASSOCIATED VPR ALLEVIATES A POST-INTEGRATION BLOCK TO HIV-1 
INFECTION OF DENDRITIC CELLS 
Overview 
 Viral protein R (Vpr) is an HIV-1 accessory protein whose function remains poorly understood. In 
this report, we sought to determine the requirement of Vpr in facilitating HIV-1 infection of monocyte-
derived dendritic cells (MDDCs), one of the first cells to encounter virus in the peripheral mucosal tissues. 
We characterize in this report a significant restriction to Vpr-deficient virus replication and spread in 
MDDCs alone and in cell-to-cell spread in MDDC – CD4+ T cell co-cultures. This restriction to HIV-1 
replication in MDDCs was observed in a single round of virus replication and was rescued by expression 
of Vpr in trans in the incoming virion. Interestingly, infections of MDDCs with viruses that encode Vpr 
mutants either unable to interact with DCAF1/DDB1 E3 ubiquitin ligase complex or a host factor 
hypothesized to be targeted for degradation by Vpr also displayed a significant replication defect. While 
the extent of proviral integration in HIV-1 infected MDDCs was unaffected by the absence of Vpr, 
transcriptional activity of the viral LTR from Vpr-deficient proviruses was significantly reduced. Together, 
these results characterize a novel post-integration restriction to HIV-1 replication in MDDCs and that Vpr 
interaction with the DCAF1/DDB1 E3 ubiquitin ligase complex and the yet-to-be identified host factor 
might alleviate this restriction by inducing transcription from the viral LTR. Taken together, these findings 
identify a robust in vitro cell culture system that is amenable to addressing mechanisms underlying Vpr-
mediated enhancement to HIV-1 replication.  
Importance 
 Despite decades of work, function of the HIV-1 protein Vpr remains poorly understood, primarily 
due to lack of an in vitro cell culture system that demonstrates a deficit in replication upon infection with 
viruses in the absence of Vpr. In this report, we describe a novel cell infection system that utilizes primary 
human dendritic cells, which display a robust decrease in viral replication upon infection with Vpr-deficient 
HIV-1. We show that this replication difference occurs in a single round of infection and is due to 
decreased transcriptional output from the integrated viral genome. Viral transcription could be rescued by 
virion-associated Vpr. Using mutational analysis we show that domains of Vpr involved in binding to the 
DCAF1/DDB1/E3 ubiquitin ligase complex and prevention of cell cycle progression into mitosis are 
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required for LTR-mediated viral expression, suggesting that the evolutionarily conserved G2 cell cycle 
arrest function of Vpr is essential for HIV-1 replication.  
Introduction 
HIV-1 encodes a number of proteins that allow for entry and replication in human cells.  In 
addition to the structural or enzymatic proteins that have well defined functions in the replication cycle, 
there are also a number of small, accessory proteins. Accessory proteins encoded by HIV-1 are not 
always necessary for replication in vitro, but are absolutely essential for replication in vivo (1). These 
proteins serve to counteract host restriction factors that would normally limit HIV-1 infection (1, 2). Of the 
accessory proteins encoded by HIV-1, Vpr is the only one whose function remains relatively unclear.  
Vpr is a small, 96 amino acid, 14 kDa protein that is packaged into the budding virion through 
associations with the p6 region of Gag (3–10). This association allows Vpr to be present in the cell at a 
relatively high quantity (~200-300 molecules/virion) upon initial infection (11). Previous studies have 
extensively characterized the outcome of Vpr expression in various cell types. In cycling cells, Vpr 
expression results in G2/M cell cycle arrest which culminates in induction of apoptosis (12–14). It is well 
established that Vpr-mediated G2/M cell cycle arrest is mediated though its association with the 
Cul4A/DCAF/DDB1 E3 (CRL4DCAF1) ubiquitin ligase complex (15–17). In addition, HIV-1 Vpr has been 
shown to recruit and degrade a number of DNA-damage response (DDR) proteins, including the SLX4-
SLX1/MUS81-EME1 structure-specific endonuclease complex (SLX4com), Uracil DNA glycosylase 2 
(UNG2), and helicase-like transcription factor (HLTF) (18–21) via the CRL4DCAF1 complex resulting in 
G2/M cell cycle arrest though it still remains unclear what role this process plays during HIV-1 infection.  
Though a number of previous studies have examined the requirement of Vpr on HIV-1 replication 
in various cell types, including primary CD4+ T cells and monocyte-derived macrophages (MDMs), 
differences in virus replication have not been consistently observed (18, 20, 22–26). Vpr expression is 
dispensable for infection in activated CD4+ T cells in vitro (22–25, 27), presumably due to the well 
characterized cytostatic and cytopathic functions of Vpr in cycling cells (12). In contrast, recent studies in 
MDMs suggest that Vpr is necessary for HIV-1 envelope (Env) expression, and the purported 
consequence of infection of MDMs with Vpr-deficient viruses was reported to be decreased viral 
production and reduced cell-to-cell spread to CD4+ T cells (22, 28). Notably, there has been considerable 
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heterogeneity in replication differences between wild type and Vpr-deficient viruses and host responses to 
virus infection in MDMs, presumably due to donor and experimental variability between studies (12, 29, 
30). Additionally, it has also been reported that Vpr expression in macrophages can both inhibit or induce 
type I interferon (IFN) responses (18, 28, 31–34).  
Dendritic cells (DCs) are sentinel cells that bridge innate and adaptive immunity (35). They 
actively patrol peripheral tissues, including mucosal sites of HIV-1 transmission, in search of foreign 
pathogens. Because of this, MDDCs are among the first cells to interact with HIV-1 upon sexual 
transmission of the virus (36–40). While MDDCs are less susceptible to infection than activated CD4+ T 
cells and macrophages, they are still able to be infected ex vivo at a low but consistent level (41–44). In 
contrast to work with MDMs and CD4+ T cells, there have been isolated descriptions of effects of Vpr on 
HIV-1 replicative capacity in MDDCs (41, 44), with no consensus on the mechanisms accounting for Vpr-
mediated enhancement of virus replication. In this study, we use MDDCs as a model system to 
investigate the role of Vpr during infection. We find a robust replication defect of Vpr-deficient HIV-1 in 
MDDCs and, contrary to previous studies (44), the replication defect was not due to decreased Env 
expression in Vpr-deficient HIV-1 infected cells. Rather, the block to ΔVpr virus infection was at the step 
of viral transcription and could be rescued by addition of Vpr in trans into the virion in a single round 
infection analysis. We found that mutations, Vpr-Q65R and Vpr-H71R, which ablate association of Vpr 
with the CRL4DCAF1, or Vpr-R90K which does not induce G2 cell cycle arrest (17, 45–50), displayed 
similar decreases in replication and viral transcription in single round of infection analysis. Together these 
data shows a novel post integration block to HIV-1 replication in MDDCs at the point of viral transcription 
that is alleviated by virion-associated Vpr.  
Results 
Vpr-deficient viruses display a replication defect in DCs  
 HIV-1 replication in MDDCs is restricted at the reverse transcription step by SAMHD1 that 
controls the size of the cytosolic dNTP pools (51, 52). Despite the presence of SAMHD1, MDDCs remain 
susceptible to HIV-1 infection in vitro at a low but measurable level (44, 53–55). We infected MDDCs with 
replication competent wild type (WT) or Vpr-deficient (∆Vpr) CCR5-tropic Lai-YU2 and harvested cells for 
intracellular p24Gag expression by flow cytometry analysis 3 days post infection. Input for these infections 
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was normalized based on infectious titer of the viruses on TZM-bl cells. As expected, CD11c+ DC-SIGN+ 
MDDCs were susceptible to viral infection, albeit to low levels (Figure 8.1A and B). Interestingly, Lai-
YU2/∆Vpr failed to establish a robust infection in MDDCs (Figure 8.1A and B), and there was a 
reproducible 3-5 fold decrease in percentage of p24Gag+ cells in ∆Vpr virus infections as compared to WT 
virus infections (Figure 8.1B). To determine the functional consequences of Vpr-deficiency on virus 
spread, DCs and PHA/IL-2-activated CD4+ T cells were infected with infectious viruses (MOI = 1) and 
cell-free culture supernatants were harvested every 3 days and analyzed for p24Gag content by an ELISA. 
While there was some donor variability, Lai-YU2/∆Vpr infection of MDDCs derived from 3 independent 
donors consistently resulted in significantly lower levels of replication than wild type Lai-YU2 infection 
(Figure 8.1C). In contrast to the substantial attenuation of virus spread in Lai-YU2/∆Vpr infected DCs, 
both viruses replicated to a similar extent in activated CD4+ T cells (Figure 8.1E), in agreement with 
previously published studies (22–25, 27). These results suggest that Vpr plays an important role in 
facilitating HIV-1 infection of DCs.  
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Figure 8.1. Infection with Vpr-deficient HIV-1 results in attenuated virus replication in MDDCs and 
MDDC-T co-cultures.  
(A) FACS profiles of mock infected MDDCs or MDDCs infected with Lai-YU2 or Lai-YU2/∆Vpr (MOI =1) at day 3 post 
infection. Cells were stained for CD11c, DC-SIGN and p24Gag. From left to right, plots shown depict the gating 
strategy for the flow cytometry analysis and include plots of forward scatter/side scatter to exclude cellular debris, 
anti-CD11c/anti-DCSIGN staining to identify MDDC population, and DC-SIGN/p24Gag staining to identify 
productively infected MDDCs in mock infected, or WT (Lai-YU2) and ∆Vpr infected DCs. (B) The mean (± SEM) 
percentage of DC-SIGN+ intracellular p24Gag positive MDDCs determined from infections of cells derived from three 
donors infected as in (A). (C) Replication kinetics of Lai-YU2 and Lai-YU2/∆Vpr in MDDCs infected at MOI =1. MDDC 
supernatants were harvested every three days and analyzed for p24Gag content by an ELISA. Data shown are the 
mean (± SEM) for three independent experiments with MDDCs derived from three independent donors. (D) 
Schematic of DC-T cell co-culture set up. MDDCs were infected with Lai-YU2 or Lai-YU2/∆Vpr (MOI = 1). At two days 
post infection, autologous CD4+ T cells (PHA/IL2 treated) were added at a 2:1 ratio to MDDCs or infected with cell-
free virus in parallel (MOI = 1). Supernatants were harvested on day 6 and day 9 post infection (day 3 or 6 for cell-
free CD4+ T cell infection), and the p24Gag content in the culture supernatants determined by an ELISA. (E) The 
data shown is the kinetics of p24Gag production in cell culture supernatants from a representative infection of 
MDDCs only, CD4+ T cell only or MDDC - CD4+ T cell co-cultures. (F) The mean (±SEM) p24Gag present in the 
supernatant from five independent donor infections of CD4+ T cells only or DC-CD4+ T cell co-cultures at day 6 post 
infection (day 3 post infection for cell free CD4+ T cell infections). Significance calculated using paired student’s T 
tests where *p<0.05, **p<0.01, ***p<0.001. 
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 Numerous studies have demonstrated robust HIV-1 replication in DC-T cell co-cultures at levels 
greater than that observed in infections of either cell type alone, and is dependent on rapid highly efficient 
transmission of DC-derived progeny virions to CD4+ T cells across infectious synapses (42, 43, 54–60). 
We sought to determine the effect, if any, of Vpr-deficiency on DC-mediated virus spread to CD4+ T cells. 
MDDCs were first infected with wild type Lai-YU2 or Lai-YU2/∆Vpr and cultured for two days, prior to 
initiation of co-culture with autologous activated CD4+ T cells (Figure 8.1D). There was a substantial 
enhancement of virus replication in co-cultures infected with WT virus, compared to ∆Vpr virus infections 
(Figure 8.1E and F; ~7-fold increase).  Interestingly the difference between WT and ΔVpr virus replication 
in DC-T cell co-cultures was greater than that observed in infections of MDDCs or CD4+ T cells alone 
(Figure 8.1E and F). Together, these results suggest that the replication defect observed in MDDCs 
infected with HIV-1/ΔVpr translates to CD4+ T cells during cell-to-cell contact and transmission.  
Defects in Vpr infection are independent of viral glycoprotein expression  
 Previous studies have suggested a requirement for Vpr in maintaining robust HIV-1 gp120 
expression in MDMs and MDDCs by counteracting a myeloid cell-intrinsic mechanism of Env degradation 
(22, 28, 44). To begin to understand the underlying mechanism accounting for the replication defect of 
HIV-1/ΔVpr in DCs, we examined viral protein expression in MDDCs infected with wild type Lai-YU2 or 
Lai-YU2/∆Vpr (MOI = 3). Infected cells were lysed 6 days post infection for quantitative western blot 
analysis. We did not observe any steady-state differences in gp120 expression when normalized to Gag 
(p55 and p24) levels in MDDCs infected with WT or ΔVpr viruses (Figure 8.2A). Quantification of 
immunoblots from infected MDDC lysates derived from four independent donors showed no significant 
differences in gp120 expression (Figure 8.2B). We next sought to determine if Vpr-deficiency might result 
in decreased gp120 incorporation in virus particles derived from productively infected DCs. MDDC culture 
supernatants were harvested on multiple days post infection and pooled supernatants were concentrated 
over a sucrose cushion prior to western blot analysis. We again failed to observe any significant 
differences in levels of gp120 incorporation between virus particles derived from WT or ΔVpr infected 
MDDCs (Figure 8.2C and D). The consistency of the replication defect of HIV-1/ΔVpr virus in MDDCs in 
the absence of any significant differences in gp120 expression suggests that previously hypothesized 
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Vpr-dependent enhancement of gp120 production is unlikely to account for the observed replication 
defect in the present study (28, 44).  
 
Figure 8.2. Vpr does not regulate Env expression in infected MDDCs or incorporation of Env into 
MDDC-derived virions.  
(A) Western blot analysis of mock infected, Lai-YU2 (WT) or Lai-YU2ΔVpr infected MDDCs (MOI = 3) for p55Gag and 
gp120 expression at day 6 post infection. (B) Quantification of western blots for p55Gag and gp120 in infected 
MDDCs as in (A) from four independent experiments. The gp120 band intensity was quantified and normalized to 
p55Gag from experiments with infected MDDCs derived from 4 donors. Data shown are mean (± SEM). (C) Western 
blot analysis of p24Gag and gp120 expression in mock infected, Lai-YU2 (WT) or Lai-YU2ΔVpr infected MDDCs 
(MOI = 5). MDDC culture supernatants were harvested at days 3, 6, and 9 post infection, pooled and concentrated 
over a 20% sucrose cushion and virus pellets lysed for western blot analysis. (D) Quantification of western blot 
analysis from MDDC-derived virions from three independent donors. The band intensity for gp120 was quantified and 
normalized to p24Gag band intensity. Data shown are mean (± SEM). Significance calculated using a one sample T 
test where N.S>0.05. 
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Infection with Vpr-deficient HIV-1 does not induce type 1 IFN 
 Exposure of target cells to type I IFN potently restricts HIV-1 replication in vitro (61–69). In 
addition, recent studies have suggested that infection with ∆Vpr virus induces type I IFN (18, 28, 31–34). 
Hence, we sought to determine if induction of an early type I IFN response in HIV-1/∆Vpr infections of 
MDDCs accounts for the restricted virus replication and spread. MDDCs infected with wild type Lai-YU2 
or Lai-YU2/ΔVpr virus were harvested 48 h post infection, and the mRNA expression levels of IFNβ and 
the type I IFN-inducible protein, interferon-γ-inducible protein 10 (IP-10) were quantified by qRT-PCR. At 
48 h post-virus exposure, we did not detect significant increases in IFN-β mRNA levels in wild type or 
ΔVpr infected cells compared to mock infected cells (Figure 8.3A). While expression of the ISG, IP-10, 
was robustly induced by establishment of productive HIV-1 infection of DCs, differences in IP-10 mRNA 
levels between WT and ΔVpr virus infections were not statistically significant (Figure 8.3B). Note that pre-
treatment of cells with azidothymidine (AZT) reduced induction of IP-10 mRNA levels to that observed in 
mock infected cells, suggesting that induction of IP-10 expression in virus-exposed cells was dependent 
on de novo reverse transcription. In contrast, LPS treatment of MDDCs for 4 hours resulted in robust 
increases of both IFN-β and IP-10 mRNAs (Figure 8.3A, B). Inability to detect differences in mRNA 
expression levels of IFN-β in MDDCs infected with WT and ΔVpr viruses was also mirrored with the 
absence of differences in protein levels in infected MDDC culture supernatants (data not shown).  We 
used a sensitive bioassay to measure type I IFN production in infected MDDC supernatants, and failed to 
detect any type I IFN production in HIV-1 infected MDDCs over mock infected controls (data not shown) 
(70). In contrast, IP-10 was robustly secreted in both Lai-YU2 (WT) and Lai-YU2ΔVpr infected MDDC 
culture supernatants at day 3 post-infection, though the magnitude of IP-10 induction was donor-
dependent (Figure 8.3C). Furthermore, we observed a significant increase in IP-10 production upon WT 
virus infection of MDDCs as compared to mock-infected cells (Figure 8.3C). Again, AZT pre-treatment 
reduced secretion of IP-10 indicating that IP-10 production is dependent on completion of reverse 
transcription (Figure 8.3C). Taken together, these results suggest that Vpr deficiency does not result in 
the induction of type I IFNs during establishment of productive HIV-1 infection of MDDCs and is unlikely 
to play a role in the restriction of HIV-1/∆Vpr in DCs.  
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Figure 8.3. Vpr-deficiency does not result in enhanced type I IFN production in productively 
infected MDDCs.  
Quantitative RT-PCR for IFNβ (A) and IP-10 (B) transcripts in infected MDDCs at 48 hours post infection. MDDCs 
were mock-infected or infected with Lai-YU2 or Lai-YU2/∆Vpr (MOI = 2) in the presence or absence of AZT (10 µM). 
The amount of IFNβ or IP-10 transcripts in infected MDDCs was normalized to the number of cells using a GAPDH 
control, and reported as relative to that of mock infected MDDCs (set as 1) for four independent donors. LPS 
treatment for 4 hours was used as a positive control for IFNβ and IP-10 production. Data is the log-transformed mean 
(± SEM) of seven donors. (C) Secreted IP-10 in MDDC culture supernatants infected with Lai-YU2 or Lai-YU2/∆Vpr 
(MOI = 1) at day 3 post infection was measured by an ELISA. The data shown are the log-transformed mean (± SEM) 
of independent experiments with MDDCs derived from four donors for (A) and (B) and six donors for (C). Significance 
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calculated using a paired student’s T test or a one value T test (when comparing normalized data) where N.S>0.05, 
*p<0.5, **p<0.1, ***p<0.01, ****p<0.001, *****p<0.0001. 
 
Infection with ∆Vpr viruses results in decreased infection in a single round of replication and is rescued by 
virion-associated Vpr  
 To identify the step of the virus replication cycle in MDDCs that is affected by Vpr, we next 
performed single cycle of infection analysis. MDDCs were infected with HIV-1 reporter viruses 
pseudotyped with VSV-G and expressing luciferase upon establishment of infection that do (Lai-luc 
∆env/G or WT) or do not express Vpr (Lai-luc ∆env/G ∆Vpr or ΔVpr). Infection with ΔVpr virus resulted in 
a 3-5 fold decrease in luciferase expression compared to infection with WT virus (Figure 8.4A), 
suggesting that Vpr acts early in the HIV-1 replication cycle in MDDCs at steps preceding virion assembly 
and maturation. Since Vpr is a virion-associated protein, we next sought to determine whether incoming 
virion-associated Vpr was sufficient or if de novo synthesized Vpr was required for enhancement of virus 
replication in DCs. We produced Lai-luc ∆env/G ∆Vpr complemented with HA-epitope tagged Vpr in trans 
(Lai-luc ∆env/G Vpr-trans) via co-transfection of HEK293T cells with a functional HA-Vpr expression 
plasmid and the Lai-luc∆env/G ∆Vpr proviral plasmid. HA-Vpr was efficiently incorporated in ΔVpr virus 
particles to levels similar to that observed in WT virus particles (Figure 8.4B). We then infected MDDCs 
with Lai-luc ∆env/G-WT, ΔVpr, or Vpr-trans viruses and lysed the cells on day 3 post-infection. 
Incorporation of Vpr in trans within incoming virus particles rescued ΔVpr virus infection in a single-round 
assay (Figure 8.4C), suggesting that virion incorporated Vpr is sufficient for overcoming cell-intrinsic 
blocks to early steps in HIV-1 replication in DCs.  
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Figure 8.4. Infection of MDDCs with Vpr-deficient viruses results in block to HIV-1 replication in 
single round infection analysis.  
(A) MDDCs infected with 40 ng p24Gag equivalent of VSV-G pseudotyped Lai-luc ∆env (WT or ∆Vpr) were lysed 3 
days post infection, and viral replication was quantified by measuring luciferase activity in cell lysates. The luciferase 
activity in ΔVpr infected cell lysates was normalized to that of WT virus-infected MDDC lysates and reported as mean 
(± SEM) of four independent experiments with MDDCs derived from four independent donors. (B) Western blot 
analysis of Vpr incorporation in virus particles (Lai-luc ∆env/G, Lai-luc ∆env/G ∆Vpr, or Lai-luc ∆env/G Vpr-trans) 
derived from transient transfection of HEK293T cells. (C) MDDCs were infected with 40 ng p24Gag equivalents of 
viruses (Lai-luc∆env, Lai-luc∆env∆Vpr, or Lai-luc∆env∆Vpr + HA-Vpr), and lysed 3 days post infection. Cell lysates 
were analyzed for luciferase activity and the data reported is normalized to that observed with WT-virus infection and 
is mean (± SEM) from 4 independent experiments. Significance calculated using a paired student’s T test or a one 
value T test (when comparing normalized data) where *p<0.05, **p<0.01. 
 
Proviral LTR-mediated transcriptional activity is attenuated in Vpr-deficient virus infection in DCs  
 Since the block to HIV-1/∆Vpr infection in MDDCs is evident within a single round of replication, 
and is independent of the mode of virus entry (VSV-G pseudotyped virus infection was also restricted, 
Figure 8.4A), we assessed the effect of Vpr-deficiency on HIV-1 reverse transcription (RT) and integration 
efficiency in DCs. We used qPCR to measure RT-products and the number of proviruses at day 3 post-
infection using R-U5 and Alu-Gag primer pairs, respectively (71, 72). Infections were also performed in 
the presence of AZT to control for contaminating input plasmid DNA. In contrast to previously published 
findings (41), we saw no decrease in the number of RT products (Figure 8.5A) or integrants (Figure 8.5B, 
C) upon infection with ΔVpr virus compared to WT virus infections (Figure 8.5A, B and C). Previous 
studies have suggested that Vpr can modulate HIV-1 LTR transcriptional activity (29, 46, 73–75). We 
therefore asked if the block to HIV-1/∆Vpr infection occurs at the stage of viral transcript production. To 
determine the effect of Vpr on LTR-mediated transcription from proviruses, we used qRT-PCR to 
measure multiply-spliced tat/rev/nef transcripts at 48 h post infection (Figure 8.5D). Similar to our findings 
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with luciferase reporter expression in infected DCs, we observed a 4-fold decrease in the number of 
multiply-spliced HIV-1 transcripts in HIV-1/∆Vpr-infected cells suggesting that Vpr-deficiency results in 
inhibition of proviral LTR-mediated transcription in DCs.  
 
 
Figure 8.5. Viral transcription is attenuated in ΔVpr virus infected MDDCs.  
(A-C) MDDCs infected with WT or ΔVpr viruses (MOI = 2) in the presence or absence of AZT (10 µM) were lysed 72 
h post infection, and processed for DNA isolation. Note that infected cells were cultured in the presence of indinavir 
(1µM) to prevent viral spread. QPCR was used to detect early RT products (A) and integrated proviruses (B) by R-U5 
and Alu-PCR primer sets and the number of integrated proviruses normalized to early RT products for each infection 
is shown in (C). The data reported is the mean (± SEM) of three independent experiments. (D) The numbers of 
multiply-spliced viral transcripts (tat-rev-nef) in MDDCs infected with Lai-YU2 or Lai-YU2/∆Vpr (MOI = 1) was 
determined at 48 hours post infection by qRT-PCR. Viral transcripts were measured using primers specific to 
tat/rev/nef multiply-spliced transcripts. Data shown are mean (± SEM) of four independent experiments with MDDCs 
derived from four donors. (E) Quantification of 4 kb class of splice variants for MDDCs infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI = 2) for 72 hours. The data was normalized, log10 transformed, and then graphed according to splice 
acceptor usage. Histograms show fold changes in splicing from D1 to each of the 5 viral splice acceptor sites A1 
through A5 relative to a WT control.  Splicing was quantified using a Primer ID-splicing assay for MDDCs from two 
independent infections (e), productively infected CD4+ T cells (F) and HeLa cells (G) and is data from a single deep 
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sequencing experiment. Significance calculated used unpaired student’s T test where *p<0.05, **p<0.01, and 
***p<0.001. 
 
We next sought to determine if the decrease in multiply-spliced viral mRNA levels in HIV-1/ΔVpr-
virus infected MDDCs were driven by changes in the pattern of viral mRNA splicing. We used a novel 
Prime ID-tagged deep sequencing assay (76, 77) to determine the relative abundance of different splice 
variants in WT and ΔVpr infected DCs, and compared viral splice site usage to that observed in WT or 
ΔVpr-infected CD4+ T cells and HeLa cells (Figure 8.5E-G). Data depicts the relative quantity of 4 kb 
singly-spliced mRNA for each splice acceptor and is reflective of the changes observed in the 1.8 kb 
multiply-spliced mRNA (data not shown). We detected minor differences in splice acceptor usage 
between WT and ∆Vpr infections in MDDCs. We observed small decreases in the use of the Vif [A1] and 
Vpr [A2] splice acceptors and a small increase in the use of the Tat [A3] splice acceptor, but these 
differences were well within the normal range of splicing variation seen in productive viral infections (77). 
These small differences in splice site usage were consistently observed in infections of CD4+ T cells and 
HeLa cells.  Since the differences in splicing are both relatively small and observed in two cell types 
(primary activated CD4+ T cells and HeLa cells) that do not restrict ∆Vpr virus replication, it is unlikely that 
efficiency of viral mRNA splicing or choice of mRNA splice acceptor sites is a contributing factor to the 
restricted replication of ΔVpr virus in MDDCs. 
Mutations in the C-terminal end of Vpr or those that disrupt binding to CRL4DCAF1 ubiquitin ligase 
attenuate viral replication in DCs  
 A range of functions have been attributed to Vpr, including G2/M cell cycle arrest, enhancing 
fidelity of reverse transcription, nuclear import and/or nuclear tethering of the pre-integration complex, and 
induction of apoptosis (12–14, 30, 41, 46, 78). To clarify which of the known functions of Vpr are 
important for enhancing HIV-1 replication in DCs, a panel of mutations were introduced in Vpr ORF with 
previously characterized effects on Vpr functions. HEK293Tderived virus particles were analyzed by 
quantitative western blotting to assess incorporation of mutant Vpr proteins into viral particles (Figure 
8.6A). While all viral mutants expressed and incorporated Vpr in virus particles, the mutants Vpr-F34I and 
Vpr-H71R had slightly decreased incorporation levels of Vpr compared to wild type viruses (Figure 8.6A), 
though both wild type and Vpr-mutant viruses were equally infectious on TZM-bl cells on a per particle 
basis (Figure 8.6B). MDDCs were infected with replication competent HIV-1 (WT or Vpr-mutants) at equal 
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MOIs and the extent of viral replication was measured by periodic quantification of p24Gag in cell-free 
culture supernatant by an ELISA (Figure 8.6C). Since there was donor-to-donor variability in the kinetics 
and extent of virus replication in DCs, we calculated the area under the curve of replication kinetics 
obtained from four independent infections (Figure 8.6D). As depicted in Figure 8.6C and D, infection with 
both Vpr-Q65R and Vpr-H71R mutant viruses resulted in significantly attenuated virus replication and 
spread, similar to what was observed with ΔVpr virus replication in MDDCs (Figure 8.6C and D). In 
contrast, replication of both Vpr-F34I and Vpr-W54R mutants was not significantly different from that 
observed with wild type virus infections (Figure 8.6C and D). Cumulative analysis revealed that replication 
of Vpr-Q65R and Vpr-H71R mutants, which lack the ability to associate with the CRL4DCAF1 complex (16–
18, 30, 45, 46, 49, 79, 80), was significantly reduced (p<0.01), similar to that observed with ΔVpr virus 
infection (Figure 8.6D). Interestingly, replication of Vpr-F34I mutant which incorporates reduced levels of 
Vpr in virions (Figure 8.6A), and displays reduced association with the nuclear envelope, (30, 45, 50) was 
slightly enhanced over that observed with wild type virus replication (Figure 8.6D; p<0.01), suggesting a 
threshold amount of functional Vpr that is still present in the incoming virus particle is sufficient for 
establishment of productive infections in DCs. The mutation Vpr-W54R, which ablates binding of Vpr to 
UNG2 (19, 45, 80–82) had a negligible effect on viral replication in DCs.  
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Figure 8.6. Vpr mutants deficient for interaction with DCAF1/DDB1/E3 ubiquitin ligase and 
inducing G2 cell cycle arrest are attenuated in a single cycle of replication analysis in MDDCs.  
(A) Representative western blot analysis of HEK293T- derived Lai-YU2 (WT) and indicated Vpr mutant viruses used 
for MDDC infections. Blots were probed with anti-p24Gag, anti-Vpr and anti-gp120 antibodies. (B) Infectivity of Lai-
YU2 and corresponding Vpr mutants in TZM-bl cells is reported as the number of infectious units (blue cells) per ng of 
p24Gag equivalent and are the mean (± SEM) of three independent viral preparations. (C) Viral growth curves of four 
independent infections of MDDCs with Lai-YU2 and indicated Vpr mutants in DCs. Viral growth was determined by 
analyzing p24Gag release into cell culture supernatants at days 3, 6, 9 and 12 post infection and determined by 
ELISA. (D) Area under the curve compiled for four independent MDDC infections represented in (C) normalized to 
WT virus infection, set as 1 (mean ± SEM). (E) The percentage of p24Gag positive MDDCs at day 3 post infection as 
measured by intracellular p24Gag staining and FACS analysis. Cells were treated with indinavir (1 µM) post virus 
exposure to prevent viral spread. The data was normalized to WT virus infection, set as 1, and depicts the mean (± 
SEM) of three independent infections of MDDCs from three donors. (F) MDDCs infected with 40 ng p24Gag 
equivalents of Lai-luc ∆env/G (WT or Vpr mutants) were lysed 3 days post infection, and viral replication was 
quantified by measuring luciferase activity in cell lysates. The luciferase activity in Vpr-mutant infections was 
normalized to that of WT virus infections, set as 1, and the data shown are the mean (± SEM) for three independent 
experiments. (G) Western blot analysis of HEK293T-derived Lai-GFP ∆env/G (WT) or indicated Vpr mutant virus 
particles. (H) MDDCs infected with Lai-GFP ∆env/G (WT) or indicated Vpr-mutants (MOI = 3) were harvested at day 3 
post infection and processed for FACS analysis. The data shown is the mean percentage of GFP+ cells (± SEM) of 
five independent experiments with cells derived from five independent donors. Significance calculated using a paired 
student’s T test or a one value T test (when comparing normalized data) where *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
We next sought to determine which of these Vpr mutants could recapitulate the single cycle of 
replication defect observed with HIV-1/ΔVpr infection in MDDCs (Figure 8.4A). We infected MDDCs with 
either replication competent viruses (Lai-YU2, WT or Vpr mutants, MOI = 1) in the presence of a protease 
inhibitor (indinavir) or with equal amounts of p24Gag equivalents of Lai-luc ∆env/G encoding the various 
Vpr mutations. Similar to the results observed with replication competent viruses, both the number of 
p24Gag-postitive cells (Figure 8.6E) and luciferase production (Figure 8.6F) from infections with Vpr-Q65R 
and Vpr-H71R mutants were significantly attenuated in a single round of infection compared to isogenic 
WT viruses. While the host protein targeted by HIV-1 Vpr to induce G2 cell cycle arrest has not been 
identified, the C-terminal tail of the protein has been proposed to bind the unknown host factor, and 
mutations in the C-terminal tail of Vpr abrogate the ability of Vpr to induce G2 cell cycle arrest (45).  To 
determine the role of Vpr-mediated G2 cell cycle arrest on virus infection enhancement in DCs, an 
additional mutation, Vpr-R90K was introduced in GFP-expressing single-cycle virus (Lai-GFP ∆env/G). 
The Vpr-R90K mutant can bind CRL4DCAF1 complex but fails to induce G2 arrest in cycling cells (45, 50, 
80). Despite equivalent incorporation into the virion as WT Vpr (Figure 8.6G), infection of MDDCs with 
Vpr-R90K mutant resulted in significant infection defect in single round analysis (Figure 8.6H), similar to 
what was observed in infections with ∆Vpr or Vpr-Q65R viruses, suggesting that interaction with a 
putative host factor whose degradation is critical for the induction of G2 cell cycle arrest is required to 
enhance HIV-1 infection of DCs. Together, our data suggests that there is a novel block to HIV-1 infection 
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in MDDCs in the absence of Vpr that is present in a single round of infection and manifests at the stage of 
viral transcription. Further studies are underway to determine the exact mechanism by which Vpr 
alleviates the DC-intrinsic block to HIV-1 replication. 
Discussion 
 In the work presented here, we examined the role of Vpr in establishing productive HIV-1 
infection of DCs. Previous work in the field suggests that Vpr likely regulates a complex network of host 
interactions that may vary depending on the cell type infected. We find that, unlike what has been 
previously observed in activated CD4+ T cells and monocyte-derived macrophages (20, 22–25, 29), 
infection of MDDCs with ∆Vpr viruses was significantly attenuated when compared to WT HIV-1 infections 
(Figure 8.1), similar to the findings reported by de Silva et al (41). Interestingly, Vpr-mediated 
enhancement was observed within both a single round viral infection as well as in spreading infections, 
contrary to what has been reported previously (28, 41). Furthermore, the single round replication defect 
could be rescued by complimenting back Vpr in trans in the incoming virion (Figure 8.4) indicating that 
incoming virion-associated Vpr is necessary for the establishment of efficient HIV-1 infection of DCs. 
Initiating infections with the Vpr mutants, Vpr-Q65R, Vpr-H71R and Vpr-R90K that either lack the ability to 
engage the CRL4DACF1 complex or bind the yet-to-identified host factor(s) necessary for inducing G2 cell 
cycle arrest, displayed similar replication deficits to that observed with ∆Vpr virus in both spreading 
infections and single round infection analysis (Figure 8.6).  
 Surprisingly, the block to ΔVpr virus replication in MDDCs was evident at a post-integration step 
and resulted in reduced numbers of viral mRNAs, suggesting that Vpr is acting either directly or indirectly 
to enhance transcription from the viral LTR (Figure 8.5). It has been reported previously that Vpr can 
transactivate the viral LTR in a number of cell types and that this function correlates with the ability of Vpr 
to induce G2 cell cycle arrest (26, 29, 46, 73, 75). Previous studies have also shown that both SIVmac and 
SIVagm Vpr can also transactivate their respective LTRs (74, 83, 84), suggesting that this is a conserved 
function among non-human primate lentiviral Vpr proteins. While it is possible that Vpr-mediated 
transactivation could be more robust in DCs than in CD4+ T cells (Figure 8.1E), another hypothesis is that 
Vpr is indirectly activating transcription to promote infection in cells that have a higher barrier to infection.  
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Unlike most of the other lentiviral accessory proteins, Vpr is actively packaged into the budding 
virion through associations with the p6 region of Gag (3–6, 10). Our work in MDDCs suggests that there 
may be a novel role for virion-associated Vpr to enhance viral transcription and increase infection of DCs. 
These findings are at odds with recently published studies on the role of Vpr in modulating de novo HIV-1 
Env production in productively infected macrophages and MDDCs (28, 44). While we do occasionally see 
a decrease in viral Env production during infection with ΔVpr virus in MDDCs (one out of four donors 
tested), infection of MDDCs from most of the donors revealed no differences in Env expression or virion 
incorporation (Figure 8.2). It is possible that the use of different viral clones, primary cell variation derived 
from multiple donors, or different infection conditions might play a role in the differences between our 
results and those described previously. Since we observed infection differences in a single-round 
infection assay, putative effects of Vpr on Env expression are unlikely to play a role in establishment and 
spread of virus infection in MDDCs and DC-T cell co-cultures. 
HIV-1 is not unique among primate lentiviruses in expressing a protein that functionally allows for 
infection of DCs. HIV-2 and certain SIV lineages express Vpx, another small accessory protein that 
targets host restriction factor SAMHD1 for proteosomal degradation by recruiting it to the CRL4DACF1 
complex, and facilitates infection of MDDCs (51, 52, 85). Interestingly, Vpr-mediated replication 
enhancement in MDDCs was substantially attenuated upon infection with Vpr mutants (Q65R or H71R; 
Figure 8.6F) that lack ability to interact with CRL4DCAF1 complex, or upon infection with Vpr-R90K mutant 
(Figure 8.6H), that fails to interact with the host factor(s) hypothesized to be recruited to the CRL4DCAF1 
complex for proteosomal degradation. Since Vpr is introduced into target cells along with the incoming 
virion because of its association with the viral capsid, we hypothesize that early interactions of Vpr with a 
host factor and recruitment of that protein to the CRL4DCAF1 complex for proteosomal degradation is 
essential for promoting HIV-1 replication in DCs, similar to the ability of Vpx from SIVmac/SIVsmm/HIV-2 
lineages to promote infection of DCs.  
 Across primate lentiviral Vpr evolution, induction of DDR and G2 cell cycle arrest are conserved 
functions, and Vpr proteins from diverse primate lentiviruses have been shown to associate with and 
degrade many DDR regulatory proteins including the SLX4com, HLTF, and UNG2 (18–21, 80, 81, 86–
89). While DDR activation may represent a cell-intrinsic antiviral response, it has been suggested that 
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both RNA and DNA viruses induce DDR signaling to promote cellular conditions that are favorable for 
viral replication (83, 90–93). For instance, induction of DDR signaling activates ataxia-telangiectasia 
mutated (ATM) kinase which results in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) activation (94, 95). Additionally, the DDR pathway also directly activates pro-inflammatory responses 
through the induction of interferon regulatory factors (IRFs) or through the recruitment of co-activators 
and chromatin modifying complexes, such as ten-eleven translocation methylcytosine (TET) 
dioxygenases, which we hypothesize might also activate viral transcription (96). Since the barrier to 
successful establishment of infection in non-cycling, metabolically quiescent cells like MDDCs is higher 
than that in activated CD4+ T cells or MDM, Vpr-mediated activation of NF-κB and co-activator 
recruitment to the viral LTR might be a viral strategy for overcoming the restrictive cellular environment 
and for optimal production of progeny virions.  In line with this hypothesis, numerous studies have 
documented that Vpr is able to modulate NF-κB activity in different cell lines and primary cells, though 
these studies rarely agree on the mechanism of regulation or direction of modulation (26, 75, 97–102). 
Recent work from Höhne, et al has shown similar effects of Vpr on viral replication in non-activated 
primary CD4+ T cells, which have similar barriers to infection as MDDCs including increased expression 
of SAMHD1 and low baseline NF-κB activity (26, 103, 104). Some studies have shown virion-associated 
Vpr-dependent activation of NF-κB occurs via a transforming growth factor-β-activated kinase 1 (TAK1) 
signaling cascade, while other studies have shown that secreted or synthetic Vpr stimulates NF-κB 
signaling through a TLR4-dependent mechanism (75, 99, 100, 102). Our data also demonstrates 
upregulation of IP-10 upon HIV-1 (WT) infection (Figure 8.3C) which is also dependent on NF-κB 
activation (105–107).These results suggest a link between Vpr-mediated NF-κB activation in MDDCs and 
enhanced viral gene expression and pro-inflammatory cytokine secretion, which may act in vivo to 
enhance recruitment, activation and infection of CD4+ T cells, resulting in increased viral dissemination 
(Figure 8.1E) (27, 75, 99).  
Studies with peripheral blood myeloid MDDCs and monocyte-derived MDDCs from HIV-1 elite 
controllers have shown that these cells may be critical for viral control, acting to capture virus and 
enhance T cell-specific immunity to HIV-1, while being less susceptible to HIV-1 infection compared to 
MDDCs from healthy controls (108, 109). Understanding the mechanisms that control HIV-1 replication in 
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MDDCs which are overcome by Vpr, might lead to new insights on viral dissemination and persistence in 
vivo, and development of novel anti-HIV-1 therapeutics. 
Materials and Methods  
Plasmids  
 HIV-1 proviral plasmids Lai/YU2 env, Lai/Bal, Lai-luc ∆env (Env deficient HIV-1 containing a 
luciferase reporter gene in place of nef), Lai-GFP ∆env (Env deficient HIV-1 containing GFP in place of 
nef) and the HA-Vpr expression plasmid have been previously described (30, 110). Proviral Lai (CXCR4-
tropic) clones containing Vpr mutations, F34I, W54R, and H71R and frame-shift mutation in Vpr (ΔVpr) 
have been described previously (30, 46, 80, 111). These Vpr mutations were transferred to Lai-YU2 env, 
Lai-luc ∆env or Lai-GFP ∆env proviral plasmids using Apa I and Sal I restriction sites. To create proviral 
clones encoding Vpr-Q65R mutation, the Apa I – Sal I fragment of Lai-YU2 env was subcloned into 
pSL1180 cloning vector (Stratagene) and site directed mutagenesis was preformed using a kit 
(QuikChange II, Agilent Technologies) and the following primers: 5’-
GCCATAATAAGAATTCTGCGACAACTGCTGTTTATCCATTTC-3’ and 5’-
GAAATGGATAAACAGCAGTTGTCGCAGAATTCTTATTATGGC-3’. The mutated fragment was ligated 
back into Lai-YU2 env, Lai-luc ∆env or Lai-GFP ∆env using Apa I-Sal I restriction sites. The point 
mutation Vpr-R90K was derived by sub-cloning the Sal I – BamH I fragment into pSL1180 and via site 
directed mutagenesis (QuikChange II, Agilent Technologies) using the following primers: 5’-
CGTTACTCAACAGAGGAGAGCAAAAAATGGAGCCAGTAGATCCTAGAC-3’ and 5’-
GTCTAGGATCTACTGGCTCCATTTTTTGCTCTCCTCTGTTGAGTAACG-3’. The mutated fragment was 
cloned back into Lai-GFP∆env.  
Cells and viruses 
 MDDCs were derived from monocytes isolated from peripheral blood mononuclear cells as 
previously described (112). TZM-bl and HEK 293T cells have been described previously (112–114). 
Replication competent Lai-YU2 env viruses were derived using calcium phosphate mediated transient 
transfection of HEK 293T cells, as described previously (115). HIV-1 vectors were generated from 
HEK293T cells via co-transfection of Lai-luc∆env or Lai-GFP∆env with VSV-G expression plasmid. Virus-
containing cell supernatants were harvested 2 days post-transfection, passed through 0.45 µm filters, and 
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stored at -80°C until further use. For some experiments, virus particles were concentrated by 
ultracentrifugation on a 20% sucrose cushion [24,000 rpm at 4˚C for 2 h with a SW28 rotor (Beckman 
Coulter)] (116). The virus pellets were resuspended in PBS, aliquoted and stored at -80 °C until use. The 
capsid content of HIV-1 was determined by a p24Gag ELISA while the infectious titer was determined via 
infecting TZM-bl cells (114, 117). Viral replication in MDDCs and DC- T cell co-cultures was determined 
by measuring p24Gag content in cell culture supernatants at indicated days post infection by an ELISA 
(117). Infection of MDDCs using luciferase reporter virus was analyzed using Bright-Glo Luciferase 
System (Promega) as previously described (118).  
Drug treatments 
 In indicated experiments, cells were pretreated with zidovudine (AZT, 10 µM, NIH AIDS Research 
and Reference Reagent Program) for 30 minutes at 37°C prior to infection and AZT concentration was 
maintained for the duration of the cultures, or cells were treated with indinavir (1 µM, NIH AIDS Research 
and Reference Reagent Program) post-virus exposure.  
Quantitative western blotting  
 To detect Gag and Env in cell and virus particle lysates, cell lysates (normalized to equivalent 
amounts of cell-associated Gag content) or 100 ng p24Gag virus equivalents (as determined by 
quantitative ELISA) were run through SDS-PAGE gels and transferred using a semi-dry transfer 
apparatus to nitrocellulose membranes as previously described (116). Blots were blocked and probed 
with rabbit anti-gp120 (a gift from Dr. Nancy Haigwood) and mouse anti-p24Gag (clone p24-2, NIH AIDS 
Research and Reference Reagent Program), followed by goat anti-mouse IgG DyLight 680 (Pierce) and 
goat anti-rabbit IgG DyLight 800 (Pierce). To determine Vpr incorporation, a polyclonal rabbit anti-Vpr 
antibody (clone 1-50, NIH AIDS Research and Reference Reagent Program) was used followed by goat 
anti-rabbit IgG DyLight 700. The membranes were scanned with an Odyssey scanner (Li-Cor). 
Quantitative RT-PCR  
 For the quantitation of IFNβ and IP-10 mRNA, MDDCs (2-4x106 cells) were mock infected or 
infected with Lai-YU2 or Lai-YU2ΔVpr (MOI = 2). At 48 h post infection, cells were harvested for RNA 
isolation using RNAeasy (QIAGEN) RNA isolation kits and cDNA was synthesized using oligo dT primers 
and Superscript III RT (Invitrogen). cDNA corresponding to 200 ng of RNA was analyzed by qRT-PCR 
 202 
using SYBR green (Invitrogen) to quantify mRNA levels for IFNβ (forward primer: 5’-
ATTCTAACTGCAACCTTTCG-3’ and reverse primer: 5’-GTTGTAGCTCATGGAAAGAG-3’), IP-10 
(forward primer: 5’-TCATTGGTCACCTTTTAGTG-3’ and reverse primer: 5’-
AAAGCAGTTAGCAAGGAAAG-3’) and GAPDH (forward primer: 5’-AGGGATGATGTTCTGGAGAG-3’ 
and reverse primer: 5’-CAAGATCATCAGCAATGCCT-3’). The ΔΔCT value relative to GAPDH in the 
mock-infected cultures was set to 1, and the data from the infected cultures reported as fold 
enhancements.  To determine the extent of de novo viral transcription, the number of tat-rev-nef multiply 
spliced transcripts was determined by qRT-PCR using SYBR green as described previously (58), with the 
following primer set: forward primer, 5’-GCGACGAAGACCTCCTCAG-3’ and reverse primer, 5’-
GAGGTGGGTTGCTTTGATAGAGA-3’. The data were normalized to GAPDH levels. As a control, 
MDDCs were treated with AZT (10µM) for 30 min prior to infection and drug levels were maintained 
during the course of infection.   
Quantification of viral integration 
 To determine the number of proviral integrants, MDDCs (3x106 cells) were infected with virus 
(MOI = 3) for 2 h at 37˚C, washed with PBS twice and cultured for 72 h before cells were lysed for DNA 
extraction with a DNeasy kit (QIAGEN). As a background control, MDDCs were treated with 10 µM AZT 
for at least 30 min prior to infection. Quantitative Alu-PCR was performed using 20 ng of DNA with the 
following primer sets, as described previously (72). For the first step, the following primers were used: 
Alu-forward 5′-GCCTCCCAAACTGCTGGGATTACAG-3′ and Gag-reverse 5’-
GCTCTCGCACCCATCTCTCTCC-3’. For the second step, the following primers were used: R-U5-F: 5′-
GCCTCAATAAAGCTTGCCTTGA-3′ and R-U5-R: 5′-TCCACACTGACTAAAAGGGTCTGA-3′ with the 
following probe: R-U5-Probe: 5′-FAM-CCAGAGTCACACAACAGACG-TAMRA-3′. The data were 
normalized to a standard curve generated from infected HEK293 cell DNA (71, 72).  
Splicing assay   
 The assay details are described separately in detail (77). Briefly, cDNA primers with an internal 
random sequence block (Primer ID; (76)) were designed to be within the env intron, to measure the 4 kb 
size class of spliced viral RNAs, or spanning the D4/A7 splice junction to measure the 1.8 kb size class. 
The reverse primer for the 4 kb size class was: 5’-
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GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNGTACGCTAATACTTGTAAA
GATTGCAGTACATGTACTACTT-3’ and the reverse primer for the 1.8 kb size class was: 5’- 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNCAGTCTGAGCTGGGAGGT
GGGTTGC-3’. Whole cell RNA from infected cells was purified and used in a cDNA reaction. After 
removal of the cDNA primers, PCR was carried out using a downstream primer encoded in the cDNA 
primer tail and a forward primer placed just upstream of the D1 major donor site in the 5' noncoding 
region, 5’-
GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNTGCTGAAGCGCGCACGGCAAG-3’. 
PCR products were sequenced using the MiSeq platform, and sequence reads with the same Primer ID 
were collapsed into a single read (to correct for skewing during PCR since each unique Primer ID tag 
represents a separate viral mRNA template). Data were processed using customized scripts that are 
available on request. The number of unique Primer IDs for each spliced product was used to determine 
the relative level of splicing from each splice donor to each splice acceptor in the viral genome with the 
exception of splicing events to the nef splice acceptor A7. 
Cytokine measurements 
 Secreted IP-10 in MDDC culture supernatants was measured using a commercially available 
ELISA kit (Becton Dickinson). Secreted levels of bioactive type I IFN in infected MDDC supernatants was 
measured using a HEK293 ISRE-luc cell line which expresses luciferase under the control of an IFN-
inducible promoter carrying the IFN-stimulated response element (70). Briefly, HEK293 ISRE-luc cells 
(8x104) were incubated with MDDC culture supernatants for 21 hours. Cells were lysed and luciferase 
activity in the cell lysates analyzed with Bright-Glo Luciferase System (Promega), as described above. 
Serial dilutions of recombinant interferon alpha ranging from 200-0.39 units/ml (PBL Interferon Source) 
were added to cells in each experiment for generating a standard curve.  
FACS  
 Intracellular fluorescence-activated cell sorter (FACS) analysis for p24Gag was done using FITC-
conjugated anti-p24Gag monoclonal antibody (KC57; Coulter) as previously described (117). Surface 
staining for CD11c was done using APC-conjugated anti-CD11c (Clone B-ly6, Becton Dickinson). Cells 
were analyzed using either LSRII or FACSCalibur (Becton Dickinson) instruments. 
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